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The ionotropic receptors including nicotinic acetylcholine (nAChR), y-aminobutyric 
acid type A and C  (GABAa/c),  serotonin (5HT-3) and glycine receptors (GlyR) all 
comprise the cys-loop  receptor  family.  A pentameric  configuration  is  adopted  by 
these  receptors  featuring  a  large  extra  cellular  domain,  four  transmembrane  (M) 
spanning domains and an intracellular compartment primarily contributed from the 
M3-4  loop.  The  recent  advent  of an  X-ray  crystal  structure  of the  related  ACh 
binding protein from snail, Lymnaea stagnalis,  and an electron micrograph nearing 
atomic  resolution of the transmembrane domains  for the  Torpedo nAChR provide 
the  opportunity  to  homology  model  the  structures  of  all  cys-loop  ligand-gated 
receptors and investigate critical  elements of receptor function with unprecedented 
accuracy.
By  using  homology  modelling  to  guide  site-directed  mutagenesis  in  combination 
with whole-cell patch clamp electrophysiology, molecular elements that mediate the 
biphasic modulation of glycine receptors by Zn2* were investigated.  The structure 
of a previously identified low sensitivity inhibitory Zn2+ site was clarified revealing 
critical  determinants  of  GlyR  subtype  selectivity  for  Zn2*  mediated  inhibition. 
Intriguingly these  experiments  also  revealed  a novel  functional  asymmetry at this 
site suggesting that one specific side of the site directs downstream transduction of 
the inhibitory Zn2^ effect.  This enabled the elucidation of a hydrophobic pathway 
leading directly through  the core of the  GlyR  from  the  inhibitory Zn2+   site to  the 
agonist binding site suggesting a mechanism for Zn2* mediated inhibition.
This  study  also  investigated  the  structural  basis  for  Zn2*  enhancement  of GlyR 
function.  A  comparative  study  of  GlyR  al  and  a2  followed  by  a  directed 
mutagenesis regional scan led to the identification of a complete and novel site for 
Zn2+ potentiation.  Further studies also elucidated a potential mechanism of action 
for  this  site  by  identifying  an  important  gating  component  of the  GlyR,  which 
exhibited a strong interaction with this novel potentiation site for Zn2+.
1These studies demonstrate the power of a homology modelling strategy to resolve 
key  elements  of  cys-loop  ligand-gated  receptor  function.  Identifying  and 
understanding  receptor  modulation  by  allosteric  effectors  is  a  key  requisite  to 
understanding  receptor  function.  This  work  describes  the  key  structural 
determinants  involved  in  the biphasic Zn2+  modulation of GlyRs both  in terms of 
actual binding sites and downstream effector mechanisms.
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12Chapter 1 
Introduction
Inhibitory neurotransmission: The glycine receptor
Of all the molecules  so  far identified  as neurotransmitters,  the  simplest is  glycine. 
This achiral amino acid is vital for all known life and is the most basic building block 
of  all  amino  acids.  Despite  its  apparent  simplicity  glycine  forms  a  critical 
component  of  many  cellular  proteins  endowing  peptide  backbones  with  extra 
flexibility and  unique  functions.  This  simplicity is  also  able to  code  for multiple 
modes of neurotransmission.  Glycine can act as an agonist for strychnine-sensitive 
inhibitory  glycine  receptors  (Lynch,  2004)  and  as  a  co-agonist, or  modulator, of 
excitatory  N-methyl-D-aspartic  acid  (NMDA)  receptors  (Mayer  and  Armstrong, 
2004).  Furthermore, glycine  is  a  crucial  ingredient  for many metabolic  processes 
including nucleotide biosynthesis.  With regards to mammals this molecule comes 
under the title of a non-essential amino acid as it can be synthesised within cells and 
is  not  required  from  the  diet.  This  process  requires  the  enzyme  serine 
hydroxymethyl transferase, which acts on another amino acid, serine, itself obtained 
from a glycolytic intermediate (Voet and Voet,  1996).  Since the requirement for this 
most simple of organic building blocks began, glycine has shaped the properties of 
almost all proteins and been a major driving force in the progression of metabolic 
processes and neurotransmission.
The  race  to  identify the  chemical  correlates  of neurotransmission,  which  included 
glycine,  came  about  from  the  initial  impetus  generated  in  the  1950s.  Within  this 
period  it  became  clear  that  neurotransmission  in  higher  vertebrates  required 
communication  between  central  nervous  system  (CNS)  neurones  that  were  not 
physically touching and that this process was primarily chemically mediated (Nicoll, 
1988).  The  consensus  towards  glycine  acting  as  a  specific  neurotransmitter  was 
cautious due to the abundant number of cellular processes this molecule was already 
known to be involved in.  Howeve^opinion began to change upon the publication in 
1965  of a paper by Aprison  and  Werman,  which  showed that glycine fulfilled the 
first  criterion  of any  substance  that  is  classified  as  a  neurotransmitter.  The  four
13requirements, listed below, are considered to be important for designating a chemical 
as a conventional neurotransmitter (Ottersen and Storm-Mathisen, 1990).
1.  The  presynaptic  criterion  -   In  order  for  a  molecule  to  elicit  a  rapid 
communication  event  across  a synaptic junction it must  initially be present 
within the presynaptic cell.
2.  Release  criterion  -  Upon  depolarisation  of  the  presynaptic  cell  the 
neurotransmitter in question must be released in quantities sufficient for it to 
mediate a downstream effect.
3.  Identity  of  action  criterion  -   Exogenous  application  of  the  putative 
transmitter substance should mimic the effects on the postsynaptic neurone.
4.  Removal  criterion -   If transmission  is  to  retain  a  dynamic  status  then  the 
system must reset rapidly for subsequent incoming signals and this therefore 
requires an efficient neurotransmitter removal service.
The landmark paper of Aprison and Werman,  (1965)  along with  follow-up  studies 
(Graham, Jr. and Aprison,  1966; Johnston,  1968) demonstrated the presence of both 
glycine and GABA at significant levels through a cross section of the cat spinal cord. 
This research was given further credence when measurements of the glycine content 
was correlated with a number of small neurones present in the spinal cord  (Davidoff 
et al.,  1967a;DavidofT et al.,  1967b).  Finally, the advent of autoradiography and the 
loading of neurones with [3H]glycine allowed the distribution of this amino acid to 
be observed using electron microscopy, firmly establishing the presence of glycine in 
synaptic  vesicle  structures  and  presynaptic  terminals  (Hokfelt  and  Ljungdahl, 
1971;Ljungdahl and Hokfelt, 1973;Matus and Dennison, 1971;Price et al., 1976).
Verification of the release criterion for glycine proved more difficult to attain.  These 
techniques  primarily  relied  upon  the  loading  of  neuronal  tissue,  in  this  case 
hemisected or slices of spinal cord,with [14C]glycine and then electrically stimulating 
the  tissue  to  evoke  release.  Several  studies  all  achieved  success  in  selectively 
measuring  [14C]glycine  release  over  non-specific  release  such  as  that  of  loaded 
[3H]insulin  (Aprison,  1970a,b;  Roberts  and  Mitchell,  1972;Osbome  et  al., 
1973;Mulder and Snyder,  1974).  These studies^ however, met with limited success 
perhaps  as a result of the efficient reuptake of this neurotransmitter upon  synaptic 
release (Mulder and Snyder, 1974).
14The  postsynaptic  action  criterion,  was  demonstrated  using  electrical  recordings 
accompanied  by  iontophoretic  applications  of exogenous  glycine.  Early  studies 
demonstrated that stimulation of presynaptic cells from the lumbosacral spinal cord 
produced membrane responses in motoneurones directly comparable to those elicited 
by exogenous glycine application (Werman et al.,  1967;Werman et al.,  1968).  The 
measurements using applied glycine produced a fall in membrane resistance, a rapid 
membrane hyperpolarisation and an inhibition of electrogenesis, all of which are now 
attributed  to  actions  via  the  GlyR.  Latter  studies  reproducing  these  results  also 
revealed  that  (3-alanine, another  agonist  of the  GlyR, could  also  act  in  a  similar 
fashion,  though  at the time it was not known that  its  action was mediated via the 
same receptor (Curtis et al., 1968;ten Bruggencate and Sonnhof, 1972).
With regards to a rapid removal system for glycine from the synaptic cleft after its 
release,  initial  evidence  supported  a  selective  reuptake  mechanism.  Neal  (1969) 
reported a rapid uptake of labelled glycine by rat spinal cord slices.  Furthermore, in 
keeping with the observation that the spinal cord seemed to possess far higher levels 
of glycine than the brain (Kelly and Kmjevic,  1969) it was revealed that the spinal 
cord  maintained  both  high  and  low  affinity  glycine  reuptake  processes  while  the 
brain  retained  only  a  low  affinity  uptake  mechanism  (Johnston  and  Iversen, 
1971;Logan  and  Snyder,  1972).  The  rate  of this  uptake  in  the  spinal  cord  was 
measured using [U-14C]glycine into synaptosomes and was shown to occur against a 
large  concentration  gradient  suggesting  an  active  uptake  mechanism  (Aprison  and 
McBride,  1973).  Thus by the middle of the  1970s all four criteria for glycine as a 
neurotransmitter  had  been  established  to  a  sufficient  level  to  strongly  implicate 
glycine as a genuine chemical neurotransmitter.
It  should  also  be  noted  that  these  studies  were  complimented  by  experiments 
demonstrating a selective blockade of the GlyR.  Such a selective blockade of spinal 
cord  motoneurones mediating  inhibitory synaptic  transmission was  identified  early 
on in response to the application of the alkaloid strychnine.  This naturally occurring 
molecule  is derived  from the  Indian tree Strychnos  nux vomica  and was  shown to 
selectively  inhibit  the  response  elicited  via  GlyRs,  only  inhibiting  GABAaR 
mediated responses at much higher concentrations (Davidoff et al., 1969;Curtis et al.,
151971).  This  important  discovery  enabled  receptor  distribution  studies  using 
[3H]strychnine, which revealed comparable staining patterns to those for the agonist 
glycine at postsynaptic inhibitory locations in the spinal cord and brain stem (Young 
and Snyder, 1973;Young and Snyder, 1974).  Eventually this high affinity ligand was 
used to initiate the first direct selective purification of GlyRs via affinity purification 
columns  paving  the  way  for  biochemical  characterisation  and  subsequent  cloning 
studies (discussed later).
The physiology of glycine receptors
Distribution
The spinal cord was the ideal preparation for many of the original distribution studies
for GlyRs.  However, even early glycinergic neurotransmission studies eluded to the
possibility  that  active  GlyRs  may  exist  elsewhere,  most  notably  the  hindbrain,
including the medulla oblongata, and the pons (Werman et al.,  1968; Aprison et al.,
1968;Aprison et al.,  1969;Galindo et al.,  1967;ten Bruggencate and Sonnhof,  1972).
Meanwhile the presence of glycine and therefore the prospect of putative glycinergic
transmission  appeared  low  in  higher  brain  regions  including  the  cerebral  cortex
(Kelly and Kmjevic,  1969).  Distribution studies of mRNA levels across a range of
developmental stages up to adulthood revealed that the GlyR family exhibits a broad
distribution  of potentially  functional  receptors  throughout  the  CNS  (Kuhse  et  al.,
1991;Malosio  et al.,  1991a;Nikolic  et al.,  1998).  The relative importance of these
receptors  in  synaptic  communication  is  likely to  vary between  tissue  preparations
with  studies  identifying direct  inhibitory synaptic  responses mediated by GlyRs  in
cerebellar  golgi  cells,  retinal  ganglion  cells  and  auditory pathway medial  superior
olive cells (Dieudonne,  1995;Protti et al.,  1997;Tian et al.,  1998;Smith et al., 2000).
Whereas,  other  reports  have  only  validated  functional  GlyR  responses  following
exogenous  agonist  application  with  the  significance  of  synaptic  receptors  not
addressed,  such  as  in  cortical  and  amygdala  neurones,  and  oligodendrocytes
(Belachew et al.,  1998;Okabe et al.,  2004;Danober and Pape,  1998).  At the other
extreme,  recordings  from hippocampal neurones  and rat dopaminergic neurones of
the substantia nigra suggest GlyRs from these regions are exclusively extrasynaptic
with no spontaneous activity observed and whole-cell glycinergic currents are only
recorded in response to exogenous agonist application (Mangin et al., 2002;Mori et
al., 2002).  The synaptic GlyR expression patterns are also in close agreement with
16the reported distribution of the two  selective plasma membrane glycine transporter 
proteins.  These  sodium/chloride-dependent  transporters,  GLYT1  and  GLYT2 
(Guastella et al.,  1992;Liu et al.,  1993), are localised to the spinal cord and the brain 
stem with GLYT1  also present in the diencephalon and retina and GLYT2 expressed 
in the cerebellum (Kim et al., 1994;Zafra et al., 1995).
The role of the glycine receptor
Given the prevalence of this receptor in intemeurones and motoneurones throughout 
the spinal cord and brain stem this suggested that the GlyR played an important role 
in the coordination of skeletal muscle movements.  Most notably, lamina la spinal 
intemeurones, which are regulated via a strong glycinergic input, play a critical role 
in mediating reciprocal inhibition in stretch reflex circuits allowing for relaxation of 
the  antagonist  muscle  (Lodge  et  al.,  1977;Kandel  et  al.,  2000).  A  role  for  a 
glycinergic  component  in  motor  control  circuits  is  demonstrated  by  selective 
disruption upon consumption of strychnine,  a potent convulsing agent,  and also  in 
the rare hereditary disease, hyperekplexia.  This disorder is  a result of detrimental 
mutations  within  the  GlyR  protein  family  leading  to  dysfunctional  glycinergic 
neurotransmission,  which  is  manifest  in  patients  as  an  overly  pronounced  startle 
response to unexpected stimuli (Rajendra and Schofield,  1995a).  The patient startle 
response stereotypically involves facial grimacing, hunching of shoulders, flexure of 
arms and clenching of fists, most notably this is due to an increase in muscle rigidity, 
known  as  hypertonia  throughout  the  body  of the  patient.  Animal  models  of this 
syndrome also exist, which are again due to  faulty glycinergic signalling following 
receptor mutations.  These include the oscillator, spasmodic and spastic mouse lines 
and  myoclonus  in  dogs,  horses  and  cows,  all  of which  feature  a  loss  of muscle 
coordination and hypertonia (Holland et al.,  1970;Lane et al.,  1987;Gundlach et al., 
1988;Gundlach et al., 1993;Buckwalter et al., 1994).
Besides the  important contribution of GlyRs to  motor coordination these receptors
also  play  significant  roles  in  other  neuronal  pathways.  The  GlyR  is  expressed
throughout  the  lateral  and  medial  superior  olive  and  the  medial  nucleus  of the
trapezoid  body,  and  evidence  suggests  this  glycinergic  circuitry  is  critical  for
tonotopic map  formation and  sound localisation by the auditory apparatus  (Kungel
and Friauf,  1997;Smith et al., 2000;Kapfer et al., 2002;Kim and Kandler, 2003).  In
17addition,  motor coordination  is  not  the  only process  that obtains  feedback  via the 
spinal  cord as the peripheral  sensation pathways  including those that mediate pain 
also communicate with higher brain regions in this manner.  GlyRs are prevalent in 
spinal cord lamina I and II, where modification of the inhibitory apparatus can alter 
the strength of the mediated chronic inflammatory pain response and it has recently 
been  shown  that  a specific  GlyR plays  a vital  role  in  this process  (Ahmadi  et al., 
2002;Ji et al., 2002;Harvey et al., 2004).
In  addition  to  an  inhibitory  neurotransmitter  role  for  glycine,  a  large  body  of 
evidence now suggests GlyRs also play important roles in neuronal development by 
regulating differentiation and neurite outgrowth, via an excitatory action of the GlyR. 
Due  to  the  depolarised  nature  of the  chloride  equilibrium  potential  in  embryonic 
tissues, GlyRs elicit depolarising potentials at these stages.  An electrophysiological 
study using microelectrodes on hemisected spinal cords demonstrated the strongest 
excitatory effect by GlyRs and GABAaRs at embryonic day 16 (El6), with gradual 
weakening and  finally a reversal  of excitation by postnatal  day 2  (P2)  (Wu  et  al., 
1992).  This excitatory effect may instigate downstream developmental processes via 
activation  of  Ca2+  transients  as  activation  of  GlyRs  in  neocortical  cells  and  in 
neonatal  lateral  superior olive cells caused elevations of intracellular Ca2+  (Flint et 
al.,  1998;Kullmann et al.,  2002)  and excitatory embryonic  spinal cord GlyRs have 
also been shown to influence both intracellular calcium and neurite outgrowth (Tapia 
et al.,  2001).  It has not yet been possible though to  show that differentiation and 
neurogenesis is a direct consequence of GlyR modulation of Ca2+ transients.  Studies 
investigating the differentiation of retinal photoreceptor precursor cells and cortical 
neurogenesis suggest GlyRs acting via this depolarising mechanism may contribute 
crucially to these developmental events (Zhou, 2001; Young and Cepko, 2004;Flint et 
al., 1998).
Glycine receptor synaptic signalling partners
Experiments  to  address  how  glycinergic  inhibitory neurotransmission  is  integrated
within the vast complexity of neuronal systems have revealed a number of interesting
ways  in  which  this  neurotransmission  may  be  modulated.  Perhaps  of  most
significance  is  the  potential  partnership  that  exists  between  the  GlyR  and  the
GABAaR.  Both these receptors are present in lamina I and II of the spinal cord, the
18brain  stem  and  in  cerebellar  Golgi  cells.  In  each  case  they  are  capable  of co- 
localising  at the  same  synapses  to  induce mixed  inhibitory postsynaptic  potentials 
with mixed decay components, a faster glycinergic decay and a slower GABAergic 
decay  (Jonas  et  al.,  1998;Chery  and  de  Koninck,  1999;0'Brien  and  Berger, 
1999;Donato and Nistri, 2000;Dumoulin et al., 2001;Keller et al., 2001;Russier et al., 
2002).  This  suggests  that  these  two  receptor  families  may  work  together  to 
coordinate and regulate motor control.  This supposition is supported by the effective 
treatment of patients with hyperekplexia upon administration of phenobarbitone or 
clonazepam,  both  enhancers  of GABAaR  function  (Andermann  and  Andermann, 
1988).  The mechanism of GlyR and GABAaR synergy may not always be exactly 
equivalent across different tissue preparations.  In lamina I of the spinal cord, GlyRs 
are  localised  on  the  postsynaptic  membrane  directly  opposing  the  presynaptic 
terminals while GABAaRs are positioned further away in the periphery around the 
GlyRs  (Chery  and  de  Koninck,  1999).  In  the  case  of retinal  photoreceptor  cell 
maturation,  which  again requires the activation of both  GlyRs and GABAaRs,  the 
two receptor types are instead thought to be activated by the common agonist, taurine 
(Young and Cepko, 2004).  Another interaction identified between the GlyR and the 
GABAaR is a negative feedback loop whereby activation of one receptor type will 
reduce  the  amplitude  and  increase  the  rate  of desensitisation  of the  subsequently 
activated  alternate  receptor type.  In  the  spinal  cord  dorsal  horn  this  inhibition  is 
phosphorylation dependent and is asymmetric with pre-activation of GlyRs inhibiting 
subsequent activation of GABAaRs more strongly than vice versa (Li et al., 2003).
The interaction between the neurotransmitters GABA and Gly is not only restricted
to the postsynaptic membrane however, with presynaptic GABAbRs of the auditory
brainstem  nucleus  able  to  attenuate  the  amplitude  of  postsynaptic  glycinergic
potentials  by  reducing  glycine  release  (Lim  et  al.,  2000).  On  the  other  hand
presynaptic  spinal  GlyRs  in  the  dorsal  commissural  nucleus  and  metabotropic
glutamate receptors from rat hypoglossal motoneurones have been shown to enhance
the  amplitude  and  frequency of glycinergic  postsynaptic  transmission,  respectively
(Donato and Nistri, 2000;Jeong et al., 2003).  Interestingly though, type II mGluRs
have  also  been  shown  to  reduce  the  frequency  of  glycinergic  transmission  in
mechanically  dissociated  rat  spinal  cord  neurones  (Katsurabayashi  et  al.,  2001).
Finally,  GABA  neurotransmission  is  unlikely  to  be  the  only  factor  influencing
19glycinergic neurotransmission as activation of presynaptic purinergic P2X2 receptors 
has  also  been  suggested  to  enhance  the  frequency  of  postsynaptic  glycinergic 
signalling in a Zn2+ dependent manner (Laube, 2002a).
Intracellular signalling interactions with the glycine receptor 
Besides  a  rapid  extracellular  modulation  of  glycinergic  neurotransmission 
postsynaptic  GlyR  function  can  also  be  regulated  by  a  number  of  intracellular 
processes.  One of these is phosphorylation.  The GlyR was first demonstrated to be a 
substrate  for both cAMP-dependent protein kinase  (PKA)  and protein kinase  C  in 
1990 (Song and Huang,  1990).  PKA has been shown to  significantly enhance the 
amplitude of GlyR mediated responses (Ruiz-Gomez et al.,  1991;Katsurabayashi et 
al.,  2001)  and  both  protein  tyrosine  kinases  and  calcium-calmodulin  dependent 
protein kinase II are capable of enhancing glycinergic neurotransmission (Xu et al., 
1999;Caraiscos et al., 2002).  Interestingly, the GlyR also appears capable of directly 
interacting with a G-protein py dimer, which increases the channel open probability 
in response to glycine, potentially allowing GlyR modulation by a whole host of G- 
protein coupled receptors (Yevenes et al., 2003).  Another potential contribution to 
GlyR enhancement may arise via an as yet unreported cytoplasmic factor, which can 
mediate  the  effects  of Ca2+  influx  to  increase  the  apparent  affinity  of the  GlyR 
(Fucile et al.,  2000).  These modulatory processes are presumably of physiological 
significance, though their exact role remains unreported.
GlyR subtypes: Their respective distributions, properties and functions
Isolation of  glycine receptor subtypes
The isolation of the first pure component of the glycinergic signalling pathway was 
achieved  in  1982 when Pfeiffer et al purified a glycine receptor complex  from the 
spinal  cord  using  affinity  chromatography.  The  purification,  using  a  strychnine 
derivative  bound  to  a  column,  yielded  a  protein  complex  comprising  of  three 
different molecular weights, 48 kD, 58 kD and 93 kD.  Subsequent analysis revealed 
that  the  48  kD  component  retained  properties  consistent  with  GlyRs  from  native 
tissues, namely a high affinity for the antagonist strychnine and displacement of this 
binding by three GlyR agonists, glycine, p-alanine and taurine.
20Molecular cloning of a GlyR subunit from the rat followed five years later revealing 
that  the  GlyR  al  shared  significant  sequence  homology  with  the  nAChR  family 
(Grenningloh  et  al.,  1987b)  and  the  GABAa  receptor  family  (Grenningloh  et  al., 
1987a).  Owing to the conserved presence of two cysteine residues at a fixed distance 
of  13  amino  acids  apart,  the  three  families  were  consigned  to  a  new  receptor 
superfamily  known  as  the  cys-loop  family  of ligand-gated  ion  channel  receptors 
(Karlin and Akabas,  1995).  Subsequent studies identified the human (h) GlyR al 
orthologue  and  another hGlyR variant designated  a2,  which retained  76  %  amino 
acid  sequence  identity  to  its  al  counterpart  (Fig  1.1;  Grenningloh  et  al.,  1990a). 
These  studies  were  further  complimented  when  the  rat  cDNA  sequence 
corresponding to the 58 kD protein was determined (Grenningloh et al.,  1990b) and 
later verified in human form (Handford et al., 1996).  This subunit had a significantly 
increased molecular weight and lacked the ability to bind strychnine (Pfeiffer et al., 
1982).  Unsurprisingly therefore, this protein had a lower sequence identity to the al 
subunit of 47 % and was therefore classified as GlyR p.
21hGlyRal  --- MYSFNTLR-   -LYLSGAIVFFSLAASKEAEAARSATKPMSPSDFLDKLMGRTSG    23
hGlyRa2  MNRQLVNILTALFAFFLETNHFRTAFCKDHDSRSGKQPSQTLSPSDFLDKLMGRTSG    30
hGlyRa3  -MAHVRHFRTLVSGFYFWEAALLLSLVATKETDSARSRSAPMS PSDFLDKLMGRTSG--  23
uanGlyRa4              MS PSDFLDKLMGRTSG--  16
hGlyRp  MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNIL  39
hGlyRal  ----- YDARIRPNFKGPPVNVSCNIFINSFGSIAETTMDYRVNIFLRQQWNDPRLAY-N  76
hGlyRa2A  ----- YDARIRPNFKGPPVNVTCNIFINSFGSVTETTMDYRVNIFLRQQWNDSRLAY  -   S  83
hGlyRa2B  IA -  a2B variant
hGlyRa3  ------YDARIRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAY-S  76
nnnGlyRa4  ----- YDARIRPNFKGPPVNVTCNI  FINSFGSVTETTMDYRVNVFLRQQWNDPRLAY-R  69
hGlyRP  NRLLVS  YDPRIRPNFKGIPVDVWNI  FINS  FGSIQETTMDYRVNIFLRQKWNDPRLKLPS  99
Pi-2 loop
hGlyRal  EYP-DDSLDLDPSMLDSIWKPDLFFANEKGAHFHEITTDNKLLRISRNGNVLYSIRITLT  135
hGlyRa2  EY  P- DPSLDLDPSMLDSI WKPDLFFANEKGANFHDVTTDNKLLRISKNGKVLYSIRLTLT  142
hGlyRa3  EYP-DDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLT  135
mmGlyRa4  EYP-DDSLDLNPSMLESI WKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLI  129
hGlyRp  D  FRGSDALTVD  PTMYKC  LW  KPD  L  F  FAN  E  KSANFHDVTQENILLFIFRDGDVLVSMRLSIT  158
loop A
hGlyRal  LACPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQEQGA-VQVADGLTLPQFILK-EEK  193
hGlyRa2  LSCPMDLKNFPMDVQTCTMQLESFGYTMNDLIFEWLSDGP-VQVAEGLTLPQFILK-EEK  200
hGlyRa3  LSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAP-VQVAEGLTLPQFLLK-EEK  193
xmnGlyRa4  LS  CPMDLKNFPMDIQTCTMQLES  FGYTMNDLMFEWLEDAPAVQVAEGLTLPQFILR-DEK  187
hGlyRP  LSCPLDLTLFPMDTQRCKMQLESFGYTTDDLRFIWQSGDP-VQLEK-IALPQFDIKKEDI  216
cys-loop  loop B  P8-9  loop
hGlyRal  DLRYCTKHYN-TGKFTCIEARFHLERQMGYYLIQMYIPSLLIVILSWISFWINMDAAPAR  252
hGlyRa2  ELGYCTKHYN-TGKFTCIEVKFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR  259
hGlyRa3  DLRYCTKHYN-TGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR  252
mmGlyRa4  DLGYCTKHYN-TGKFTCIEVKFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPAR  246
hGlyRp  EYGNCTKYYKGTGYYTCVEVIFTLRRQVGFYMMGVYAPTLLIWLSWLSFWINPDASAAR  276
loop C  Ml
hGlyRal  v|LG  I   IrviTMTTQBsGS  RASLPKVS  YVKAIDI  wflvCLLFVFSALLEYAAVNFVS    308
hGlyRa2  \JlG iBtvItMTT  J S G S RASLPKVSYVKAIDHMVCLLFVFAALLEYAAVNFVS  315
hGlyRa3  \^GI|TvItMTTQ|SGSRASLPKVSYVKAIDIWi J vCLLFVFSALLEYAAVNFVS    308
nanGlyRa4  V'MLGIBTVwrMTTQBSGSRASLPKVSYVKAIDIWNMVCLLFVFAALLEYAAVNFVS    302
hGlyRP  V§LGl|svfSLASE§TTLAAELPKVSYVKALDVWLjACLLFGFASLVEYAVVQVMLNNPK  336
M2  M2-3  loop  M3
hGlyRal  RQHKELLRFRRKRRHHKSPMLNLFQ------ EDEAGEGRFNFSAYGMGPACLQAKD    358
hGlyRa2  RQHKEFLRLRRRQKRQNKE-------------EDVTRESRFNFSGYGMG  -   HCLQVKD    358
hGlyRa3  RQHKELLRFRRKRKNK§EAFALEKF^RFfp3MDDEVRE|RFSFTAYGMGP-CLQAKD    363
mmGlyRa4  RQHKE  FMRLRRRQRRQRME-------------EDI  IRESRFYFRGYGLG-HCLQARD    345
hGlyRP  RVEAEKARIAKAEQADGKG-------------GNVAKKNTVNGTGTPVHISTLQVGETRCK 384
INTRACELLULAR M3-4 DOMAIN
hGlyRal    GISVKGANNSNTTNPPPAPSKSPEEMRK 986
hGlyRa2  --------------------------------- GTAVKATP  -   AN  -   PLPQPP—   KDGDAIKK |82
hGlyRa3  --------------------------------- GMTPKGPNHPVQVMP  KSPDEMRK  $96
mmGlyRa4  ------ gephyrin binding site  GGPMEGSS  -1YSPQPPTPLLKEGETMRK 374
hGlyRp  KVCTSKSDLRSNDFSIVGSLPRDFELSNYDCYGKPIEVNNGLGKSQAKNN— KKPPPAKP  442
hGlyRal  LFIQRAKKIDKISRIGFPMAFLIFNMFYWIIYKIVRREDVHNQ    429
hGlyRa2  KFVDRAKRIDTISRAAFPLAFLIFNIFYWITYKIIRHEDVHKK    425
hGlyRa3  VFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHHQQQD  432
xmnGlyRa4  LYVDRAKRIDTISRAVFPFTFLVFNIFYWWYKVLRSEDIHQAL--   408
hGlyRp  VIPTAAKRIDLYARALFPFCFLFFNVIYWSIYL-------------   47  5
M4
22Figure 1.1  GlyR family amino acid alignment.  From the beginning the domains 
are;  signal  peptide,  which  is  cleaved  from  the  mature  protein  (aquamarine), 
extracellular  domain  and  extracellular  M2-3  loop  (black),  transmembrane  helices 
(blue) and intracellular M l-2 and M3-4 domains (green).  The regions and individual 
amino acids attributed with aspects of receptor function are highlighted as follows: 
agonist  binding  (purple),  gating  (red  -  with  the  exception  of the  GlyR  P  subunit 
gephyrin binding domain, which is labelled), splice variations (yellow background), 
picrotoxin  potency  (red  background),  alcohol  and  anaesthetic  potency  (green 
background),  the  proposed  channel  gate  (grey  background),  GlyR  a3 
phosphorylation  residues  (light  blue  background).  See  also  Table  1.1  for  a more 
detailed breakdown on transmembrane domain residue functions.
With  the  rapid  rise  of molecular cloning techniques  two  further receptor  subtypes 
have  since  been  reported,  GlyR  a3  from  rats  and  humans  (Kuhse  et  al., 
1990a;Nikolic et al.,  1998) and GlyR a4 from mouse (Harvey et al., 2000).  Of the 
four a and the single P genes now discovered GlyR al  - 3 have all been shown to 
express themselves in two alternative splice variant forms (Fig  1.1).  GlyR al  and 
a3 both exhibit variation in the form of an extra exon either presenter absent, from 
the transmembrane (M) 3 -4  intracellular loop of the protein and are thus referred to 
as short (S) or long (L) variants (Malosio  et  al.,  1991b;Nikolic  et al.,  1998).  The 
GlyR a2 gene, by contrast, carries two alternate versions of exon 3 identified in rat, 
which result in a section of the N-terminus being expressed in two possible  forms 
that differ by a divergent dual amino acid substitution (Kuhse et al., 1991b).  Though 
the specific requirement within an organism for all five of these GlyR subunits is not 
known, this diversity is extended outside the mammalian lineage to the zebrafish, a 
teleost,  suggesting  maintenance  of these  divergent  orthologues  is  physiologically 
significant (Imboden et al., 2001).
Glycine receptor al - The rapid responder
An  obvious  question  with  regard  to  the  apparent  complexity  of  variable  GlyR
subtypes  is what  functional  consequences  this might have on the organism.  Such
information  has  been  obtained  by  identifying  distinct  receptor  expression  patterns
and  unique  functional  properties  as  well  as  by  discovering  naturally  occurring
receptor mutations and evaluating the consequences of artificially manipulating these
receptors  in  vivo.  The  role  of the  GlyR  al  subunit  is  clearly a critical  one with
23several naturally occurring mutations being responsible for the genetic condition of 
hyperekplexia (Zhou et al., 2002;Lynch, 2004).  The broad expression pattern of this 
subunit within the spinal cord and certain brain regions (Malosio et al., 1991a) along 
with  the  absence  to  date  of  naturally  occurring  mutations  in  any  of  the  other 
a  subunits,  suggests  that  GlyR  al  may be  the predominant  functional  isoform  in 
mammals.  Furthermore,  the  auxiliary  nature  of  the  p  subunit  and  its  almost 
ubiquitous expression throughout the central nervous system suggests this variant is 
unlikely to be able, by itself, to confer functional specificity.  However, despite these 
observations recent evidence does point to specific roles for the other a subunits in 
vivo.
Several  studies have suggested there is a developmental switch around the time of 
birth from an embryonic expression pattern where GlyR a l and a4 predominate to 
the predominant postnatal forms, GlyR al  and a3.  This raises the possibility that 
differing receptor isoforms may perform specific roles during development.  These 
initial  studies were collated  from  RNA  in  situ  hybridisation  experiments  on  GlyR 
a 1-3  (Malosio  et al.,  1991a;Watanabe and Akagi,  1995) and protein quantification 
comparing the relative amounts of the 48 kD (al) and 49 kD (a2) species (Becker et 
al.,  1988) during development.  However, further support was also obtained from a 
functional  study by Takahashi  et  al,  (1992)  where  single channel  studies  revealed 
distinct distributions of amplitudes and open times for recombinant rat GlyR al  and 
a2, which correlated with those recorded from native GlyRs in the juvenile PI6 and 
embryonic  El8  rat,  respectively.  These  observations  were  tentatively  linked  to  a 
shift  in  the  kinetics  of evoked  IPSCs  with  embryonic  tissues  exhibiting  a  more 
diffuse  IPSC  that  displayed  slower  rates  of onset  and  offset  compared  to  evoked 
IPSCs in more mature tissues.  This may mean that the embryonic GlyR a2 is not as 
suited to the rapid response dynamics required for receptors positioned at the synapse 
(Mangin  et  al.,  2003)  and  therefore  during  post-natal  development,  where  the 
organism requires more precise and rapid movement, the spinal cord up regulates to 
the more rapidly responsive GlyR a l.  Another prime example of the requirement for 
a highly coordinated and rapid signalling complex is provided by the central auditory 
system, a system which receives a strong regulatory control from GlyRs and where 
GlyR al  is not  expressed until birth when it undergoes rapid up regulation at the
24protein  level  according to  immunostaining with a selective al  antibody (mAb  2b) 
(Kungel and Friauf, 1997).
A recent study by Mangin et al  (2003) analysing recombinant GlyR a2 in a synaptic 
context, by rapidly applying brief 1   ms pulses of Gly to macropatches, revealed that 
even at  1   mM concentrations, GlyR a2 was only able to activate minimally within 
this time scale.  This suggested that the GlyR a2 subtype is not capable of supporting 
rapid  transmission  at  synapses  and  indeed  may  not  be  localised  to  the  synapse. 
Though the slow activation kinetics of GlyR a2 makes this receptor unsuitable for 
dynamic  synaptic  integration  it  is  unlikely  that  the  GlyR  a2  subunit  is  entirely 
extrasynaptic.  Takahashi  et  al  (1992)  electrically  evoked  glycinergic  IPSCs, 
presumed to be mediated by a2 receptors, in embryonic tissue.  Even as early as El6, 
acute recordings from the rat dorsal root exhibited glycinergic synaptic activity (Wu 
et al., 1992).  Furthermore rat spinal cord cultures, that are known to undergo only a 
minimal  transition  from  the  a2  to  al  subtype  during  maturation  (Hoch  et  al., 
1989;Hoch  et  al.,  1992),  still  exhibit  robust  synaptic  activity (Bloomenthal  et  al., 
1994;Laube,  2002a).  The  auxiliary  P-subunit  is, however, highly expressed  during 
culture maturation and this subunit is also an important anchoring protein to ensure 
efficient expression of GlyRs (Moss and  Smart, 2001).  In certain systems  such as 
the  basolateral  amygdala  the  receptor  subtype  is  predominantly  a2  and  its 
pharmacology is mostly in keeping with expression as an a2p heteromer (McCool 
and  Farroni,  2001).  Thus  it  may be  that  the  P  subunit  can  co  assemble  with  a l 
receptors and increase their activation kinetics (unfortunately not tested by Mangin et 
al.,  2003)  sufficiently  to  be  operable  at  the  synapse,  though  probably  still  less 
responsive than the GlyR al (Takahashi et al., 1992).
Glycine receptor a2 - The developmental subunit
Any  advantage  that  the  GlyR  al  subunit  offers  over  a2  in  mature  tissues  must 
presumably be complimented by a beneficial effect conferred by a l receptors in the 
embryo.  With  regards  to  the  proposed  suitability  of GlyR  al  to  extrasynaptic 
localisation  at  embryonic  stages  this may indeed have important consequences  for 
neuronal  development in response to  tonic  stimuli.  The presence of extrasynaptic
25GlyRs  in  cortical  plate  neurons  during  embryonic  development  has  been 
electrophysiologically validated in the neocortex with taurine the most likely agonist 
responsible  (Flint  et  al.,  1998).  A  subsequent  study  combining  RT-PCR  and 
electrophysiology confirmed  these  cortical  receptors  to  be  GlyR al  (Okabe  et  al., 
2004).  Previously, taurine deprivation of kittens in utero has been shown to cause an 
apparent disruption of normal cortical migration and differentiation (Sturman,  1986), 
in accord with a developmental role for GlyRs.  Indeed, taurine acting via GlyR al 
encourages  differentiation  of  precursor  cells  into  rod  photoreceptors  in  retinal 
cultures (Young and Cepko, 2004).  Developmental regulation by GlyR a l subunits 
may also potentially be fine tuned by varying the relative expression of the two al 
receptor splice variants, which exhibit a 4-fold variation in their sensitivity to taurine 
regardless  of co-expression  with  the  p  subunit  (Miller  et  al.,  2004).  This  is  a 
particularly tantalising hypothesis as neurones possess two genes encoding NOVA-1 
and 2 spread across the spinal cord and brain, which have the capacity to control the 
relative ratios of receptor splice variants, including GlyR a2A and 2B (Jensen et al., 
2000;Ule et al., 2003).
Although  GlyR  a l  is the predominant receptor during  embryogenesis  it  may also 
play some specialised roles  in  adult tissues.  Though the receptor subtype has not 
been validated, non synaptic GlyR mediated tonic noise, a role seemingly suited to 
GlyR  a l,  has  been  demonstrated  in  the  postnatal  hippocampus  from  P7  onwards 
(Mori et al., 2002).  Additionally, RT-PCR studies in the amygdala demonstrate that 
GlyR a l  is  the predominant  GlyR  in  this  adult preparation  (McCool  and  Farroni, 
2001).  Thus  it  would  appear that  GlyR  a l  can  remain  in  certain  adult  tissues,  a 
suggestion supported by the identification of GlyR al transcripts that are retained at 
least until juvenile stages of rat spinal cord progression (Jensen et al., 2000).
Glycine receptor a3 -  The bearer of  great pain
The expression pattern of GlyR a3 is highly localised using in situ hybridisation and
Northern  blot  studies  detecting  mRNA  transcripts  in  adults  at  low  levels  in  the
cerebellum,  frontal  lobe, temporal  lobe and putamen and no evidence of a3  in the
spinal cord (Malosio et al.,  1991a;Nikolic et al.,  1998).  Two further non-functional
studies  have both revealed  that  GlyR a3  is also  localised to  the adult mammalian
26retina  (Greferath  et  al.,  1994;Haverkamp  et  al.,  2003).  It  has  a  distinct  staining 
pattern  from  the  al  subunit  suggesting  that  a3  may  mediate  specific  retinal 
pathways in vivo, though this function can be compensated by apparent up regulation 
of other GlyR subunits in the a3 knockout animal (Haverkamp et al., 2003).  Of most 
significance  though  is  a  recent  study  demonstrating  that  despite  previous  mRNA 
studies (Nikolic et al.,  1998) GlyR a3  is in fact expressed at the protein level in a 
highly localised manner in  spinal  cord lamina II of the dorsal hom (Harvey et al., 
2004).  This  region  plays  an  important  role  in  mediating  inflammatory  pain  and 
allodynia (Basbaum,  1999).  GlyR a3, which retains a unique serine residue in the 
intracellular  domain,  underwent  phosphorylation  in  response  to  activation  of the 
PGE2  signalling  cascade  and  the  a3  mediated  inhibitory  input  was  subsequently 
attenuated (Harvey et al., 2004).  GlyR a3 knockout mice retained significant GlyR 
mediated IPSC input at lamina II but failed to down regulate the inhibitory input in 
response  to  PGE2  mediation  with  the  result  that  these  mice  were  resistant  to 
inflammatory pain when the PGE2 pathway is activated (Harvey et al., 2004).  This 
pain-induced  pathway was  shown  in  a previous  overlapping  study to  be  selective 
specifically to the prostaglandin PGE2 (Ahmadi et al., 2002).  Another study, which 
interfered with anionic homeostasis in nearby lamina I also supports the importance 
of inhibitory input into the dorsal hom for responsiveness to neuropathic pain (Coull 
et  al.,  2003).  Thus  it  would  appear  that  there  is  a  specific  role  for  GlyR  a3  in 
mammals  and  this  role  cannot  easily  be  compensated  for  by  other  ligand-gated 
receptors.
Glycine receptor a4 - The enigma
The  a4  subunit  has,  as  yet,  received  only  an  elementary  functional  analysis 
demonstrating  that  the  recombinant  homomer  bears  similarity  with  al  GlyRs 
(Harvey  et  al.,  2000).  The  same  study  went  on  to  show  with  mRNA  in  situ 
hybridisation  that  this  receptor  has  an  embryonic  distribution  akin  to  a2  and  is 
localised primarily to the spinal cord and sympathetic neurones, as well as the testis, 
suggesting it may contribute to the development of sensory and motor pathways.
27Gephyrin and the glycine receptor /3-subunit
Evidence to support a specific functional role for the p-subunit in GlyR physiology 
currently  revolve  around  its  ability  to  interact  with  a  synaptic  anchoring  protein 
called gephyrin allowing the p  subunit to selectively target ap  GlyR heteromers to 
inhibitory synapses (Meyer et al., 1995;Kneussel et al., 1999;Moss and Smart, 2001). 
When  the  GlyR  was  initially  isolated,  it  was  part  of  a  complex  featuring  a 
cytoplasmic  protein  component  with  mass  93  kD  (Pfeiffer  et  al.,  1982).  This 
component, named gephyrin, was found to exist in at least 5 different splice variant 
mRNA products in the brain (Prior et al.,  1992) though 7 have now been detected in 
the  spinal  cord  (Meier et al., 2000)  and  10 neuronal  iso forms have been  found in 
humans (Rees et al., 2003).  Even more may exist in both neuronal and non-neuronal 
tissues  since  8  of its  29  exons  so  far  verified  from  cDNA  sequencing,  have  the 
potential to generate splice variants (Ramming et al., 2000).  As suggested from the 
potential wide array of variant isoforms, expression analysis of gephyrin transcripts 
reveals a tissue distribution far beyond that of the GlyR (Prior et al., 1992;Kirsch and 
Betz,  1993;Ramming et al., 2000).  This is in agreement with proposed additional 
roles  for gephyrin  in molybdoenzyme activity in non-neuronal  tissues  (Feng et al.,
1998)  and providing a critical interaction with RAFT1  (rapamycin and FKP12 target 
1) for rapamycin immunosuppressant mediated signalling (Sabatini et al.,  1999). 
Also of interest, expression of the p subunit in aP heteromers halves single channel 
conductance (Bormann et al.,  1993) and reduces sensitivity to picrotoxin (Pribilla et 
al., 1992), though this has not yet been attributed with any functional significance. 
Kinetics and desensitisation 
Kinetics
Studies of the kinetics of ion channels usually either attempt to measure parameters 
of burst openings, closures and conductance states using single channel recordings, 
or to  evaluate  the rates  of current  onset  and offset when  using ultrafast perfusion 
systems on small receptor populations in macropatches.  The first kinetic studies on 
GlyRs  utilised  single  channel  studies  from  neuronal  systems  owing to  the  lack  of 
ultrafast  perfusion  techniques  and  molecular  cloning  strategies  available  to  attain 
pure  GlyR  populations  of receptors.  These  early  studies  focused  on  the  channel 
conductance and revealed that GlyRs could adopt a number of different conductance 
states, always at least two, and though there was a large variation in the sizes of the
28conductance states due to variations in holding potentials and driving forces the most 
commonly occurring conductance state was generally the largest, in the range 80 - 
90  pS  (Hamill  et al.,  1983;Bormann  et  al.,  1987;Twyman  and  Macdonald,  1991). 
Although these studies used spinal cord neurones, multiple conductance states with 
the  predominant  one  being  the  largest  have  now  been  obtained  in  recombinant 
systems  (Takahashi  et  al.,  1992;Grewer,  1999;Lewis  et  al.,  2003;Beato  et  al., 
2002;Beato et al., 2004).  Intriguingly, the most recent and thorough studies to date 
suggests  that  multiple  conductance  states  are  far less prolific  in pure recombinant 
populations,  with the  largest conductance being predominant  for over 80 % of all 
channel  openings  and  the  second  smaller  conductance  state  being  rarely  visited 
(Beato et al., 2002;Beato et al., 2004;Lewis et al., 2003).  Thus, variable conductance 
states might primarily reflect receptor heterogeneity in native tissue.
The  first  quantitative  single  channel  study  to  attempt  to  elucidate  an  activation 
scheme  for  spinal  cord  GlyRs  using  open-shut  time  durations  within  bursts  was 
carried  out  by  Twyman  and  Macdonald  (1991).  This  study,  using  low  agonist 
concentrations,  revealed  three  different  mean  open  times  within  bursts,  an 
observation  reproduced  in  rat  spinal  cord  slices  and  in  zebrafish  homomeric  al 
receptors (Takahashi et al.,  1992;Fucile et al.,  1999).  Furthermore, for both rat and 
zebrafish GlyRs, the mean open time durations remained the same but the frequency 
of the  longer burst  duration  relative  to  the  shortest  burst  duration  increased  with 
increasing  glycine  concentrations  (Twyman  and  Macdonald,  1991;Fucile  et  al.,
1999).  Recently, an extra very short open-time duration, has been revealed for the 
homomeric GlyR al  (Beato et al., 2002).  In addition, only the frequency of channel 
openings again increased with agonist concentration with unchanged mean open time 
durations  over  a  30-fold  concentration  range.  This  property  is  consistent  with  a 
kinetic  scheme  where  each  individual  liganded  state  switches  between  open  and 
closed but the open states are discrete, i.e. a sequential binding model (Fig 1.2).
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Figure 1.2  Kinetic schemes of GlyR activation.  A, The simplest Markov model of 
receptor activation, which assumes that either there is only one activated state (AR*) 
for the receptop or that all activated states are equivalent (AR represents the bound 
inactive  state).  B,  A  sequential  binding  model,  which  assumes  that  different 
numbers of agonist molecules bound to a receptor induce discrete activation states, 
reflected  in single channel  recordings by distributions composed of multiple open 
durations.  C,  The  complex  sequential  binding  model  (Beato  et  al,  2004)  where 
activation  states  with  the  same  number  of  agonists  bound  are  not  necessarily 
phenotypically  equivalent,  dependent  on  the  positions  of the  sites  occupied  by 
agonist.  This  suggests  that  the receptor displays  allostery i.e.  that binding of an 
agonist  molecule  may influence  the  affinity of subsequent  binding events.  D,  A 
modified  Markov  model  with  one  activation  state  and  two  desensitised  states  as 
proposed  for GlyR a2 by Mangin et al,  2003.  AD!  represents a fast desensitised 
state that can occur before the receptor activates and is dependent on a receptor with 
a  low  number  of agonist  molecules  bound,  while  AD2  represents  the  standard 
desensitisation that the GlyR may undergo after activation.  Note that desensitised 
states were not included in the other schemes as this process is poorly understand 
and cannot be accurately accounted for in these schemes.
30To date an in depth single channel study to elucidate the activation mechanism of the 
more  physiological  heteromeric  ap  GlyR  has  not  been  reported,  but  such  a 
mechanism is now available for al  homomers (Beato et al., 2004).  In the presence 
of a range of glycine concentrations from 10 pM to a saturating 1000 pM dose, open 
and shut time distributions from within bursts revealed that this data could best be 
explained by a cooperative model  favouring up to three agonist binding events per 
receptor  to  achieve  maximal  activation.  This  model  assumes  that  initially  the 
binding sites are equivalent, the obvious assumption for a homopentamer.  Then with 
each  agonist  binding  event,  the  efficacy  for  receptor  activation  increased  from 
approximately 0.4 to 8 to 40 for 1, 2 and 3 agonist molecules bound with no further 
increase upon binding of 4 or 5 agonist molecules.  This model was considered from 
the perspective of both a linear sequential binding model where the positions of the 
subunits  bound  by  agonist  do  not  matter  and  from  a  situation  where  the  subunit 
selected for the second binding step does matter, though both models provided good 
fits to the data (Fig 1.2).  At a saturating application of glycine, with an E value of 40 
the P0 is 0.98, suggesting glycine is an efficient agonist activating 98 % of a receptor 
population  or  keeping  a  single  channel  open  for  98  %  of its  burst  duration.  Of 
particular  interest,  this  model  required  a  certain  degree  of agonist  cooperativity, 
which the authors suggest is best suited by the initial singly liganded state causing an 
effect on the binding affinity of subsequent binding events but not necessarily the 
second binding event affecting the third.  Though it was not possible to determine the 
exact nature of any allostery even whether it was positive, or negative,depending on 
where and how the agonists bind, this study is important as it supports cooperativity 
in  GlyRs  and  suggests  3  agonist  bindings  are  maximally  efficacious  for 
homopentameric receptors.  It should be noted that prior studies assessing the kinetic 
scheme  for  GlyR  al  activation  applied  a  sequential  kinetic  model  where  there  is 
effectively just one  activation  state (a Markov model;  Fig  1.2) to  simplify matters 
(Walstrom  and  Hess,  1994;Grewer,  1999;Laube  et  al.,  2000).  However  both 
Twyman and Macdonald, (1991) and Beato et al, (2002 and 2004), demonstrated that 
the  GlyR  clearly  contains  3  distinct  open  states  representative  of  a  sequential 
activation model.  Additionally, studies using exponential curve fits of current onsets 
in  response  to  ultrafast  drug  applications  are  unlikely  to  be  able  to  attain  the 
resolution necessary to predict all the exponential components within the rising phase
31of the  macroscopic  activation,  particularly the  fastest  component  (Grewer,  1999). 
Therefore the study of Beato et al  (2004) is to date the highest temporal resolution 
study addressing the activation dynamics of the GlyR.
This activation mechanism may provide a guide for the GlyR <*P heteromer as the 
a subunit is thought to directly bind the agonist and so it is possible that the binding 
sites could remain equivalent.  Current studies to elucidate a kinetic model  for the 
heteromeric GlyR have resulted in the proposal of a model with two open states and 
a  reluctant  gating  step  (Legendre,  1998).  This  proposal,  which  adopted  ultrafast 
macroscopic  perfusion  techniques  to  record  from  M-cells  in  zebrafish  that 
predominantly  express  ap  heteromers  (Legendre,  1997)  will,  however,  be  an 
oversimplification  as  single  channel  studies  on  presumed  ap  heteromers  has 
previously  revealed  that  3  separate  open  states  exist  (Twyman  and  Macdonald, 
1991).  Certainly, from a macroscopic point of view, the evidence suggests that the 
p subunit does not affect activation; or inactivation rates, with these two parameters 
remaining comparable for al homomers and ap heteromers using ultrafast perfusion 
studies  on  macropatches  (Mohammadi  et  al.,  2003).  This  is  also  supported  by 
comparisons  of  recombinant  al  single  channel  burst  durations,  which  when 
summated  could  be  directly  overlaid  with  presumed  ap  native  receptor  IPSCs 
(Takahashi et al., 1992;Legendre, 1998).
Kinetic experiments have also recently been carried out to compare the mechanism 
of action elicited by the three primary GlyR agonists, glycine, p-alanine and taurine 
using both ultra-fast perfusion techniques and single-channel analysis (Lewis et al.,
2003).  These studies, on GlyR al homomers, also revealed three distinct open states 
that were distinguishable for all three agonists.  Whilst the open time durations and 
amplitudes  did  not  vary between  the  agonists  the  closed  time  durations  did  vary. 
This  was  reflected  in  the  ultrafast  macroscopic  currents  by  slower  activation  and 
faster relaxation rates of currents  evoked by saturating concentrations of p-alanine 
and  taurine  compared  to  glycine.  As  the  mean  open  time  durations,  a  direct 
reflection  of the  closing  rate,  did  not  differ,  this  suggested  that  the  closing  rate 
constants represented an intrinsic property of the receptor.  In addition to this relative
32estimates of the agonist efficacies were obtained with glycine, P-alanine and taurine 
having E values of 16, 8 and 3.4.
As has been previously mentioned an ultrafast perfusion study carried out on GlyR 
a2 revealed that this receptor exhibits a slower activation rate compared to studies on 
al  (Takahashi  et  al.,  1992;Legendre,  1998;Mangin  et  al.,  2003).  In  addition the 
relaxation and  desensitisation rates were also  slower and,  of particular interest,  an 
estimate  of glycine  efficacy at  the  GlyR  a2  revealed  a high  value  of 200,  5-fold 
higher than that for GlyR al  (Lewis et al., 2003;Beato et al., 2004).  This suggests 
that al and a l have significant differences in terms of their kinetics, a fact supported 
by the  delayed  GlyR a2  channel  openings  after exposure to  agonists,  which were 
suggested  to  represent  transitions  between  a  ligand  bound-closed  state  and  a 
desensitised  closed  state prior to  channel  opening  (Fig  1.2;  Mangin  et  al.,  2003). 
This  delayed  opening,  which  occurred  at  low  agonist  concentrations  suggesting  it 
represented low-level liganded receptors, was absent at a saturating concentration of 
agonist,  presumably  due  to  multiple  agonist  binding  events  occurring  before  the 
receptor  could  desensitise.  Thus  in  this  higher  liganded  state  the  receptor would 
always open (Mangin et al., 2003).
Desensitisation
The  reason  and  mechanism  for receptor  desensitisation  remains  enigmatic.  Most 
studies  show  that  desensitisation  consists  of  two  components  at  high  glycine 
concentrations but just one component at lower agonist concentrations (Mohammadi 
et al., 2003).  A proposed physiological role for GlyR desensitisation has so far been 
suggested  to  be  unlikely with  the  time  course  of both  desensitisation  components 
being too  slow  to  impact on  IPSC  kinetics.  Even with  rapid re-stimulation  using 
ultrafast  perfusion  techniques  akin  to  a  train  of  GlyR  IPSCs,  no  paired-pulse 
desensitisation is observed (Legendre, 1998;Lewis et al., 2003).  This is in contrast to 
certain GABAa receptor subtypes and nAChRs which exhibit much more rapid rates 
of  desensitisation  capable  of  influencing  physiological  functions  (Burkat  et  al., 
2001;Pidoplichko  et al.,  1997).  Studies to recreate recombinant GlyR populations 
more representative of their neuronal counterparts have shown that incorporation of 
the  p  subunit  does  cause  a  significant  increase  in  the  rate  of  desensitisation
33(Mohammadi  et  al.,  2003)  as  does  inducing  the  clustering  of  receptors  using 
gephyrin (Legendre et al., 2002) raising the possibility that this process could have 
some impact physiologically.
Structure-Function studies
General topology
The general topology of the GlyR was originally predicted using hydropathy analysis 
and was placed in the context of a common general architecture shared by all cys- 
loop ligand-gated ion channels.  The a and p subunits contain approximately 420 and 
470 amino acids respectively.  Starting from the N-terminus the structures comprise a 
large  extracellular  domain  of  around  200  -   250  residues,  four  transmembrane 
domains  (M1-M4)  and  a sizable  80 -   100  amino  acid  intracellular  loop  between 
M3-M4  (Fig  1.1;  Grenningloh  et  al.,  1987b).  Also  consistent  with  the  proposed 
quaternary  structure  of  other  cys-loop  receptors,  the  GlyR  is  predicted  to  co- 
assemble  into  a pentamer.  This was  initially based on sedimentation analysis and 
treatment with chemical cross-linking reagents.  The molecular weight measured was 
260, 000, which is best accounted for by the inclusion of three 48 kD a subunits and 
two 58 kD P-subunits into the pentamer (Langosch et al., 1988).  Evidence in support 
of  this  general  tertiary  and  quaternary  topology  is  based  on  medium  and  high 
resolution electron micrographs at 9A, 4.6A and 4A levels of whole Torpedo nAChRs 
(Miyazawa  et  al.,  1999;Miyazawa  et  al.,  2003;Unwin,  1993;Unwin,  1995).  Here 
globular centres of electron density based around a pseudo 5-fold axis of symmetry 
were  observed  corresponding  to  the  five  extracellular  domains  of  the  receptor 
pentamer.  This  perimeter allowed  for the presence  of a  large central  water  filled 
vestibule, through which ions could easily gain access to the extracellular side of the 
membrane lining ion channel.  In each subunit, 4 predicted a-helical transmembrane 
domains could also be distinguished as well as a globular intracellular domain.  The 
intracellular  domains  appeared  to  link  together  to  form  a  basin  such  that  ionic 
conductance was proposed to occur via pores present at the side interfaces between 
each of the subunits (Fig 1.3).  The great challenge for structure-function studies is to 
decipher  how  this  general  topological  representation  encodes  for  the  principal 
functional  properties  of  agonist  binding,  receptor  activation,  modulation 
desensitisation, ion conductance and selectivity.
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Figure  1.3  Representative model  of the monomeric  (.A)  and pentameric  (B) 
GlyR.  A, Each subunit consists of an N-terminal extracellular domain (ECD) of 
approximately 200 - 250 amino acids, four transmembrane regions (M1-M4) of 
approximately  20  amino  acids,  and  two  intracellular  loops,  Ml-M2 
(approximately  10  amino  acids)  and  M3-M4  (approximately  80  -  100  amino 
acids).  B,  Each  monomer co-assembles  into  a  functional pentameric receptor. 
The pentamer draws together the five M2 domains into the interior of the protein 
at the level of the membrane to form a functional gate and channel to control ion 
influ^ or  efflux.  The  most  likely  routes  for  ion  entry  and  exit  through  the 
solution  exposed  components  of  the  GlyR  are  via  the  large  extracellular 
vestibule,  and  on  the  intracellular  side,  via  gaps  between  the  subunit  side 
interfaces (marked by arrows).
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35The agonist binding site
Preliminary  experiments  to  isolate  the  important  protein  determinants  of agonist 
binding used the technique of peptide mapping in conjunction with [3H]strychnine. 
The  assumption  made  in  these  experiments  was  that  glycine  and  the competitive 
antagonist strychnine bind to the same part of the receptor.  Modelling studies reveal 
that despite the obvious structural disparity between these two compounds they do 
share a common element allowing them to potentially interact with some of the same 
binding site residues (Fig 1.4, Aprison et al.,  1987).  Moreover [3H]strychnine was 
able to displace glycine binding (Young and Snyder,  1973).  Focusing on the ligand 
binding a-subunit, covalent incorporation of [3H]strychnine occurred between amino 
acids 170 and 220 of the N-terminal extracellular domain (Graham et al., 1983;Ruiz- 
Gomez  et  al.,  1990).  Subsequent  site-directed  mutagenesis  studies,  targeting 
residues in and neighbouring this region, identified two discrete domains that were 
able to influence the potency and selectivity of the agonist binding site.
Strychnine
Glycine
Figure  1.4  Chemical  groups  present  in  glycine  and  strychnine, 
highlighting the structural similarity of glycine (red) with one subsection of 
the strychnine molecule (blue), which might explain the ability of strychnine 
to act as a competitive antagonist at the GlyR.
36In the first discrete motif, subsequently termed loop B, substitution of GlyR al G160 
and  Y161  with  Glu  and  Ala  mutations  respectively,  produced  receptors  with 
substantially  reduced  sensitivity  to  strychnine  (Vandenberg  et  al.,  1992a).  An 
equivalent  G167E  substitution  in  al  generated  a  receptor  with  a  dramatically 
reduced  glycine  and  strychnine  potencies  (Kuhse  et  al.,  1990b).  It  was  also 
demonstrated  that  introduction  of  conserved  equivalents  from  the  GABAaR,  to 
create  GlyR  al  F159Y  and  Y161F  mutated  subunits,  shifted  the  relative  order of 
agonist potencies  from;  glycine >  P-alanine > taurine  for the wild-type receptor to 
one  where  p-alanine  was  most  potent  and  the  GABA  potency was  also  enhanced 
(Schmieden et al.,  1993).  This suggested that these three agonists bind to a common 
site,  as  was  already  suspected  from  their  common  structural  determinants. 
Furthermore  the  ability of FI59  and  Y161  to  determine  agonist  selectivity makes 
these residues  ideal candidates to  face into the agonist-binding site.  In accordance 
with  this  hypothesis,  which  infers that  G160  may instead be acting as  a structural 
linker, introduction of a more conserved alanine instead of a glutamate at G160 does 
not  significantly  alter  glycine/ or  strychnine, potency  (Vandenberg  et  al.,  1992a). 
Additionally, though substantial perturbation of this FGY motif reduces the potency 
of strychnine, the more subtle F159Y and Y161F mutations do not, suggesting this 
domain  can  influence  strychnine  binding  but  not  to  the  same  degree  as  for  the 
agonists (Schmieden et al., 1993).
The  second  discrete  domain,  termed  loop  C,  encompasses  residues  between  GlyR 
al, Cl98 and C209, a cys-loop bridge domain unique to GlyRs.  This is not the same 
as  the  absolutely conserved  cys-loop  present  in  all  cys-loop  ligand-gated  receptors 
(Fig  1.1  -  discussed  later).  Replacement  of either  of the  bridging  residues  with 
chemically  similar  serines  produced  non-functional  receptors.  Thus, the  unique 
ability of cysteine residues to form a disulphide bridge in this region would appear to 
be critical for receptor function (Rajendra et al., 1995b).  The introduction of alanine 
residues at the even numbered positions K200, Y202 and T204 severely attenuated 
agonist  and  antagonist binding.  Substitution  of K200  reduced  strychnine binding, 
perturbation of Y202 reduced strychnine and glycine binding, and mutation of T204 
selectively  reduced  glycine  potency  (Vandenberg  et  al.,  1992b;Rajendra  et  al., 
1995b).  In addition to this, chemical evaluation of the candidate residues labelled by
37[3H]strychnine  identified  two  potential  tyrosines  as  prime  candidates,  Y197  and 
Y202.  As disruption of Y197 does not affect strychnine potency (Vandenberg et al., 
1992b)  this  strengthens  the  supposition  that  the  loop  including  Y202  is physically 
capable of ligand binding (Ruiz-Gomez et al.,  1990).  Also of interest is the pattern 
of disruption with only alternate mutations between Cl98 and the potential ‘kinking’ 
residue G205 affecting agonist and antagonist potency.  This is consistent with a (3- 
strand orientation for these residues.
Though  [3H]strychnine  covalently  labelled  residues  in the  region  al  170 -  220,  a 
third and final loop, positioned earlier on in the primary sequence and so termed loop 
A, has also been implicated in agonist binding.  This region spans from 193 to G105 
in the GlyR al  subunit and the individual residue substitutions,  193A, A101H and 
N102A,  caused reductions in glycine potency (Vafa et al.,  1999).  Furthermore the 
most significant reductions in agonist potency, involving substitutions of A101  and 
N102  did  not  reduce  the  maximal  currents  of the  lower  potency  agonist  taurine, 
suggesting this effect was selective to binding, not gating.  The potency of strychnine 
was  only moderately reduced  suggesting this  loop participates primarily in  agonist 
binding.  A  follow-up  study also  demonstrated  that  an N102C  mutant  exhibited  a 
drastically reduced agonist potency.  However an A101C mutation failed to attenuate 
agonist  potency and  instead  cysteine  substitution  of the  opposing  neighbour El03 
induced a disruptive effect on receptor function (Han et al., 2001).  This suggests that 
N102 is the primary binding residue in this loop.  In the case of 193, a mutation to 
cysteine  was  not  tested,  but  the  previously  reported  I93A  mutation  also  reduced 
agonist  maximal  currents  suggesting this  residue  may be  exerting  other  secondary 
effects rather than being engaged in agonist binding (Vafa et al., 1999).
To  further  strengthen  the  role  of  loops  A-C  in  agonist  binding,  there  is  good 
agreement  between  the  GlyR  studies  and  those  carried  out  on  other  cys-loop 
receptors,  most  notably the  GABAaR  and  the  nAChR.  Identified  residues  in  the 
Torpedo nAChR al  subunit loop B include W149 and Y151, which align perfectly 
with  GlyR  al  FI59  and  Y161.  In  loop  C,  prime  binding  site  candidates  for the 
nAChR al  include Y190, Cl92 and Cl93, which are analagous to GlyR al  K200, 
Y202 and T204, (Fig 1.5).  These five nAChR residues can all be covalently tagged
38in response to photoaffinity labelling with the competitive antagonist (N,N-dimethyl) 
aminobenzenediazonium  fluoroborate  (DDF)  (Dennis  et  al.,  1988;Galzi  et  al., 
1990;Galzi  et  al.,  1991a).  In  the  case  of the  GABAaR  p  subunit,  comparable 
residues Y157 and T160 from loop B and T202 and Y205 from loop C also exhibit 
properties consistent with roles in ligand binding (Fig 1.5; Amin and Weiss,  1993). 
Finally, regarding loop A, the GlyR al  N102 may play a similar role to W86 and 
Y93 in the al nAChR (Cohen et al., 1991;Galzi et al., 1990;Galzi et al., 1991d;Galzi 
et al., 1991b), and to HI 01 of the GABAaR al (Wieland et al., 1992;Duncalfe et al.,
1996)  and R100 of GABAaR a6 subunits (Korpi and Seeburg, 1993), as well as Y97 
and L99 of the GABAaR p2 subunit (Boileau et al., 2002; Fig 1.5).  These potential 
agonist binding site residues in the nAChR are also thought to play a direct role in 
agonist coordination (Mu et al., 2003;Sullivan and Cohen, 2000;Celie et al., 2004).
The experiments discussed here provide evidence for a conserved set of loops, A-C, 
that are involved in agonist binding by cys-loop ligand-gated receptors.  However,in 
the case of nAChR, GABAaR and 5HT3R there is evidence for the existence of five 
to six loops involved in agonist binding (for reviews see Cromer et al., 2002;Reeves 
et al., 2003).  These loops contribute to an intersubunit binding site.  For example,in 
the case of a GABAaR containing a and p  subunits, residues are contributed from 
loops A-C on the p subunit and loops D-F on the a subunit (Cromer et al., 2002). 
Currently  for  GlyRs,  a  contribution  from  loops  D-F,  in  a  and  p  subunits,  to  the 
agonist binding process has not been reported and it may be that the agonist glycine 
is  small  enough  such  that  loops  A-C  from  the  a-subunit  are  wholly sufficient  to 
mediate the necessary binding interactions.
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Figure  1.5  Cys-loop receptor family amino acid alignment.  The conserved 
locations of the agonist binding residues in loops A-C are highlighted; GlyR al 
in yellow, nAChR a in blue, GABAaR P2 in purple.
39Such functional  studies support a conserved location for the agonist-binding site in 
the  cys-loop  family  of  receptors;  however,  they  do  little  to  increase  our 
understanding of the structure of this site, or inform us how each residue contributes 
to  the  binding  process.  Medium  resolution  electron  micrographs  of the  Torpedo 
nAChR revealed the presence of a potential agonist pocket located about halfway up 
the extracellular domain of each subunit.  This pocket was surrounded by twisted P- 
sheet  strands  at  the  interface  of neighbouring  subunits  but  was  not  of sufficient 
resolution  to  determine  the  locations  of  binding  loops  A,  B  and  C  (Fig 
1.6/l)(Miyazawa  et al.,  1999).  These  data have  since been  superseded by what  is 
unquestionably  the  most  significant  breakthrough  in  our  understanding  of  the 
structure of cys-loop receptors.  Brejc et al, published in 2001, a high 2.6A resolution 
crystal  structure  of a  cys-loop  receptor related  protein  known  as  the  acetylcholine 
binding protein from the snail Lymnaea stagnalis.  This soluble protein shares a low 
but significant 20 % homology with the N-terminal, extracellular domain of the cys- 
loop receptor family and importantly it places loops A, B and C in proximity to act as 
ideal coordinators of agonist binding (Fig 1.6B,C & 1.7/1, B).  The location of this site 
is  equivalent  to  the  previously  identified  pocket  in  medium  resolution  electron 
micrographs suggesting that the AChBP does retain a comparable overall topology to 
the  extracellular  domain  of  cys-loop  receptors.  This  structure  presents  the 
extracellular domain as an initial a-helix, which then runs into two parallel sheets of 
P-strands where the two sets of p-strands run perpendicular to each other (Fig 1.6A & 
1.7/1,B).  In  the case of the AChBP  it has been possible to  crystallize this protein 
coordinated  to  three  different  ligands  including  the  agonists,  carbamylcholine  and 
nicotine, to give precise insight into the exact structural interactions that occur during 
agonist binding (Celie  et  al.,  2004).  Due to  the  low homology this protein  shares 
with the GlyR it is not possible to gain such an exact insight into the glycine binding 
site, however this homology model has already served as a powerful structural guide 
in future studies to determine the importance of domains spread throughout the cys- 
loop receptor extracellular regions.
40Figure  1.6  Current  structural  assumptions  that  can  be  made  about  the  GlyR 
extracellular domain.  A, A longitudinal section through an intermediate resolution 
structure  (4.6  A  electron  micrograph)  of the  torpedo  nAChR  a  subunit.  The 
highlighted  extracellular domain (dashed green box) of a potential  ligand binding 
cavity half-way up the domain from the membrane (arrow; adapted from Miyazawa 
et al, 1999).  B, A homology model (see Materials and Methods) from the inside face 
(from the vestibule; see inset) of the GlyR al  subunit based on the crystal structure 
of AChBP (Brejc et al, 2001).  Starting with an initial helix  (brown) this structure 
then forms two parallel sheets of p-strands, which run perpendicular to each other 
creating  inside  (pink  strands)  and  outside  (white  strands)  facing  sheets.  Notable 
features  include;  the  agonist  binding  domain  consisting  of loop  A  (red),  loop  B 
(orange) and loop C (yellow), again predicted to reside half way up the extracellular 
domain  (arrow);  the  gating  domain  consisting  of the  pi-2  loop  (green),  cys-loop 
(light blue) and  P8-9 loop (dark blue).  C and £), Close-up of the agonist binding 
domain from a side on perspective (C; see inset) and gating domain from the outside 
face  perspective  (Z);  see  inset)  with  important  residues  displayed  and  labelled. 
Colour schemes of ribbons are as in (B).  For reference, alternate nomenclature from 
Brejc, et al, is as follows; P1-P2 -  L2, cys-loop - L7, p8-p9 - L9.
41Figure  1.7  Position  of the agonist binding site  in the pentameric  extracellular 
homology model.  A, Three neighbouring subunits (white, green and blue) from a 
pentamer, viewed from the outside face (see inset).  The binding site from the white 
subunit consists of loop A (red), loop B (orange) and loop C (yellow).  The agonist- 
binding site is most likely accessed  from the outer face of the subunit and  at the 
intersubunit boundary (marked by arrow).  B, Profile of the whole pentamer, viewed 
from above (see inset), displaying the same information.
The transduction process
Deciphering components specifically involved in the receptor activation process has 
benefited significantly from the availability of the AChBP crystal structure.  This is 
due  to  the  difficulties  that  arise  in  differentiating  between  components  that  are 
influencing the initial agonist-binding event to the closed receptor and those which 
determine  the  subsequent  effectiveness  of  channel  opening.  Thus,  a  structural 
appreciation  of the  receptor  aids  in  predicting  and  isolating  residues  that  have  a 
genuine  significance  in  ligand-binding  and  channel-gating.  Unfortunately,  no 
unliganded crystal structures of the AChBP have so  far been resolved (Celie et al.,
2004).  This means there is no measurement yet of the movements that loops A to C 
undergo upon agonist binding.  However, medium resolution electron micrographs of 
the  Torpedo nAChR have been obtained  in the  agonist-bound  and  unbound  states 
(Miyazawa et al.,  1999;Unwin,  1993;Unwin, 1995).  These studies revealed that the 
agonist-bound  a-subunit  experiences  a  ‘local  disturbance’  of the binding  site.  In 
addition the extracellular domain underwent a set of small axial rotations presumably 
to transmit activation to the channel region.  Of particular interest was the realisation
42that  the  a  subunit  transition,  upon  binding  ligand,  converted  it  to  an  orientation 
similar  to  that  already  assumed  by  the  P  and y  subunits,  which  experienced  only 
minimal reorganisation during receptor activation.  This situation may be analogous 
to the GlyR where the a subunit is also the principal agonist binding subunit and so 
the  GlyR  p  subunit  may  remain  conformationally  stationary  at  least  from  the 
perspective  of  its  extracellular  domain  (Fig  1.8A,B).  Using  the  AChBP  crystal 
structure, a more recent study has attempted to map the movements that occur in the 
extracellular domain during agonist activation by fitting the most conserved p-strand 
regions to the 4.6A electron micrographs of the nAChR extracellular domains.  This 
study  revealed  that  the  AChBP  crystal  structure,  which  has  the  putative  agonist 
HEPES bound and therefore may be in the activated conformation already, could be 
overlaid  with  a  good  fit  to  the  p,  y  and  5  subunits,  but  not  the  a  subunit  of the 
unbound-closed nAChR (Unwin et al., 2002).  This is also most consistent with the 
non-ligand binding p, y and 5 subunits existing in a conformation close to that of the 
activated  state  for the extracellular domain,  whilst  the  a  subunit does not.  It  was 
possible  to  overlay  the  AChBP  with  the  nAChR  a  subunit  surface  topology  by 
simply  reorienting  the  set  of p-strands  that  are  on  the  inside  face  of the  subunit 
relative to those on the outer face of the subunit.  This simple  15 -  16 ° rotation of 
the  inner  face  strands  consequently  means  that  the  interface  of the  subunit 
undergoes a greater degree of movement compared to the *+’ interface of the subunit 
(nomenclature of Fu and Sine,  1996; Fig  1.8A,B).  This reorientation may therefore 
be  the  driving  force  for  downstream  communication  with  the  channel.  Currently 
there is no such evidence to validate this information in the GlyR.  Furthermore these 
studies were unable to address the primary movements that occur in the immediate 
vicinity of the agonist binding site due to the more flexible nature of the loops A to 
C.  With regards to these initial movements the information is relatively speculative, 
though  a mutation  in the GABAaR  P  subunit  in a position  equivalent to  GlyR al 
A101  of loop A does produce a spontaneously open receptor (Boileau et al., 2002). 
Also of interest is a Psi value analysis of a nine amino acid segment overlapping with 
and immediately following on from the A loop in nAChR a subunits.  This technique 
attempted to measure the order of domain movements during receptor activation and 
revealed that the nine amino acid segment moves early on in the activation process
43(Chakrapani et al., 2003).  Thus it may be that the A loop is the actuator that enables 
downstream extracellular movements.
A.  Closed state B.  Open state
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Figure  1.8  Hypothesis for cys-loop receptor activation, based on rotation of the 
extracellular  agonist  binding  a  subunit  of the  GlyR.  A,  Closed  and  B,  Open 
conformations  of the  GlyR.  The  pentamers,  viewed  from  above  the  receptor, 
represent  cartoons  of the  rotation  that  is  undertaken  specifically  by  the  agonist 
binding a subunit (red).  The non-ligand binding p subunits (blue) are proposed to 
already reside in the active conformation.  The green rectangles denote the a-helix 
present  in  each  extracellular subunit domain  for extra definition of each  subunits 
orientation.  The green circles represent the approximate axis of rotation for the a 
subunits during activation.  The homology models reflect enlargements of a single 
al  subunit from the cartoon pentamer in the same alignment (red box; also viewed 
from above).  The green circles represent the axis of rotation and demonstrate that 
during the 15 -  16 ° rotation of the inner sheet relative to the outer sheet (indicated 
by black arrow), the internal *-* side of the subunit will undergo a greater movement 
than the internal *+* side of the subunit.  This rotation of the extracellular domain of 
the GlyR a subunit is proposed to transmit downstream to the helical bundle and 
induce channel opening.
44One limitation of the combined AChBP-electron micrograph analysis is that it does 
not indicate which are the critical regions for transmitting the agonist binding effect 
down to the channel.  Initial mutagenesis experiments targeted residues predicted to 
reside close to  the transmembrane interface based on primary sequence due to the 
absence  of  a  high-resolution  structural  model.  Likely  candidates  to  mediate 
communication from this interface to the extracellular domain consist of the section 
immediately prior to Ml, the M2-M3 linker domain or the C-terminal tail from M4. 
The  significant  size  of the  12-13  amino  acid  M2-M3  linker,  its  apparent  central 
location and its direct link to two membrane segments including M2, the pore lining 
helix (discussed later) makes this the most likely candidate.  Early functional studies 
did indeed point to the M2-M3  linker as part of the gating mechanism.  Initially a 
naturally occurring mutation was identified in patients with the human startle disease 
that  replaced  a  positively  charged  GlyR  al  R271  with  an  uncharged  leucine  or 
glutamine (see review Rajendra, 1995a).  Subsequent functional studies revealed that 
these receptors had significantly reduced sensitivities to glycine and the higher single 
channel  conductance states were  abolished  sufficient to reduce whole-cell  currents 
by 90 % (Langosch et al., 1994;Rajendra et al., 1995c).  Furthermore the cell surface 
receptor expression  levels,  assessed by  [3H]  strychnine binding,  were  not  reduced 
and glycine binding,  as assessed by its ability to displace  [3H]strychnine, was only 
reduced by 50 -   100 fold, in comparison to glycine potency, which was reduced by 
230 - 410 fold.  Further evidence supporting a role for this arginine residue in gating 
was  the  abolition  of  p-alanine  and  taurine  evoked  currents.  By  contrast,  the 
sensitivity of the receptor to these compounds, measured in terms of their ability to 
inhibit  glycine  mediated  currents,  was  unaffected  suggesting  that  the  efficacy  of 
p-alanine and taurine had been reduced to such an extent that they were now unable 
to  activate  the  receptor  (Rajendra  et  al.,  1995c).  Since  identification  of R271,  a 
functional  scan  of the  M2-M3  loop  has  identified  further  residues  that  influence 
receptor function in a manner consistent with an involvement in gating (Lynch et al.,
1997).  Moreover,  substituted  cysteine  accessibility  mutagenesis  (SCAM) 
experiments in this region on the open and closed receptor conformations revealed a 
differential  pattern  of accessibility  supporting  a  movement  of this  domain  during 
activation (Han et al., 2001).  In the context of the original  structural  evidence on 
nAChRs,  suggesting the ligand binding a and structural  P  subunits do not undergo
45comparable  movements  during  receptor  activation,  a  second  SCAM  study  on  the 
GlyR p-subunit yielded no obvious effects on receptor potency when p subunit M2- 
M3 residues were mutated to cysteines.  In addition there were no obvious effects on 
function upon application of a cys-modifying reagent in the open,or closed,receptor 
conformations to ap heteromeric receptors containing Cys mutated p subunits in the 
M2-M3  region  (Shan  et  al.,  2003).  In  accord with the  evidence  that  the  M2-M3 
linker is a critical gating component, naturally occurring mutations and site-directed 
mutagenesis  studies  on  this  domain  in  nAChRs  and  GABAaRs  also  revealed 
impaired  receptor  function  in  a  manner  consistent  with  an  influence  on  gating 
(Campos-Caro et al., 1996;Kusama et al., 1994;Sigel et al., 1999;Baulac et al., 2001). 
Also of interest is the characterisation of two nearby GlyR al  residues  Q266  and 
S267, both present on the extracellular side of the M2 domain.  These residues when 
mutated to create Q266H and S267Q GlyRs impair function in a manner consistent 
with gating (Moorhouse et al., 1999;Findlay et al., 2003).
Due to the juxtaposition of the M2-M3 linker to the channel it is easy to appreciate 
how this domain can influence receptor activation but prior to resolving the AChBP 
structure it was not clear how components of the extracellular ligand-binding domain 
communicate across to the M2-M3 linker.  The AChBP crystal structure provided a 
possible solution as the p-strands and loops located at the base of this structure could 
now  be  identified  and  would  be  in  an  ideal  location  to  interact  with  the 
transmembrane segments and the M2-M3  loop (Brejc et al., 2001) (Fig  1.9A,B).  A 
recent study proposed an electrostatic interaction between two loops at the base of 
the  extracellular  domain  and  the  M2-M3  linker  (Kash  et  al.,  2003a).  Charge 
reversals at GABAaR al D57 from the pi-2 loop, D149 from the cys-loop and K279 
from the M2-M3 linker, all disrupted receptor function in a manner consistent with 
gating.  However, paired charge reversal of the M2-3 linker, K279D, with either the 
pi-2  loop D57K,  or the cys-loop  D149K mutation,  the GABAaR regained a large 
degree of receptor function.  This suggested that these domains interacted regardless 
of charge orientation.  Since this study a high 3A resolution electron micrograph of 
the M1-M4 segments including the M2-M3  linker has been reported (Miyazawa et 
al., 2003).  This structure was paired up with the extracellular domain and predicted
46that the  pi-2 loop, the cys-loop and the M2-M3  linker are in prime orientation for 
communication (Fig 1.9A,B).
Figure  1.9  Interactions  between  the  extracellular  domain  and  the 
transmembrane domains.  The structure is based on a homology model of the 
AChBP  (Brejc  et  al,  2001)  and  the  torpedo  nAChR  transmembrane  domains 
(Miyazawa et al, 2003) paired together.  A, Whole subunit and B, close-up of the 
gating interactions.  The pi-2 loop (green) and the cys-loop (light blue) of the 
extracellular domain are closely apposed to the M2-3 loop (red) and the top two 
turns of the M2-3 helices (purple; individual helices are labelled on the diagram) 
which  rise  out  above  the  membrane  (white  dashed  line).  Residues  in  the 
interacting domains that influence receptor properties consistent with gating are 
displayed and labelled.
47In  the  context  of  the  GlyR  individual  alanine  substitutions  have  been  made 
throughout  the  cys-loop  domain.  This  approach  identified  a  number  of residues 
including al  D148 (corresponding to GABAaR al D149), that significantly reduced 
glycine  potency  and  maximal  currents,  as  well  as  taurine  potency  and  relative 
efficacy, consistent with an effect on channel gating (Schofield et al., 2003;Schofield 
et al., 2004).  Charge reversals introduced at the GlyR al  pi-2 loop E53  and D57 
residues,  also  disrupted  receptor  function  in  a  manner  consistent  with  gating 
(Absalom et al., 2003).  Furthermore a K143 residues in the cys-loop was shown to 
change  its  accessibility pattern in  a SCAM  study suggesting this  domain,  like the 
M2-M3 linker can change its conformation during activation (Absalom et al., 2003).
Howeve^it is unlikely that electrostatic communication between the pi-2 loop, the 
cys-loop and the M2-M3 linker can be generalised throughout the cys-loop receptor 
families as attempts to reproduce a similar correlation in the GABAaR  P2  subunit 
and in the GlyR, failed (Absalom et al., 2003;Kash et al., 2003b).  Also non-charge 
related substitutions in the pi-2 loop can cause subtle effects on receptor potency as 
was originally discovered for the spasmodic mouse, which has the A52S mutation in 
GlyR al  (Ryan et al., 1994;Saul et al.,  1994).  This same location in the a l subunit, 
which is the source of splice variance between a2A and a2B (Fig 1.1) also causes a 
reduction in glycine potency at the a2A subunit in a manner consistent with a gating 
effect  as  the  relative  efficacy  of  taurine  is  attenuated  (Miller  et  al.,  2004). 
Furthermore, a recent chimeric study generated a non-functional cys-loop receptor by 
pairing the extracellular domain of the AChBP to the transmembrane segments of the 
5-HT3A R.  Function was then restored to this receptor by progressively substituting 
each of the three loops at the base of the extracellular domain, the p 1  -2 loop, the cys- 
loop and the  P8-9 loop, with those of the 5-HT3A R.  Only when all three of these 
loops, not just the two identified previously by Kash et al  (2003a) were restored, was 
there an effective return of the receptor’s gating properties (Bouzat et al., 2004).  In 
the case of the nAChR, the hydrophobic V44 from the pi-2 loop is predicted to be in 
close apposition with the M2-M3  domain (Miyazawa et al., 2003).  These authors 
propose that this residue docks into a hydrophobic pocket at the end of the M2-3 loop 
and  upon  activation  the  rotation  of the  extracellular  domain  twists  this  residue
48exerting  an  effect  on  the  M2-M3  loop  to  induce  channel  opening.  Together this 
evidence  suggests that the gating process  is most  likely a combination of charged 
polar  and  apolar  interactions  that  can  occur between  the  three  base  loops  of the 
extracellular domain and the M2-M3 linker.
The ion channel and its opening mechanism
A large body of evidence, accumulated from the nAChR, supports the view that the 
M2 domain of cys-loop receptors is responsible for forming the channel and contains 
the  gate  responsible  for  opening  and  shutting  of  this  channel  (for  review  see 
Devillers-Thiery et al., 1993).  The M2 segment of the cys-loop receptor family is the 
most  conserved  domain between  subunits,  highlighting the important nature  of its 
role. For GlyRs, a mutagenesis study identified a residue on the intracellular cusp of 
M2  that  is  critical  for  determining  the  maximal  conductance  state.  A  G254A 
substitution  in  GlyR  al  increased  its  maximal  conductance  state  in  symmetrical 
chloride solutions  from 86 pS  to  107 pS bringing it in line with GlyR al and a3, 
which have an alanine at this position and have maximal conductance states of 111 
and 105 pS, respectively (Bormann et al.,  1993).  One major difference between the 
channels of the GlyR and the nAChR is their ionic selectivity.  Whilst the nAChR 
favours cation conductance, the GlyR channel has an anion permeability sequence of 
SCN>r>N0 3  >Br>Cr>HCO">acetate>F‘>propionate  (Bormann  et  al.,  1987)  and 
the responsible M2 residues have now been identified (Galzi et al.,  1992;Keramidas 
et al., 2000).  It is beyond the scope of this introduction to describe the multitude of 
experiments that have been carried out to discern the architecture of the channel and 
its ability to determine selectivity of anionic conductance in the GlyR (for review see 
Rajendra  et  al.,  1997;Lynch,  2004).  However^ from  the  perspective  of receptor 
activation and possible allosteric modulation there are a number of relevant points to 
be raised.  The general structure of the pore for the  Torpedo nAChR suggests that 
M l-4 exist as membrane spanning a-helices with M2 positioned on the interior face 
such  that  the  pentamer  contains  an  inner  ring  of five  M2  helices  (Fig  1.10A,B; 
Miyazawa et al.,  1999;Miyazawa et al., 2003).  These M2 helices are 40 A long with 
two turns of each helix rising out above the extracellular membrane face.  These are 
connected via a short M2-M3 linker to the M3 segment, which also protrudes above 
the membrane face by two turns of an a-helix (Fig  1.9A,B; Miyazawa et al., 2003).
49Each  of  the  five  subunits  align  the  M2  helices  to  display  residues  of  the 
corresponding location at the same position thus creating rings of residues in register 
spanning across the membrane.  The exact location of the gate is still contentious but 
is probably located just over halfway down the pore towards the intracellular side, 
corresponding to an 8 A stretch of helix, where the pore diameter is less than 3.5 A. 
This section includes a critically conserved ring of hydrophobic leucines (nAChR al 
L251; GlyR al L261 in Fig 1.10,4,5) and just over one helical turn above this a ring 
of Val 255 residues (Labarca et al., 1995;Miyazawa et al., 2003).  In this context the 
location  L251  in  the  closed  state,  represents  a  ring  of residues  that  form  what 
is  effectively  a  ‘hydrophobic  girdle’  between  the  M2  helices.  This 
hydrophobic  girdle  operates by creating an energetic barrier for ion permeation as 
ions must  shed  their hydrated water shell  before  being  able to  fit through  such  a 
small pore.
With regards to the activation mechanism, the current hypothesis is that the gate, and 
therefore the location of the leucine and valine rings, opens up through a sideways 
rotation  of each  M2  helix  (Miyazawa et al.,  2003;Unwin,  1995).  This  may arise 
through each M2 segment moving individually to gradually weaken the stable closed 
channel  state, or a synchronised group movement of all  the M2  domains  together. 
The basis of this hypothesis was in part due to the presence of two predicted flexible 
loops, the M l-M2  linker and M2-M3  linker,  at either end of the pore lining helix 
(Fig  1.105).  The relevance of the GlyR M l-M2  loop in gating is apparent from a 
hyperekplexia  autosomal  recessive  mutation  (I244N)  that  was  identified  in  this 
region  (Fig  1.10C;  Rees  et  al.,  1994).  Mutant  receptors  exhibited  decreased 
sensitivity to glycine and smaller maximal current responses, which could in part be 
attributed to an effect on channel gating.  Thus it would seem that both flexible loops 
at either end of M2 can influence gating and may be acting as hinges.  One potential 
problem  with  this hypothesis  is  that  if the  M2  leucine  residues  do  form  a tightly 
enclosed gate then where does the space arise from for the helices to each rotate to 
the  side?  Fortunately,  the  structural  data  does  predict  the  presence  of a  sizeable 
water  filled  pocket  on  the  back  of M2  between  M2  and  M3  (Fig  1.10D),  which 
allows space for  M2  movement.  In  addition,  experiments  investigating a putative
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Figure  1.10  The transmembrane 
domains.  A,  Modelled  Ml-4
domains  of  a  pentamer  (from
above)  showing  their  orientation
around the central ion channel pore, 
which is  formed  from the  five M2 
domains  (inside the  yellow  dashed 
circle).  B, The Ml -4 domain of two 
opposing subunits (side profile), the 
green  box  highlights  the  hydrophobic  girdle,  which  represents  the  gate
approximately two  thirds  of the  way  down  the  channel  in  the  M2  domains,
corresponding to L261  in GlyR al.  At either end of M2 is the Ml-M2 (yellow) 
and  M2-M3  (green)  loops  proposed  to  act  as  two  hinges  that  allow  the  M2 
domain to rotate sideways and open the channel.  C, Identification of residues 
involved  in  gating,  conductance,  desensitisation  and  sensitivity  to  alcohols, 
anaesthetics,  picrotoxin and cyanotriphenylborate.  The helices are colour coded 
and labelled (side profile).  Due to the multiple roles of most of these residues, 
their  functions  are  presented  in  Table  1.1.  D,  View  from  above  of the  four 
helices  from  a  single  subunit,  highlighting  the  location  of the  water  filled 
vestibule  behind  the pore  lining M2  domain  (white dashed  circle).  The  two 
residues implicated in determination of alcohol and anaesthetic potency are also 
presented.
51GlyR al 
residue
Location Influential roles References
A52 pi-2 loop PTX sensitivity, 
Gating
(Miller et al., 2004)
(Ryan et al., 1994;Saul et al., 
1994;Miller et al., 2004)
L142, 
F145, 
PI 46, 
D148
cys-loop Anaesthetic sensitivity, 
Gating
(Schofield et al., 2004) 
(Absalom et al., 2003;Schofield 
et al., 2003;Schofield et al., 
2004)
1244 Ml Desensitisation,
Gating
(Breitinger et al., 2001) 
(Breitinger et al., 2001)
A254 M2, (2’) Conductance, 
Desensitisation 
CTB sensitivity, 
PTX sensitivity
(Bormann et al., 1993)
(Zhang et al., 1994) 
(Rundstrom et al., 1994) 
(Pribilla et al., 1992) 
(ffrench-Constant et al., 1993)
T258 M2, (6’) PTX sensitivity (Gurley et al., 1995)
L261 M2, (9’) Channel gate (Unwin, 1993) 
(Labarca et al., 1995)
Q266 M2, Gating (Moorhouse et al., 1999)
S267 M2, (15’) Anaesthetic and 
alcohol sensitivity, 
Gating
(Mihic et al., 1997) 
(Findlay et al., 2003)
R271 M2, Conductance/Gating, 
PTX efficacy
(Rajendra et al., 1995) 
(Lynch et al., 1995)
A288 M3 Anaesthetic and 
alcohol sensitivity
(Mihic et al., 1997)
Table 1.1  The functions associated with residues in the GlyR transmembrane 
domains.  Nearby  residues  from  the  pi-2  loop  and  cys-loop  that  influence  the 
pharmacology of antagonists linked to the membrane region are also included.  See 
Fig 1.10C,D for structural information on the location of these residues.
52binding site for alcohols between M2 and M3 revealed that altering the size of amino 
acid  side chains present on M2  and M3  controls the  ‘cutoff  point  for the  size of 
alcoholic molecules that are able to enhance receptor function.  This suggests that the 
size of the channel lumen is determined by the side chain moieties present (Wick et 
al., 1998).  Another experimental observation that is consistent with the M2 rotation 
hypothesis  was  determined  by  labelling  the  nAChR  p  subunit  at  A267  of M2 
(equivalent to GlyR al  Q266, Fig 1.1 OQ with a fluorophore tetramethylrhodamine. 
Upon  agonist  evoked  receptor  activation  there  was  a  shift  in  the  fluorescence 
emission peak to lower wavelengths in accord with the fluorophore entering a more 
hydrophobic  environment  (Dahan  et  al.,  2004).  This  is  consistent  with  the  M2 
domain twisting to move the A267 into a more hydrophobic location near M3  and 
M4.  It is worth mentioning that although the GlyR  p  subunit may have a limited 
effect  on  gating  via  its M2-M3  linker (Unwin  et  al.,  2002;Shan  et  al.,  2003),  the 
experiment above suggests that the M2 domains in the non-ligand binding subunits 
still undergo a conformational shift during receptor activation.  In support of this, the 
mutation L285T, in the leucine gate of the GlyR P M2 domain, increases the glycine 
potency, presumably by destabilising the closed conformation (Shan et al., 2003).
The intracellular domain
The  intracellular  domain  is  associated  with  the  most  uncertainty  as  regards  its 
structure.  The only available insight into its structure is from a medium resolution 
4.6  A  electron  micrograph  (Miyazawa  et  al.,  1999)  but  this  is  of  insufficient 
resolution  to  pinpoint  individual  amino  acids.  However,  it  does  suggest  that  the 
intracellular domain is ordered and projects inwards from each subunit to form a cap 
with significant apertures between the sides of the subunit interfaces through which 
ions could flow (Fig 1.3).  These apertures, though sizeable, may at least in the case 
of the 5-HT3R, control channel conductance (Kelley et al., 2003).
For  the  GlyR,  the  intracellular  domain  has  been  attributed  with  three  functions. 
Firstly, the P-subunit contains an 18 amino acid insert in this region that is vital for 
gephyrin binding and receptor anchoring (Meyer et al.,  1995;Kneussel et al.,  1999); 
secondly,  both  GlyR  al  and  a3  have  variable  splice  insertions  in  the  M3-M4 
intracellular  loop,  which  contain  consensus  phosphorylation  sites  capable  of
53modulating channel function.  In this regard, an M2-M3 S346 residue in the GlyR a3 
subunit is such a consensus, for PKA, which is vital for determining sensitivity to the 
PGE2  pain  induced  pathway  (Harvey  et  al.,  2004).  Finally,  the  two  intracellular 
Ml-M2 and M3-M4 domains have also been shown to have an important influence 
on  the  rate  of  receptor  desensitisation.  This  is  supported  by  the  fact  that 
phosphorylation can modulate the rate of desensitisation  for GlyR al  (Gentet and 
Clements,  2002).  In  addition,  a3  splice  variants,  which  are  distinguished  by the 
presence or absence of a 15 amino acid insert in the M3-4 intracellular domain, have 
different  desensitisation  profiles.  This  property  was  primarily  attributed  to  the 
presence  of three  hydroxyl  groups within  this  domain  located  at T325,  Y334  and 
S337  (Breitinger  et  al.,  2002).  Furthermore  a  study  on  residues  throughout  the 
M l-M2  loop  shows  that  disruptions  in  this  region  influence  the  rate  of receptor 
desensitisation (Breitinger et al., 2001).
In  summary,  the  structure-function  studies  seem  to  support  the  presence  of  a 
localised  agonist-binding domain  formed by,  in the  case  of the  GlyR,  loops  A-C. 
The subsequent activation event from this site may possibly be mediated via loop A 
and the end result of this is a downstream predicted 15° rotation of the internal face 
of the extracellular domain  GlyR a  subunit.  This rotation exerts its effect on the 
three base loop regions,  pi-2, the cys-loop  and P8-9, which in turn reorganise the 
M2-M3 linker and this twists the M2 domain into an open conformation made easier 
by the flexible Ml-M2 loop at the other end of M2 and a water filled lumen at the 
back  of  M2.  As  should  be  realised,  this  overall  scheme  remains  relatively 
speculative  and  the  fine  details  are  only  partially  described.  One  aspect  that  is 
particularly  evident  from  these  studies  is  the  limited  identification  of molecular 
components  responsible  for  the  different  functional  properties  amongst  GlyR 
subtypes.  While studies now  suggest that the GlyR al  and 2  subtypes activate at 
different  rates  (Mangin  et  al.,  2003)  there  have  been  no  reports  elucidating  the 
molecular  components  responsible  for  this.  Furthermore,  though  intracellular 
domains may be able to influence desensitisation there is no structural data on these 
regions and it is impossible to even speculate how this process is induced.  In terms 
of  single  channel  studies,  residues  have  been  identified  which  can  account  for 
subtype  variations  in  the  main  conductance  states,  however  there  have  been  no
54molecular correlations to elucidate the residues responsible for different GlyR open- 
closed times and agonist efficacies.  Thus, a vast repository of data is still required 
before those properties that enable receptors to exert unique physiological effects are 
determined from a molecular aspect and linked to the receptor activation process.  In 
addition,  relatively  little  is  known  about  how  principle  GlyR  modulators  such  as 
alcohols, anaesthetics, picrotoxin and Zn2+ exert their effects (Laube et al., 2002b). 
It is the job of structure-function studies to now attempt to decipher the molecular 
correlates  of subtype  specificity  and  modulator  action  and  to  place  these  in  the 
context of the newly elucidated receptor binding-activation pathway.  As the focus of
“ Si
this study is on the modulator Zn  , and how it can interplay with receptor function, 
the  next  section  will  deal  with  a  few of the prime  GlyR modulators  and  what  is 
known of their mechanisms of action.
Pharmacology
Alcohols and anaesthetics
Anaesthetics and alcohols are able to potentiate both GABAaRs and GlyRs.  This 
potentiation  can  occur  at  low  nanomolar  concentrations  dependent  on  alcohol  or 
anaesthetic structure (Downie et al., 1996; Wick et al., 1998). The evidence suggests 
these  two  classes  of compound  may act  via  a common  site.  Indeed,  two  critical 
determinants  in  the  GlyR  al  subunit,  S267  from  M2  and  A288  from  M3,  can 
determine whether or not alcohols and anaesthetics potentiate GlyRs (Mihic  et al.,
1997).  These  two  residues  are  located  towards  the  extracellular  side  of  the 
membrane and on either side of the predicted water filled lumen between M2  and 
M3, an ideal location for a binding site (Miyazawa et al., 2003; Fig  1.10C,£>).  The 
presence  of this  region  as  a  binding  site  for  modulators  is  strengthened  by  the 
phenomenon of alcoholic ‘cutoff.  This is characterised by an increased potency for 
the n-alcohols,  as the chain length increases,  which reaches a ceiling (Wick et al.,
1998) after which the potency stays unchanged, or begins to drop with longer chain 
lengths.  This  ‘cutoff  varies between cys-loop receptors with the cutoff occurring 
earlier on the GABAaR p subunit than for the GlyR (Mascia et al.,  1996;Mihic and 
Harris,  1996) and can be reversed by switching the differential identities of GlyR al 
S267 and A288 with the equivalent residues from the GABAaR p subunit (Wick et 
al.,  1998).  This  suggested  that  these  residues  altered  the  size  of  the  cavity,
55supporting its potential as a binding site.  From the location of this putative binding 
site it would seem sensible that in order for anaesthetics and alcohols to mediate their 
potentiating effects these molecules would facilitate the movement of the M2 domain 
either  directly/ or  by  aiding  the  M2-3  hinge  movement.  SCAM  experiments  of 
residues from the al  GlyR, including S267 and A288, revealed that the accessibility 
of both these residues increased upon receptor activation suggesting that this lumen 
does indeed undergo a conformational change during activation and that alcohols and 
anaesthetics could perhaps facilitate this process  (Lobo et al., 2004).  Intriguingly, 
individual alanine substitutions across the whole of the neighbouring GlyR cys-loop 
revealed a number of positions where potentiation by the anaesthetics halothane and 
isofluorane was ablated (Schofield et al.,  2004).  Thus,  several  facets of the GlyR 
gating apparatus appear to be able to influence anaesthetic modulation.
Picrotoxin (PTX) and cyanotriphenylborate (CTB)
These two molecules are both antagonists at GlyRs (Pribilla et al.,  1992;Rundstrom 
et al.,  1994;Miller et al., 2004) and highlight the caution that must be taken when 
ascribing a mechanism of action for an inhibitor based on the location of residues 
that determine its sensitivity.  Originally, residues in M2 were identified that affected 
antagonist potency in both cases.  The high sensitivity of GlyR al to CTB, compared 
to  a2,  was  reversed  by  substituting  G254  for  the  a2  alanine  counterpart 
(Fig  1.10Q(Rundstrom  et  al.,  1994).  Similarly  for  PTX,  replacing  part  of the 
P  subunit M2 domain with a corresponding portion from the al  subunit, markedly 
increased  the  sensitivity  of ap  heteromers  to  PTX  (Pribilla  et  al.,  1992).  The 
inhibition  by  CTB  was  in  keeping  with  a  direct  action  at  M2  as  CTB  was  use- 
dependent,  uncompetitive,  and  the  block  was  enhanced  at  positive  membrane 
potentials (Rundstrom et al., 1994).  The original conclusion for PTX also suggested 
this molecule was partially inhibiting receptor function by channel blockade (Pribilla 
et al.,  1992).  However the mechanism of PTX action  at GlyR al  has  since been 
shown to act in a manner more consistent with competitive antagonism (Lynch et al., 
1995).  Furthermore,  GABAa  receptors  are  rendered  picrotoxin  insensitive  by 
introduction of the GlyR p residue F282 located towards the base of M2 (Gurley et 
al., 1995), which is a threonine in GABAa receptors and in the high sensitivity GlyR 
al  (T258; Fig 1.10C).  This suggests these two receptors share similar components
56for PTX action and also in GABAaRs, PTX does not have the profile of an open 
channel  blocker.  Another residue  from  the  GABAaR  corresponding  to  GlyR  al 
G254  located  at the base of the channel beneath GlyRp  F282,  also  influences the 
potency  of PTX  action  by  up  to  100-fold  (ffrench-Constant  et  al.,  1993).  This 
GABAaR residue has also been shown to be important in desensitisation (Zhang et 
al.,  1994) and it has been proposed that PTX may act via an allosteric mechanism, 
preferentially  binding  activated  receptors  and  stabilising  them  in  agonist-bound 
closed  conformations  (for review  see  Hosie  et  al.,  1997).  In  support  of the  M2 
region being a possible PTX binding site, SCAM studies on these residues showed 
that the GABAaR equivalent to GlyR a G254 is less accessible in the presence of 
PTX (Xu et al.,  1995).  Despite this, disruption of the GlyR al  R271  residue at the 
other end of M2  (Fig  1.1 OQ can also influence PTX modulation by switching the 
properties of PTX from competitive to non-competitive and even to a potentiator of 
glycine evoked responses at low concentrations (Lynch et al., 1995).  Furthermore a 
residue in the extracellular gating domain pi-2 loop of the GlyR al receptor has also 
been shown to modestly influence the PTX potency (Fig 1.10C)(Miller et al., 2004). 
It  should  be  noted  that  PTX  is  in  fact  a  mixture  of two  separate  components, 
picrotoxinin  and  picrotin,  both  of  which  have  the  same  potency  at  the  GlyR 
suggesting they mediate their effects in a similar manner (Pribilla et al., 1992).
Zinc
The molecular basis of  Zn2+  modulation of  glycine receptors
The  first  study  to  investigate  the  modulation  of GlyRs  by  Zn  ,  earned  out  by 
Bloomenthal  et  al,  (1994)  revealed  a  biphasic  profile  such  that  Zn  exerted 
potentiation at low 0.1-10 pM concentrations and inhibition at higher concentrations. 
This profile was directly comparable between homomeric GlyR a2 and heteromeric 
GlyR  a2p  and  was  also  similar  for  native  GlyRs  from  rat  spinal  cord  cultures 
(Bloomenthal et al., 1994).  This data was later reproduced for GlyR al  showing that 
the inhibitory site was selective for Zn2+ over Ca2+ and Mg2+ with only Ni2+, from the 
metal ions tested, able to replicate the Zn2+ mediated inhibition process (Laube et al., 
1995).  Since these original reports, independent studies have verified the biphasic 
profile  of  modulatory  Zn  on  native  GlyRs  in  various  neuronal  preparations
57indicating that this phenomenon is most likely retained throughout the majority of, if 
not all, glycinergic systems (Li and Yang, 1999;Han and Wu, 1999).
The  follow-up  study  by  Laube  et  al  (2000)  identified  a  putative  GlyR  al  D80 
residue  as  a  plausible  coordinating  residue  for  Zn2+  potentiation  (Laube  et  al., 
2000;Laube et al., 2002b; Fig  1.11).  Though this moiety is acidic and is therefore 
one  of  the  favoured  chemical  groups  for  Zn2+  coordination  at  binding  sites,  a 
subsequent  independent  study  demonstrated  that  this  residue  only  ablated  Zn2+  
enhancement of glycine evoked responses and not those of another endogenous GlyR 
agonist  taurine,  believed to bind to  the  same  site  as  glycine  (Lynch  et  al.,  1998).
94- This suggested that D80 is unlikely to form part of a single Zn  site necessary for 
agonist enhancement and instead is somehow linked either to glycinergic or zincergic 
transduction.  In addition to this, the study by Lynch et al  (1998) identified a number 
of residues in the GlyR M2-M3 linker region that also abolished Zn2+ enhancement. 
Though these residues did not bear the traits of classical Zn2+ binding moieties their 
location in the M2-M3  linker believed to be a pertinent component of the  agonist 
gating apparatus (Lynch et al.,  1997;Han et al., 2001;Kash et al., 2003a) suggested 
that Zn2+ potentiation may mediate  its effect by influencing receptor gating.  This 
assertion is also supported by the demonstration that Zn2+ was able to enhance the 
relative  efficacy  of the  partial  agonist  taurine  but  did  not  increase  the  maximal 
response for the full agonist glycine, which as discussed previously has a P0 of 0.98 
(Laube et al., 2000).
Whilst  advances  in  determining  the  molecular  basis  of Zn2+  enhancement  have
9 4 - essentially  stagnated  since  these  studies,  reports  to  identify  components  of Zn 
mediated inhibition have continued to make progress.  The first such study used the
94- histidine  scanning  technique  to  individually  replace  these  potential  Zn  binding 
residues  in  the  extracellular  ligand  binding  portion  of the  protein  with  non-Zn2+  
coordinating alanines.  This led to the critical identification of GlyR al  HI07 and 
HI09, as both GlyR a lH 107A  and GlyR a lH 109A  were resistant to  1   mM Zn2+ when 
co-applied  with  glycine  (Harvey  et  al.,  1999;  Fig  1.11).  Another  report 
complemented  these  findings  by  demonstrating  that  alanine  substitution  of  the 
nearby GlyR  al  T112,  and  also  less  profoundly El 10,  reduced  the  sensitivity of
58GlyR al to Zn2+  mediated inhibition (Laube et al., 2000; Fig 1.11).  Interestingly, the 
molecular  basis  of proton  inhibition  appears  to  overlay to  some  extent  with  the 
inhibitory  site  as  Zn2+   inhibition  has  a  lower potency when  the  concentration  of 
protons is increased at pH 5.4 suggesting the two ions compete with each other for 
the  same  site (Harvey et al.,  1999).  A more recent study has  identified GlyR al 
HI09  and  T112  as  the  critical  components  for proton  inhibition,  but  not  HI07, 
suggesting  that  though  the  sites  overlap,  the  reliance  on  certain  residues  such  as 
HI07 is different (Chen et al., 2004).
HI 07 HI 09
Figure  1.11  Residues  identified  in  the  extracellular 
domain  that  influence  Zn2+   potentiation  and  inhibition. 
Homology model  from  the  inside  face  (see  inset)  of two 
neighbouring  GlyR  al  subunit  extracellular  domains. 
Residues implicated in Zn2+  mediated potentiation, D80, and 
Zn2+  mediated inhibition HI07, HI09, El 10 and T112, are 
displayed and labelled.  For ease of comparison with other 
characterised domains the extracellular domain is presented 
in a similar manner to previously as two parallel plates of P- 
strands,  which  run perpendicular to  each  other,  the inside 
face  in  pink  and  the  outside  face  in  white.  The  agonist 
binding domain is  also  shown, consisting of loop A (red), 
loop B (orange) and loop C (yellow), as well as the gating 
domain,  pi-2  loop  (green),  cys-loop  (light blue)  and  P8-9 
loop (dark blue).
59Critically  the  importance  of GlyR  al  H107,  H109  and  T112  in  Zn2+  mediated 
inhibition have all been independently verified in the most up to date study on Zn2+ 
inhibition (Nevin et al., 2003).  This report used a GlyR structural model based on 
the homologous AChBP protein (Brejc et al., 2001).  The resultant model predicted 
that  the  inhibitory  Zn2+  site  between  HI07  and  HI09  could  in  fact  form  at  the 
interface  between  two  subunits  (Fig  1.11)  and  the  authors  produced  evidence  in 
support of this by demonstrating that co-expression of a lH 107A  and a lH 109A  recovered
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near wild-type sensitivity to Zn  mediated inhibition.  If the binding site was located 
solely  within  the  confines  of  each  individual  subunit  then  co-expressing  these 
mutated  receptors  to  form  mixed  pentameric  complexes  would  not  recover  Zn2+ 
inhibition as each individual site would still lack one of the Zn2+ binding residues. 
However  if  the  site  were  interfacial  then  mixed  pentameric  complexes  would 
produce receptors where some of the sites contained two non-binding alanines whilst 
others retained the full Zn2+ binding apparatus and could mediate Zn2+ inhibition.  In 
addition to this the authors were unable to reproduce these results in the context of 
GlyR al  T112 leading to the postulate that this residue has only an indirect bearing 
on the site of Zn2+ inhibition.
Zn2+  as a potential endogenous modulator of  glycine receptors 
Neurotransmitter  release  from  a  single  synapse  is  generally  considered  to  be  a 
selective pairing between a specific neurotransmitter and its ligand-gated receptor; 
however  in  some  circumstances,  communication  may be  more  complex.  Such  a 
situation  can  arise  from  the  synaptic  co-release  of different  neurotransmitters  e.g. 
GABA  and  glycine  in  the  spinal  cord,  which  occasionally  work  together  to 
simultaneously activate two types of postsynaptic receptors.  This co-release property 
can  also  be  extended  to  the  paired  release  of a  neurotransmitter  with  a  receptor 
modulator,  e.g.,  co-release  of  the  NMDA  receptor  agonist  glutamate  and  its 
synergistic partner, glycine (Johnson and Ascher,  1987;Corsi et al.,  1996).  A slight 
modification  of this  theme  exists  where  the  slow  diffuse  release  of a  modulator 
allows  for  long  term  modulation  of postsynaptic  receptors,  e.g.,  in  neurosteroid 
modulation of GABAa receptors (Belelli and Herd, 2003;Lambert et al., 2003;Stell 
et  al.,  2003).  One  prime  candidate  for  the  role  of an  endogenous  modulator  of 
neurotransmission is the transition metal cation Zn2+.  The significance of this cation
60in neurotransmission and whether it participates in fast synaptic co-release,  a slow 
diffuse  release,  or  even  simply  exists  as  a  background  modulator  present  at  a 
constant concentration  as  a  ‘cationic  veneer’  across the plasma membrane,  is  still 
debated.
The initial evidence favouring Zn  as a physiologically relevant synaptic modulator
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relied on histochemical studies using Zn  staining reagents such as Timms’ sulphide 
(Danscher,  1981),  sodium  selenite  (Danscher,  1982)  and  fluorescent  probes,  to
' j ,
establish  the  presence  of  Zn  across  many  discrete  brain  regions  (Danscher, 
1984;Danscher et al.,  1985;Danscher,  1996;Frederickson  et al.,  1987;Frederickson, 
1989;Frederickson  et  al.,  1992).  Further  studies  revealed  that  Zn2+  is  selectively 
packaged  into  numerous particular cell types,  including:  fibres from the perirhinal 
cortex  to  the  neocortex  and  septum;  amygdala  (Perez-Clausell  et  al.,  1989;Perez- 
Clausell,  1996); neurones of the dorsal cochlear nucleus (Frederickson et al.,  1988), 
cerebellum,  thalamus  (Mengual  et  al.,  2001),  brain  stem,  spinal  cord,  retina  and 
olfactory bulb (see Frederickson,  1989;Frederickson et al., 2000).  The most famous 
example is the hippocampal mossy fibre innervation  from the dentate gyrus to the 
CA3 pyramidal neurones (Haug et al.,  1971;Crawford and Connor,  1972;Slomianka, 
1992).  Though the concentration of free intracellular Zn2+ is believed to be very low, 
possibly picomolar for most cell types (Simons,  1991), the labelled ‘zinc-containing 
neurones’  (Frederickson  et  al.,  2000)  revealed  intense  Zn2+  staining  in  a  pattern
^  i
consistent  with  the  packaging  of Zn  into  synaptic  vesicles  in  axonal  terminal
2+ boutons.  This  fits  with  the  principal  characteristic  required  for Zn  to  act  as  a 
dynamic neuromodulator, its presence in a loosely bound, mobile form available for 
rapid release at the synapse (Frederickson et al., 2000).
In keeping with a zincergic action at synapses, an efficient reuptake and repackaging 
pathway is required.  Though the exact molecular components of the initial reuptake 
stage  from  the  extracellular  space  have  not  been  determined  a  relatively  high 
sensitivity,  0.3  -   20  pM  saturable  transport  has  been  reported  (Howell  et  al., 
1984;Wensink et al., 1988; Colvin et al., 2000a;Colvin et al., 2000b).  The sensitivity 
of this process  is unlikely to be relevant to the estimated nanomolar to picomolar 
background levels of extracellular Zn2+ (Kay, 2003) but may be sufficient to have an
61impact at the synapse where concentrated Zn2+ release could presumably reach much 
higher concentrations.  Likely candidates for the downstream protein machinery of 
Zn2+ repackaging have^ however^ been elucidated with Zn2+ proposed, upon cellular 
re-entry,  to  bind  proteins  such  as  metallothionein  ID,  which  may  facilitate  Zn2+  
translocation to  synaptic vesicles  for sequestration via the Zn2+  transporter,  ZnT-3 
(Palmiter  et  al.,  1996).  ZnT-3  is  specific  to  the  nervous  system  and testis  and  a 
ZnT-3  knockout  mouse  exhibits  a  complete  absence  of  histologically-reactive 
vesicular Zn2+  in the brain  (Palmiter et al.,  1996;Cole et al.,  1999;Wenzel  et al., 
1997).
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Whilst  the  evidence  so  far  suggests  Zn  is  located  and  packaged  at  synapses, 
experiments  to  detect  a  genuine  neuronal  release  and  subsequent  functional 
consequence  mediated  by  Zn2+  have  proved  difficult  to  obtain.  Initial  studies 
attempting  to  address  this  issue  loaded  the  hippocampal  mossy fibre  system  with 
Zn  and  measured  subsequent  release  into  the  superfusate  upon  depolarisation 
using high K+, kainate (Assaf and Chung,  1984), or electrical stimulation (Howell et
y   i
al.,  1984).  Measurements  of the  Zn  concentration  after  such  chronic  treatment 
suggested this cation could attain 300 pM in the synaptic cleft.  Further fluorescent 
assay based studies and atomic absorption spectroscopy suggested that depolarisation
ji
caused  Zn  to  reach  significant  levels  in  the  extracellular  media  (Budde  et  al., 
1997;Thompson et al.,  2000;Li  et al., 2001;  Varea et al., 2001;Ueno  et al.,  2002). 
One  report  using  the  highly  sensitive  fluorescent  Zn2+  probe,  FluoZin-3,  in
y ,
hippocampal  slice  preparations  does,  however,  suggest  that  the  levels  of  Zn 
released  during  synaptic  transmission  are  far lower,  even of the order  1-10 nM 
(Kay, 2003).  This study even suggests that Zn2+ release may not be significant as a 
dynamic process and instead Zn  exists at a low background level accumulated on 
extracellular  membranes  in  the  form  of a  veneer,  which  could  modulate  highly 
sensitive  ligand-gated  receptors.  Functional  studies  using  electrophysiology  to
y i
address  whether  Zn  is  actually  present  at  the  synapse  modulating  neuronal 
receptors generally supports the assertion that indeed the concentrations of Zn  are 
likely to be low, mainly because there is little evidence available for a Zn2+ mediated
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effect.  Two independent functional  studies looking at synaptic Zn  release in the 
hippocampus suggest that postsynaptic NMDA receptors can undergo modulation by
62synaptic Zn2+ that is possibly co-released with glutamate (Ueno et al., 2002;Vogt et 
al.,  2000).  Given the nanomolar sensitivity of some NMDA receptor subtypes  in
9 4 - these  studies to Zn  mediated  inhibition,  this  suggests the concentrations  of Zn 
released  are  also  in  this  range.  An  additional  study of Zn2+  modulation  of tonic
9 4 - GABAaR  mediated  currents,  possibly  by  overspill  of Zn  into  the  extrasynaptic
94- space,  also  supported  the  claim  that  Zn  can  exist  as  a  modulator  of neuronal 
receptors  (Ruiz  et  al.,  2003).  The  sensitivity  of  these  extrasynaptic  GABAa 
receptors can be variable, suggesting Zn2+ concentrations of high to low micromolar 
(Brickley et  al.,  1999;Draguhn  et  al.,  1990;Hosie  et  al.,  2003).  Furthermore,  the
94- likely physiological relevance of synaptic Zn  is in keeping with a modest role for 
this cation in neuromodulation as the Zn-T3 knockout mouse, which lacks synaptic 
vesicular Zn2+,  is  devoid of any obvious phenotype  (Cole et al.,  1999;Cole  et al., 
2001).  This  suggests that either this phenomenon is unimportant or that receptors
94- can compensate for this normally subtle effect and that the reliance on Zn  is only 
realised under certain confined circumstances (Cole et al., 2000).
With regards to any specific role this potential cationic modulator may play in GlyR 
synaptic  activity,  there are currently no  direct  functional  studies to  support  such a 
claim.  However, the receptor sensitivity, at least for Zn2+ mediated enhancement of 
recombinant  GlyR responses,  is  high  at 0.1  -   10  pM.  This would be relevant to 
synaptic Zn2+ release,  especially as the onset of potentiation is rapid  (Suwa et al., 
2001).  In addition to this, zinc-containing neurones are present throughout the spinal 
cord, the most concentrated home of the GlyR,  and these zinc-containing vesicles 
have  been  identified  side-by-side  with  glycine  containing  vesicles  at  presumed 
glycinergic  axonal  boutons  (Birinyi  et  al.,  2001 ;Jo  et  al.,  2000;Velazquez  et  al., 
1999;Wang et  al.,  2001).  It  has  also  been  shown  in  the  zebrafish  hindbrain  that 
glycinergic  EPSC  currents  maintain  this  high  sensitivity  to  Zn2+  enhancement  as 
application of a Zn2+ chelator increased the decay rate of the IPSC responses (Suwa
94- et  al.,  2001).  This  suggested very low,  submicromolar concentrations of Zn  are 
sufficient  to  enhance  glycinergic  neurotransmission  by  extending  the  IPSC  decay
94- phase, though it does not prove that Zn  was released synaptically as contaminating
•  94- nanomolar concentrations of Zn  in the saline used are sufficient to account for this 
effect (Paoletti et al., 1997;Wilkins and Smart, 2002).
63Aims of the present study
Whilst  some  available  data  hints  at  potential  regions  of the  GlyR  that  may  be 
important  for  Zn2+   modulation  of  GlyRs  there  are  still  large  gaps  in  our 
understanding of both the Zn2+ binding sites and any possible transduction pathways 
by which this modulator may act.  Given  the possible  significance  of Zn2+  as  an 
endogenous modulator of GlyRs and the insight that determining the molecular basis 
of such events might bring, both in terms of how the GlyR operates and also how 
other cys-loop receptors may be allosterically modulated, this study aims to elucidate 
these  specific  molecular  correlates.  The  techniques  adopted  revolve  primarily 
around  the  established  stratagem  of  site-directed  mutagenesis  to  elucidate  the
7+ function of specific amino acids with regard to Zn  binding and transduction.  This 
approach was undertaken with structural homology modelling of the GlyR based on 
the homologous AChBP crystal structure, a tool that vastly enhanced the power of 
the site-directed mutagenesis strategy.  In some cases, additional SCAM experiments 
were  implemented  to  assess  the  accessibility  of  potential  Zn  binding  sites. 
Furthermore  pharmacological  characterisations  of spinal  cord  culture  GlyRs  were 
also carried out to link any recombinant pharmacological observations with in vivo 
receptor populations.
These  techniques  and  tools  have  revealed  a  surprising  wealth  of  information 
regarding  Zn2+  modulation  of  GlyRs  from  both  a  binding  and  transduction 
standpoint.  Firstly, the molecular basis of subtype divergence in sensitivity to both 
Zn2+  inhibition  and  enhancement  was  revealed.  Secondly,  original  and  novel 
candidates  of the  Zn2+   inhibition  site  were  characterised  and  evaluated  for  their
7 ,
relative  likely contributions  to  direct  binding  and  transduction  of Zn  inhibition. 
Thirdly, the study uncovered a family of Zn2+ activated receptors, and through this 
discovery,  it  was  possible  to  isolate  a  direct  and  specific  hydrophobic  pathway 
through  the  core  of the  GlyR  a  subunit  that  could  mediate  transduction  of the 
inhibitory Zn2+ site to reduce glycine binding and receptor activation.  Fourthly, upon
7 .
determining the molecular basis of a differential potency for Zn  between GlyR al 
and a l it was possible to identify a specific area of the GlyR as a strong candidate
7 ,  #   t  t
for a Zn  potentiation site.  As a consequence of this, a critical control element of
64this site was also determined, which implied that the Zn2+ potentiation site is able to 
exert  its  enhancement  by  affecting  the  cys-loop  gating  domain  to  increase  the 
efficacy of the receptor.
Whilst  these  results  will  be  of  interest  to  those  engaged  in  structure-function 
determinations  of the GlyR and also  other cys-loop receptor family members,  this 
data unexpectedly offered potentially more than just an insight into the action of Zn 
itself.  The hydrophobic pathway identified in this study and the nature of the process 
by  which  Zn  is  proposed  to  mediate  its  inhibitory  effect  suggest  that  this 
transduction  pathway  is  an  ideal  structure  to  mediate  the  initial  downstream 
conformational shift by which the GlyR and other cys-loop receptors may activate. 
Under such a proposition, agonist binding would induce a downstream collapse of 
the hydrophobic pathway allowing for destabilisation of polar interactions between 
the ‘+’ and  subunit faces and subsequent twisting open of the extracellular domain 
of the receptor.  In keeping with previous evidence, this twisting would move loops 
of the proposed  extracellular gating domain which would  impinge  on the  M2-M3 
loop and transmit to the M2 pore lining to elicit channel opening (Miyazawa et al., 
2003;Unwin et al., 2002;Kash et al., 2003b;Bouzat et al., 2004).  Identification of 
such a candidate pathway was totally unexpected and highlights the importance of 
such  studies  as  modulatory  domains  undoubtedly  feed  into  agonist  processing  at 
some stage and therefore always offer insight into mechanisms of agonist action.
65Chapter 2 
Materials and Methods
Reagents
All laboratory reagents were purchased from Sigma and tissue culture reagents were 
purchased from GIBCO unless stated otherwise.  Water for use in electrophysiology 
was filtered through an ELGA PURELAB Prima machine, whilst molecular biology 
grade water underwent a further purification process through an ELGA PURELAB 
ultra to remove trace ionic and organic impurities.
Molecular biology: Glycine receptor cDNAs
The work carried out in this project relied on the initial availability of a number of 
wild-type cys-loop ligand-gated receptor clones.  Human (h) GlyR alL, hGlyR a2A 
and rat (r) GlyR a3S cDNAs were cloned into the vector pCIS2 (obtained from Dr. 
R.J.  Harvey).  pCIS2  is  a  non-commercially  available  plasmid  vector  originally 
developed  by  H.  Betz  (Grenningloh  et  al.,  1990)  and  this  is  a  low  copy number 
plasmid  that  contains  an  ampicillin  resistance  coding region.  The  splice  variants 
selected  for study  from each GlyR subtype,  alL  (long)  and a3S,  contain  or omit 
respectively, an intracellular TM3-4 loop amino acid insert compared to their spliced 
partners (Malosio  et al.,  1991b;Nikolic  et al.,  1998).  This  selection is unlikely to 
influence  the  subject  of this  study,  the  extracellular  modulation  by  Zn2+,  which 
previous  evidence  and  the  data  presented  here  suggest  is  mediated  through  the 
extracellular domain of the protein.  In the case of GlyR a2A, this splice variant does 
differ  from  its  a2B  counterpart  in  the  extracellular  domain  by  a two  amino  acid 
substitution.  However the  functional  consequences  of this  substitution  have been
•  *  9+ examined previously and do not have any obvious bearing on the property of Zn 
modulation of GlyRs (Miller et al., 2004).  The human GlyR  p  cDNA was cloned 
into pcDNA3.i+ and provided by Dr. P.J. Groot-Kormelink.  All other cDNAs used, 
namely murine (m) m5-HT3A iwas cloned into pRK5.  Also, jellyfish enhanced green 
fluorescent protein (EGFP; in pEGFP-1) was obtained from Clontech.  The GlyRp 
subunit  was  used  in  a  different  vector  (PCDNA3.1+)  so  that  high  yields  could  be 
obtained upon purification, as highly saturating levels of this plasmid were required 
in transfections to ensure homogeneous expression of GlyR ap heteromers.
66Site-directed mutagenesis
During the course of this project more than 100 GlyRs containing single^or multiple; 
point  mutations  were  generated  and  tested  therefore  only  general  details  of the 
specific mutations made, or the oligonucleotide primers used^are included here.  To 
insert an amino acid point mutation into a protein it is necessary to first substitute the 
corresponding nucleotide bases  at the  DNA  level.  This  is  done by hybridising  a 
synthetic  DNA  primer  containing  the  mutated  base(s)  of interest  to  a  wild-type 
cDNA in a plasmid and then extending the primer with a polymerase to make a copy 
of the rest of the cDNA in its vector.  This process is repeated in a manner similar to 
the  cycling  in  PCR to  amplify the vector containing the  directed point mutant  to 
sufficient levels for detection using bacterial cloning (scheme highlighted in Fig 2.1).
DNA melting (95  °C- 30 s)
Heat  DNA  plasmid  to  melt  it 
▼   into two separate strands
Annealing phase (55  °C- 60 s)
O
  Complementary synthetic forward and reverse 
primers  containing  the  mutated  bases  of 
interest anneal to the wild type cDNA at the 
position where the mutation is to be inserted
I   Extention phase (68 °C—  14 mins; 2 mins/1 Kb of  DNA)
The DNA polymerase PfuTurbo extends oligonucleotide primers 
X  using free deoxynucleotide triphosphates (dNTP) to create new 
mutated copies of the original wild-type cDNA plasmid
Cycling -18 times
Geometric amplification of mutated DNA 
to  creates  many  copies  of  the  mutated 
DNA plasmid for subsequent isolation
Figure 2.1 Schematic of the site-directed mutagenesis technique.  Mutated cDNAs, 
which will  later yield proteins with targeted amino acid substitutions for structure- 
function  studies are generated by a three stage PCR amplification strategy involving
DNA  melting,  primer  annealing  and  extention  of the  mutated  primer  in  a  cycle
repeated 18 times.
67Oligonucleotide  primers  (Invitrogen)  were  designed  to  be  24  -  34  nucleotides  in 
length, ending and starting with cytosine or guanosine to improve the efficiency of 
hybridisation  surrounding  the  unmatched  region.  At  least  six  matching  bases 
encompassed  either  side  of the  mutated  base(s)  of  interest  and  where  possible 
primers were designed to contain an even mixture of each of the four bases, dATP, 
dCTP,  dGTP  and  dTTP,  avoiding  long  stretches  of  any  one  base  and  possible 
sequences that may allow for hairpin loop formation within the oligonucleotide.  In 
some  instances  an  automated  online  oligonucleotide  design  engine  was  used, 
available  from  Stratagene  (web  address
http://labtools.stratagene.eom//Forms/SVLogin.php).
The site-directed mutagenesis protocol was modified from the Quikchange kit recipe 
(Stratagene):
PCR reaction mixture
5 pi of 10 x reaction buffer (Stratagene)
1  pi of 100 ng/pl double stranded cDNA plasmid template 
1  pi of 100 ng/pl forward synthetic mutated oligonucleotide primer 
1  pi of 100 ng/pl reverse synthetic mutated oligonucleotide primer 
1  pi of 40 mM dNTP mix (dATP, dCTP, dGTP and dTTP)
40.5  pi dH20
0.5 pi of PfuTurbo DNA polymerase (Stratagene)
This  reaction  mixture  underwent  the  following  PCR  cycling  process  in  a 
ThermoHybaid  PCR  machine  (Thermo  Life  Sciences  Ltd)  with  a  preheated  lid 
element negating the need for any mineral oil overlay:
Cycle 1  - 95 °C for 30 seconds {PfuTurbo activation phase)
Cycle 2-18 - 95 °C for 30 seconds (melting phase)
- 55 °C for 1  minute (hybridisation phase)
- 68 °C for 14 minutes (extention phase)
Successful PCR mutagenesis was verified by the presence of a significant band of 
DNA  (of approximately 7  Kb  in  size  corresponding to  amplified  cDNA plasmid) 
when 10 pi of PCR product, mixed with 4 pi gel loading buffer, was run on a 1.5 % 
agarose  gel  (BDH)  in  TAE  buffer  (0.04  M  Tris-acetate,  0.001  M  EDTA)  with 
1   pl/100 ml ethidium bromide at  100 mV for 1   hour alongside a 1   kB DNA ladder
68(Invitrogen).  Unsuccessful  mutagenesis reactions,  as  verified by the  absence  of a 
clear band,  were  repeated by varying  either the  hybridisation  temperature,  adding 
0.5  pi of 10 mg/ml bovine serum albumin (BSA; New England Biolabs), or adding 
1   pi  50  mM  MgSC>4.  If  mutagenesis  was  still  unsuccessful  then  fresh 
oligonucleotides varying in sequence were ordered.  All mutagenesis reactions were 
subsequently successful.
The PCR product was incubated with 1   pi of Dpn I (New England Biolabs) at 37 °C 
for 2 hours.  This selectively digests methylated DNA, in this case the original parent 
cDNA strands, which are methylated by bacteria during cloning. The PCR amplified 
templates  however  are  unmethylated  as  these  were  generated  from  individual 
unmethylated nucleotide bases with PfuTurbo during the PCR amplification stage. 
The  digested  PCR product  is then  transformed  into  chemically competent  TOP 10 
E.coli  bacteria  (Invitrogen  -   in  exact  accordance  with  the  manual).  Final 
transformed bacterial aliquots were plated onto ampicillin Lb agar plates (12.8 g Lb 
agar powder/ 400 ml molecular biology grade water +100 pg/ml ampicillin spread 
across twenty 10 cm Petri dishes under sterile conditions) as all the vectors used in 
this project contained an ampicillin resistance coding region.
Subsequent successful mutagenesis experiments typically yielded  10 - 200 colonies 
per plate of which 2 colonies were picked and pipetted into separate 5 ml aliquots of 
Lb  broth  (20  g  Lb  broth  powder/  1000  ml  molecular biology grade  water +100 
pg/ml ampicillin) to be grown overnight for 15 hours at 37 °C in an Orbital Shaker 
SI50, shaking at 250 rpm.  DNA was purified using the Qiagen miniprep kit and then 
sequenced externally by Wolfson  Institute of Biomedical  Research where only the 
initial provision of a small DNA aliquot and some sequencing oligonucleotide were 
required.  Receptors  that  yielded  results  deemed  to  be  important, or  which  had 
unexpected propertiesjwere re-sequenced across the full length of the cDNA region. 
Correctly generated mutated receptor cDNA constructs were grown in bulk using the 
Qiagen maxiprep kit in accordance with the recommended protocol to concentrations 
of 500 -  1000 pg/ml ready for transfection into mammalian cells.
69Basic  stocks  of  all  wild-type  receptor  clones  and  point-mutated  receptors  were 
maintained by the  subsequent  transformation  and  cloning  of remaining DNA  into 
DH5a E.coli bacteria (Invitrogen) followed by the selection of a bacterial colony to 
bulk up and maxiprep into fresh DNA as and when required.
Cell culture and transfection
HEK cells (ATCC CRL1573) were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with  10 %  foetal calf serum (FCS), 2 mM glutamine,  100 
units/ml penicillin G and 100 pg/ml streptomycin, incubated at 37 °C in 95 % air - 
5  % CO2 (Smart et al.,  1991) and were passaged two to three times weekly.  Cells 
(passage no. 10-25) transfected by one of two methods depending on requirements.
1)  Electroporation technique:  One 50% confluent,  10 cm sterile Petri dish of 
HEK  cells  was  washed  with  and  resuspended  in  Optimem  (final  0.5  ml 
volume)  taking  care  to  wash  away  any  trace  FCS  as  this  disrupts  the 
electroporation process.  The 0.5  ml cell aliquot,  supplemented with DNA 
plasmid for transfection in a cuvette, was electroporated at 400 V, infinite 
resistance,  125  pF  using  a  Biorad  Gene  Electropulser  n.  Cells  were 
subsequently shaken over a 10-minute period and then plated to achieve 20 
%  confluence  on  poly-L-lysine  (100  pg  ml'1 )  coated  35  mm  coverslips 
(BDH)  and used  for electrophysiology the  next  day.  This technique was 
used  in  Chapter  3  with  plasmids  containing  GlyR  a  cDNA  clones  co­
transfected  1:1  (3  pg:3  pg) with  a reporter plasmid expressing the  EGFP, 
final volume approximately 6 pi.  Also this method was applied to situations 
where large quantities of DNA were required such as co-expression of GlyR 
ap  heteromers,  which  need high  concentrations  of the  GlyR  p-subunit to 
ensure  its  efficient  incorporation  into  an  ap  heteromeric  complex.  The 
GlyR  p  subunit  expression  construct  was  mixed  with  GlyR  a  subunit 
plasmids  at  a  30:1  ratio  (30  pg:  1   pg,  plus  2  pg  EGFP),  final  volume 
approximately 20 pi.
2)  Calcium Phosphate technique; reaction mix:
1.5  to 3 pg cDNA plasmid plus 1  pg EGFP in final 4 pi aliquot 
20 pi CaCh (from 340 mM filtered stock)
7024  pi  2  x  HBSS  solution  (280  mM  NaCl,  2.8  mM  Na2HPC>4,  50  mM 
HEPES, pH 7.2 with NaOH and filtered)
This  was  incubated  at  4  °C  for  1   hour  and  then  pipetted  onto  HEK  cells  plated 
4 hours previously at 20 % confluence on poly-L-lysine (100 pg ml’1 ) coated 35 mm 
coverslips.  Cells  were  then  used  for  electrophysiology  the  next  day  (more  than 
18 hours later).
Neuronal spinal cord cell culture preparation
El5  embryos  were  extracted  immediately  from  terminally  anaesthetised  and 
cervically dislocated Sprague-Dawley rats by Caesarean  section and placed in ice- 
cold phosphate-buffered  saline  (PBS).  Up  to  four spinal  columns  (not more than 
four so  that  the  speed of the  culture preparation was maximised to  give healthier 
cultures)  were  excised  and  separated  from  the  meninges  and  dorsal  root  ganglia. 
Spinal  cords  were  cut  into  four  sections  and  treated  with  0.25  %  w/v  trypsin  in 
Earle’s balanced  salt solution  (EBSS)  for  15  mins at 37  °C.  The tissue was then 
washed three times  in EBSS  to remove residual trypsin and sequentially triturated 
three times using polished Pasteur pipettes of narrowing tip diameter.  Spinal cord 
cell suspensions were then centrifuged at 500 g for 5 mins and resuspended in MEM 
plating media supplemented per  100 mis with  5  ml FCS,  5  ml horse serum (HS), 
0.6  %  w/v  L-Glucose  (Sigma)  and  0.04  % w/v NaHCC>3.  Cells were plated  at  a 
density  of 5  x  105   (approximately  one  third  of an  El5  spinal  cord)  per  35  mm 
coverslip coated either with poly-L-lysine or also with an astrocyte monolayer.  High 
quality coverslips were used (Assistent) stored in 100 % ethanol and coated in poly- 
L-lysine that was suspended in a borate buffer (50 mM boric acid, 12.5 mM sodium 
tetraborate, pH 8.5 - Banker and Goslin, 1998) in an attempt to reduce the toxicity of 
poly-L-lysine to  spinal  cord neurones.  The coverslips were washed three times in 
sterile  distilled  water to  remove  excess  poly-L-lysine.  The  next  day the  primary 
culture media was 50 % replaced with Neurobasal media supplemented with 1  % v/v 
B-27 nutrient additive, 0.25 % v/v of 200 mM L-glutamine, 1  ng/ml recombinant rat 
ciliary neurotrophic factor (CNTF, Peprotech, London) and  100 pg/ml recombinant 
glial cell-line derived neurotrophic factor (GDNF; Peprotech, London).  This media 
was  replaced  again  by  75  %  with  fresh  Neurobasal  at  the  end  of the  same  day. 
Subsequently, this medium was then replenished twice weekly.  Astrocytic cultures
71were prepared from rat cortex by Dr. P. Thomas or Miss H. Da Silva in accordance 
with an original protocol derived from Banker and Goslin, (1998).  Astrocytes were 
maintained  in  astrocyte  maintenance  media  (AMM)  made  up  in  100  ml  stocks 
consisting of 77.67 ml Earle’s MEM (without glutamine); 20 % FCS; 0.6 % (w/v) 
D-Glucose;  100 U/ml Pen/Strep.  Astrocytic cultures were washed twice weekly to 
replenish  the  cells  with  fresh  AMM  and  to  wash  away  any  contaminating 
lymphocytes.  Astrocytes were passaged once every two weeks until the time they 
were required as monolayers for spinal cord cultures.  A glass scrapper was used to 
resuspend  astrocytes  after  pre-treatment  for  1   hour  with  5  ml  trypsin/EDTA  per 
10 cm dish (0.5  g trypsin,  0.2  g NaEDTA/L in HBSS  without Ca2+ and Mg2+)  at 
37  °C.  Cells  were  then  triturated  and  either  plated  in  AMM  to  achieve  10  % 
confluence for passaging later, or plated onto 35 mm coverslips at 100 % confluence 
ready for the addition of spinal cord cultures in 7 days time. (* see end of methods)
Solutions
The internal patch pipette solution contained (mM):  140 KC1, 2 MgCh,  1   CaCh,  10 
HEPES, 11 EGTA, and 2 ATP.  The pH was adjusted to 7.11  for HEK cells and 7.3 
for  spinal  cord  primary cultures  using  1M  NaOH,  (»  300  mOsm).  The  external 
saline  solution  consisted of (mM):  140 NaCl,  4.7  KC1,  1.2  MgCh,  2.5  CaC^,  10 
HEPES,  and  11  D-Glucose.  The pH was adjusted to  7.4 using  1M NaOH (« 300 
mOsm).  Primary cultured neuronal cells were superfused in external saline that also 
contained  10  pM  bicuculline,  0.5  pM  tetrodotoxin  (TTX),  20  pM 
5-aminophosphovalerate  (AP5)  and  10  pM  6-cyano-2,3-nitroquinoxalinedione 
(CNQX) to remove GABAa and glutamate receptor synaptic activity and all action 
potentials, during glycinergic whole-cell recordings.
Experiments requiring absolute control of low (1 nM - 10 pM) concentrations of free 
Zn2+ ions were carried out in the presence of a Zn2+ buffering agent.  Tricine was
7 4 - selected as the optimal buffering agent available due to its relatively low Kd for Zn  , 
estimated at around 10'5  M (Paoletti et al.,  1997).  For those studies to elucidate the 
Zn2+  potentiation  site  of the  GlyR  family  (Chapter  5)  a  concentration  of 10  mM 
tricine was used, allowing: 0.26, 0.78, 2.6, 7.8, 26, 77.5, 254 and 775 pM total Zn2+ 
to provide effective free Zn2+ concentrations of:  1,3, 10, 30, 100, 1000 and 3000 nM
72Zn2+,  respectively  (Suwa  et  al.,  2001).  For  those  experiments  investigating  a 
potential  Zn2+  transduction pathway  from  the  inhibitory Zn2+  site  (Chapter 4)  the 
requirement for tricine based recordings was far more extensive, therefore a lower
2.5  mM concentration was used as this allowed for the health of the HEK cells to be 
maintained  for  longer recording  sessions  (unpublished  observation).  To  calculate 
free  Zn2+  concentrations  in  2.5  mM  tricine,  WINMAXC  2.40  was  used 
(http://www.stanford.edu/cpatton).  The properties for tricine were entered manually 
into  the  program  (K d  =  10*5;  Paoletti  et  al.,  1997)  and  other parameters  such  as 
temperature (20 °C) and pH (7.4) could also be accounted for.  WINMAXC 2.40 was 
also used to evaluate the final free Zn2+ concentrations in the presence of the high 
affinity  Zn2+  chelator  TPEN,  100  pM,  (A,A,AT,/V,-tetrakis-(2-pyridylrnethyl)- 
ethylenediamine; KD  =  10'1 5  6; Paoletti et al.,  1997) at pH 6.4, 7.4, and 8.4.  TPEN 
properties were already predefined in the WINMAXC 2.40 database.  Both 2.5 and 
10 mM Tricine reduced the pH of the Krebs solution, which was therefore titrated 
back to pH 7.4 using 1M NaOH. TPEN had no observable effect on the pH of Krebs 
at the 100 pM concentrations used.
Cysteine  accessibility  experiments  made  use  of 2-aminoethyl  methane  sulphonate 
(MTSEA)  in  the  form  of a hydrobromide  salt  (Insight  Biotechnology  Ltd).  This 
agent covalently modified accessible Cys residues on the GlyR after incubation of 
transfected HEK cells for 1  minute in a 3 mM concentration of MTSEA.  Frozen 
powdered MTSEA, dissolved in saline was applied directly to cells within 2 minutes.
Electrophysiology
An  Axopatch  200B  amplifier  (Axon  instruments)  was  used  to  record  whole-cell 
currents from single HEK cells or spinal cord primary cultures using the patch-clamp 
technique.  HEK  cells  exhibited  resting potentials between -10  and -40  mV  and 
were  voltage  clamped  at  a  — 40  mV  holding  potential.  Recordings  were  only 
attempted  from  ideally  single,  or  occasionally  doublets/ of HEK  cells  to  ensure 
effective space clamp of the cells as these cells maintain gap junction communication 
networks.  Healthy spinal cord neurones were judged on the basis of robust dendritic 
networking (7 days in vitro (DIV) and above), resting potentials of — 40 to -60 mV 
and  steady  holding  currents.  These  cells  were  clamped  at  -70  mV.  Cells  were 
visualised  with  a  differential  interference  contrast  Nikon  microscope  with
73epifluorescence attachment to identify EGFP transfected cells.  A Y-tube was used to 
rapidly apply drugs and Krebs solutions (exchange rate i.e.  10-90 %, rise time of a 
maximal  saturating glycine  concentration was  approximately 7-20 ms)  to  patch- 
clamped cells.  Patch electrodes were fabricated from borosilicate glass (GC150T-10 
from Harvard Apparatus Limited) using a Narashige PC-10 puller with resistances 
after polishing of 4 - 5 MQ.  All recordings were performed in constantly perfusing 
Krebs at room temperature (20 - 22 °C).
Data acquisition and analysis
All recorded current signals were filtered using a low  pass Bessel filter set to 3 kHz 
(-36dB  per  octave).  Data  were  recorded  in  20  s  acquisition  periods  directly to  a 
Pentium IV,  1.8  GHz computer running Clampex  8.0 via a Digidata  1322A (Axon 
instruments)  interface  sampling  at  200  ps  intervals.  All  digitised  currents  were 
analysed offline using Axoscope 8.2.  Acquisition periods included an initial triplet 
of  -10  mV  steps  to  monitor  the  residual  capacitance  transients  (after  initial 
compensation) and also the cell access resistance between acquisition periods.  Any 
change  of greater  than  10  %  in  the  height  of the  capacitance  transients  between 
acquisition periods  led to the data being discarded.  Experimental run-up  and run­
down was also monitored by the regular application of a submaximal concentration 
of glycine corresponding approximately to  50 % of the maximal  Gly response i.e. 
application of an EC50 agonist dose.  In the case of agonist dose response curves, the 
EC50 ‘monitor’ dose would be applied before and after application of 4 -  6 different 
doses of agonist.  When modulators  such as Zn,  or inhibitors  such as strychnine, 
were  being  tested,  control  EC50  monitor  doses  to  check  for  wash  out  of  the 
modulator/inhibitor and run-up/run-down were applied before and after every 2 -4  
test doses.  If response amplitude run-up or run-down was not observed, or was less 
than  15 %, then the test responses were normalised by linear interpolation between 
the two surrounding control agonist EC50 response amplitudes.  The maxima of EC50 
dose  response  curves  for taurine  (Fluka biochemicals)  and  p-alanine,  which  were 
demonstrated  to  be  partial  agonists  in  some  cases,  were  determined  from 
concentration response curves normalised with respect to the current activated by a 
maximal  concentration  of glycine  (usually  10  mM)  measured  in  the  same  cell. 
Inhibition dose response experiments with picrotoxin (initially dissolved in dimethyl
74sulphoxide  (DMSO)  forming  concentrated  stock  solutions),  strychnine^ or  Zn2+, 
involved pre-incubating the HEK cell with a dose of the inhibitor for 15 s to ensure 
full  equilibration,  and  then  co-applying  the  same  inhibitor  dose  with  an  EC50 
concentration  of  agonist.  For  experiments  using  the  GlyR  inhibitor  sodium 
cyanotriphenylborate (CTB -  Pfaltz  & Bauer Inc), pre-incubation was not used as 
this molecule is an open channel blocker (Rundstrom et al., 1994).
The biphasic curves, describing the Zn2+ concentration response data, were generated 
using  a non-linear  least  squares  routine  according  to  the  following modified  Hill 
equation which assumes Zn2+ binds to two distinct sites, one producing potentiation 
and the  other inhibition of the glycine-activated membrane current (Harvey et al.,
1999). For simplicity this equation assumes only one of each site per receptor rather 
than the actual five predicted to be present in a homomeric pentamer:
I  =   Inrin  +  (Ux - IM in) ([1/(1+ (E C 5(/ B D ]   -[1/(1+  (IC 5(/ B D ] ) ,   (1 )
where  I  and  1^  represent  the  modulated  peak  glycine-activated  currents  by  a 
concentration of Zn2+, B, and by a saturating concentration of Zn2+ respectively. Im jn 
represents the control glycine current in the absence of the modulator and was set to 
100  %.  E C 50  and  IC 50  define  the  Zn  concentrations  producing  a  half maximal 
potentiating  effect  and  a  50%  inhibition  of  the  maximally  potentiated  current, 
respectively. Both nn and mH  represent the respective Hill coefficients.  Where this 
equation  (1)  was  unable  to  provide  good  estimates  of the  E C 50  and  IC 50  with
y_i
acceptable errors, due to limited resolution of parts of the Zn  dose-response curves, 
the  IC 50  values were evaluated  from curve fits to the inhibitory components of the 
curve  (equation  2).  For  these  curve  fits,  the  peak  potentiation  was  taken  as  the 
maximum of the curve and the  IC 50  measured  as the point where  50 %  inhibition 
relative to this peak was attained.
The agonist concentration response curves were fitted with the Hill equation:
I/Im a x  =   [(l/1+(EC5 0 / A ) n)],  (2 )
75The EC50 represents the concentration of agonist (A) inducing 50 % of the maximal 
current evoked by a saturating concentration of agonist and ‘n’ is the Hill coefficient. 
This curve was also used to fit IC50 plots for the inhibitors picrotoxin, strychnine and 
also for Zn2+ in cases where mutated GlyRs lacked the competing Zn2+ potentiation 
component, or where equation (1) provided inadequate fits.  In some cases mutated 
GlyRs exhibiting clear biphasic  inhibition by Zn2+ were observed, these inhibitory 
dose response curves were fitted with a biphasic inhibitory curve generated by the 
equation:
I/Imax = 1  - (a X An / (An + IC50n )) + (b X An / (An + IC50n ))  (3)
All values are as previously stated but ‘a’ and ‘b’ represent proportionality constants 
reflecting the contribution to total inhibition provided by each of the two inhibitory 
components.
Where  parallel  agonist  dose  response  profiles  were  evaluated  in  the  presence  of 
incrementing concentrations of inhibitory Zn  ,  the potency of inhibition  could be 
more thoroughly evaluated to obtain a pA2 value according to the method devised by 
Schild  (Arunlakshana  and  Schild,  1959;Rocha  E  Silva  and  Schild,  1949).  Full 
concentration response curves for glycine were obtained in each HEK cell and then 
at  least  one  but  usually  more  glycine  curves  were  repeated  in  the  presence  of 
incrementing  Zn2+  concentrations  (50,  100,  200  and  500  pM).  The  curves  were 
assessed for their parallel nature and the dose-ratios (r) for Zn2+ were measured at the
' y ,
glycine E C 50 concentrations.  The mean dose-ratios for each Zn  concentration were 
then fitted with the Schild equation:
r-1 = B / Kb,
where Kb is the Zn2+ dissociation constant. The Schild equation was logarithmically 
transformed to:
log (r-1) = log B -  log Kb,
The Schild plot of log(r-l) versus log(B) was linear and if the slope of the line was 
judged to be not significantly different to unity, then the slope was constrained to one 
and the intercept on the abscissa used to determine, -logKB , which equates to the pA2* 
for Zn2+,  a  measure  of Zn2+  affinity  for the  receptor.  The  best  curve  fits  to  the 
(* pA2  = Kd)
76experimental data were achieved by applying a non linear least squares fitting routine
2
running in Origin (version 6.0)*
Structural modelling
The mature N-terminal extracellular domain (ECD) of the human GlyR al  subunit 
was modelled on the crystal structure of the acetylcholine binding protein (AChBP; 
(Brejc, 2001  89 /id)) using the freeware program SwissProt Deep  View 3.7 available 
from http://ca.expasv.org/spdbv/.  The AChBP crystal structure was downloaded as a 
PDB  file  labelled  1I9B  from  http://www.rcsb.org/pdb/  and  loaded  into  SwissProt 
DeepView  3.7,  under  main  header  File  ->  Open  PDB  file.  The  GlyR  protein 
sequence  was  uploaded  in  a  simple  text  format  into  DeepView  3.7,  under  main 
header  SwissModel  — >   Load  Raw  Sequence  to  Model  (Fig  2.2^).  The  GlyR 
sequence was then aligned with AChBP in the alignment window (Fig 2.2A) under 
main  header  Window  — >   Alignment,  in  accordance  with  a  ClustalW  protein 
alignment (Fig 2.2B).  This alignment was submitted for modelling via the program 
interface  of  Deepview,  under  main  header  SwissModel  — >   Submit  Modelling 
Request.  Upon  submission  a dialog box  opened  and the  file was  saved  with  an 
appropriate  name  in  html  format.  Upon  saving  the  file  a  SwissModel  website 
window  opens  where the user e-mail  details were  entered  and the  location  of the 
previously saved html file was provided so the website could access the modelling 
request.  The results were requested in the  Swiss-PDB Viewer mode  and then the 
details were sent.
The  GlyR  transmembrane  domains  M l-3,  and  separately M4,  were  aligned  using 
ClustalW  and  modelled  on  the  atomic  structure  of  the  Torpedo  nicotinic 
acetylcholine receptor (nAChR) chain A (PDB label,  10ED; Miyazawa et al., 2003) 
and imported into SwissProt DeepView in the same manner to that described above. 
The final GlyR ECD  and Ml-4  structures were then empirically docked to  ensure 
that the C-terminus of the ECD linked with the N-terminus of TM1; the TM2-3 loop 
was closely apposed to the base of the N-terminal Cys loop; and that the N-terminal 
domains  did  not  sterically  hinder  each  other  when  assembled  in  a  pentameric 
complex.  The finalised models, required for presentation purposes, were processed
77using  a  3D  rendering  freeware  program  called  POV-ray  3.5  for  improved  image 
quality (available from http://www.povrav.org/).
Statistics
All statistical analysis was carried out using the Student’s t-test in Microsoft Excel. 
Comparisons of data sets recorded in the  same cell were considered paired whilst 
those from separate cells were treated as unpaired.  The analysis compared all data 
under a two-tail hypothesis and quantified significance to the 5 or 1   % levels, stated 
in the text.
* Animals were  anaethetised  in  a chamber using halothane in  accordance with the 
Scientific  Procedures  Act  (1986).  Animals  were  obtained  from  the  University 
College London pharmacology animal house, where animals were kept in accordance 
with the government guidelines on animal housing.
*2  Exponential curves for decay components of desensitisation traces (Chapter 3) and 
for rates of action of glycine EC50 currents (Chapter 5) were  fitted using Igor Pro 
version 4.01.
78hGlyR alL    MYSFNT-  -LRLYLSGAIVFFSLAASKEAEAARSATKPMSPSDFLDKLMGRTSG--
hGlyR a2A  MNRQLVNILTALFAFFLETNHFRTAFCKDHDSRSGKQPSQTLSPSDFLDKLMGRTSG---
hGlyR P  MKFLLTTAFLILISLWVEEAYSKEKSSKKGKGKKKQYLCPSQQSAEDLARVPANSTSNIL
AChBP                LDRADILYNIRQT--
hGlyR aiL    ydarirpnfkgppvnvscnifinsfgsiaettmdyrvniflrqqInI prIayne
hGlyR a2A  ------YDARIRPNFKGPPVNVTCNIFINSFGSVTETTMDYRVNIFLRQqInIsrIaYSE
hGlyR p  n rl lv s ydprirpnfkgipvdvwnifinsfgsiqettmdyrvniflrqkInIprIklps
AChBP    s rp dv i pt q rd rp v avsvslkfinilevneitnevdwfwqqtt|s|rt|awns
hGlyR alL  YPDDSLDL  -   -   DPSMLDS11FFANEKGAHFHEITTDNKLLRISRldfcjVLYSIRITLT
hGlyR a2A  YPDDSLDL--DPSMLDSI|kH lFFANEKGANFHDVTTDNKLLRISKNjKVLYSIRLTLT
hGlyR P  DFRGSDALTVDPTMYKCJkH lFFANEKSANFHDVTQENILLFIFRdIdVLVSMRLSIT
AChBP  SH-SPDQV-  -SVP-  ISS  L§vH lAAYN  -   AIS  KP  E  VLT  PQ  -   -   LARWS  d|e  VL  YM  P  SIRQR
hGlyR aiL  laIpmdlknfpmdvqtJimqlesfgytmndlifewqeqgavqvadgltlpqf-ilkeekd
hGlyR a2A  LS|PMDLKNFPMDVQtItMQLESFGYTMNDLIFEWLSDGPVQVAEGLTLPQF-ILKEEKE
hGlyR p  lsIpldltlfpmdtqrIkmqlesfgyttddlrfiwqsgdpvqlek-ialpqfdikkedie
AChBP  FSJDVSGVDTESG-ATfRIKIGSWTHHSREISVDPTTENSDDSEYFSQYSRFEILDVTQK
hGlyR alL  LRYCTKHYN-TGKFTCIEARFHLERQM
hGlyR a2A  LGYCTKHYN-TGKFTCIEVKFHLERQM
hGlyR p  YGNCTKYYKGTGYYTCVEVIFTLRRQV
AChBP  KNSVTYSCC-PEAYEDVEVSLNFRKKG
Figure  2.2  SwissProt  modelling  program  interface  and  amino  acid  homology 
alignment of hGlyR N-termini  with the AChBP.  The  alignment was based on  a 
ClustalW multiple sequence alignment and required mild manual optimisation.  Grey 
boxed residues represent critically conserved residues present through the cys-loop 
receptor family.Chapter 3 
Molecular determinants of glycine receptor ap subunit sensitivities 
to Zn2+ inhibition
Introduction
Zn2+  is  a  biphasic  modulator  of  GlyRs,  potentiating  agonist  responses  at  low 
concentrations  (0.1  -   10  pM)  and  eliciting  an  inhibitory  effect  at  higher 
concentrations (Bloomenthal et al., 1994;Laube et al., 1995).  Whilst the specific site 
of Zn2+ potentiation has to date remained difficult to define (Laube et al., 1995;Laube 
et  al.,  2000;Lynch  et  al.,  1998),  three  pivotal  structure-function  studies  have  all 
reported evidence supporting a clear role for GlyR al  amino acids HI07 and HI09 
in  Zn2+  mediated  inhibition  (Harvey et  al.,  1999;Nevin  et  al.,  2003).  These  two
^ i   #
residues  fit  the  criterion,  chemically,  of classical  Zn  binding  moieties  and  are 
predicted  to  reside  in  close  apposition  on  a  GlyR  structural  model  (Nevin  et  al.,
94- 2003), ideal for the formation of a discrete Zn  inhibitory site.
Despite this progress  there have been no  clearly defined  studies  investigating  any
94- potential GlyR subtype dependence that may exist for Zn  mediated inhibition.  This 
is of interest as it may reveal novel insight into structure-function properties of the 
site and may identify Zn2+ as a useful pharmacological tool to distinguish between 
GlyR subtypes for which there are currently few selective antagonists (Laube et al., 
2002b).  In the original  study by Laube et al,  (1995)  GlyR al  and al  were both 
shown to retain a comparable sensitivity to Zn2+ mediated inhibition, whilst a recent 
study suggests the auxiliary GlyR p subunit is not important for the inhibitory effect 
(Nevin et al., 2003).  Additionally, a comparison between the GlyR a2A and a2B 
splice variants, which differ by a dual amino acid substitution in the extracellular N- 
terminal  domain,  revealed  similar  sensitivities  to  Zn  modulation,  (Miller  et  al.,
2004).  The comparable  sensitivity of al  and a2  to  inhibitory Zn2+  suggested by 
Laube et al, (1995) is surprising as an amino acid alignment of GlyR a 1-4 plus GlyR
94- p  encompassing the specified Zn  binding site region of interest revealed that al 
differs crucially from all other GlyR subtypes at the putative Zn2+ binding residue
80HI07 (Fig 3.1).  This unique histidine is replaced by an Asn in GlyR al-3 and GlyR 
P,  a  residue  not  known  for  its  chemical  capacity  to  coordinate  Zn2+  ions  (Auld, 
2001).  Previous studies to compare the subtype dependence in GABAa receptors for 
Zn2+ inhibition have already shown that potential Zn2+  binding residues, which vary 
between GABAa subunits, appear to impart on these subunits differing sensitivities 
to  inhibitory  Zn2+  (Smart  et  al.,  1991;Draguhn  et  al.,  1990;Hosie  et  al.,  2003). 
Therefore,  it  follows  that  if GlyR al  HI07  is  a genuine Zn2" binding residue,  it 
should  alter  the  receptor’s  sensitivity  to  inhibition  by  this  divalent  cation  when 
compared to other GlyR subtypes where this histidine is absent.
This chapter aims to investigate what role,if any, GlyR al  HI07 plays in subtype 
sensitivity  to  inhibitory  Zn  .  This  influence  is  investigated  for  potential 
physiological relevance by assessing the impact of co-expression of a-subunits with
^   i  a   i
the  GlyR  p  subunit  on  Zn  inhibition  and  also  by  the  measurement  of  Zn 
inhibitory potency in a spinal cord culture preparation.  Furthermore, attempts were 
made  to  isolate  additional  variable  elements  that  might  be  responsible  for 
contributing to the differential  sensitivity observed between GlyR subtypes.  These 
studies  were  supplemented  by  an  investigation  using  the  P  subunit,  which  can 
enforce  a  fixed  stoichiometry  of Zn2+  binding  sites  upon  GlyR  heteromers,  to 
elucidate  information  about  any asymmetry of function that may exist  within the 
GlyR inhibitory Zn2+ site.
GlyR al PDLFFANEKGAH 
GlyR a2 PDLFFANEKGAN 
GlyR a3  PDLFFANEKGAN 
GlyR a4 PDLFFANEKGAN 
GlyR P  PDLFFANEKSAN
Fig  3.1  Primary  amino  acid  sequence  alignment  of  the  GlyR  family 
highlighting the unique nature of HI07 (underlined), a candidate residue in the 
inhibitory Zn"" binding site, in the GlyR al subtype.  Another important residue 
for Zn2" mediated inhibition, HI09 (blue background), is conserved throughout 
the family.
lEITTDNKLLRISR  122 
)VTTDNKLLRIS  K  129 
SVTTDNKLLRIFK  122 
IEVTTDNKLLRIFK  115 
)VTQENILLFIFR  145
81Results
Differential Zn2+ sensitivity between GlyR al and GlyR al subunits
A comparison of the sensitivities of GlyRs to Zn  mediated inhibition was initiated 
since one of the key Zn  binding residues, HI07, is present in the GlyR al  but not 
the  GlyR  a2  subtype.  Modulation  by  Zn  was  examined  using  two  different 
protocols.  The first involved co-application of varying concentrations of Zn2+ with a 
half-maximally effective (EC50) concentration of glycine.  The degree of inhibition 
was measured for the peak glycine response (Ipeak) and 4s into the co-application (I4) 
to reveal a delayed onset of inhibition (Fig 3.2A-C).  The second protocol utilised a 
pre-incubation of Zn  and only the peak glycine responses were measured as pre-
I
incubation allowed Zn  to equilibrate with the GlyR (Fig 3.2D).  Irrespective of the 
protocol, all Zn  concentration response curves exhibited a biphasic shape due to the
'y ,
potentiating  and  inhibitory  effects  of Zn  on  GlyRs.  However,  contrary  to  a 
previous report (Laube et al.,  1995), a clear difference in the potency of inhibitory 
Zn2+ was observed between GlyR al  and GlyR a2 subunits.  This was most distinct 
using the pre-incubation protocol, with a 25-fold reduction in Zn2+ potency apparent 
from an IC 50 of 15 ± 2 pM, (n = 5) for GlyR al to an IC 50 of 360 ± 40 pM, (n = 11) 
for GlyR a2 (P < 0.05; Table 3.1).  All subsequent experiments therefore utilised the 
pre-incubation protocol with Zn2+.
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Figure 3.2  Differential inhibition of glycine-activated currents by Zn2+ at GlyR al 
and  GlyR  a2  using  whole-cell  patch-clamp  recordings  from  HEK  cells.  A,  Zn2+ 
modulation concentration response curves of 50 % maximal glycine-evoked currents 
measured  at  the peak  (Ipeak)  of a 4  s  co-application  of glycine  and Zn2+.  B,  Zn2+ 
concentration response curves as in (A) but responses measured at the end of the co­
application (I4).  C, Example membrane currents comparing glycine-activated Ipeak and 
I4  for  GlyR  al  (top)  and  GlyR  a2  (bottom)  after applying  50  %  maximal  glycine 
concentrations in the absence and presence of co-applied 10,  100 and 1000 pM Zn2+. 
D,  Glycine-activated  current  following  co-application  of 50  %  maximal  doses  of 
glycine with Zn2+  after prior incubation for  15  s with an equivalent concentration of 
Zn2+ for GlyR al  and GlyR a2.  The inset shows a typical 50 % maximal glycine- 
activated current for GlyR al in the absence and presence of 1000 pM Zn2+ under the 
pre-incubation protocol.  N = 6 -  13 for all experiments.
83Histidine  107  determines  the  differential  Zn2+  sensitivity  between  GlyR  a 
subunits
Comparing the N-terminal extracellular domains of the GlyRs reveals that GlyR a2, 
like all other a variants except GlyR al, retains an asparagine (N114) residue at the 
homologous position to  the putative  Zn2+  binding residue,  HI07,  in  the  GlyR  al 
subunit (Fig 3.1).  If HI07 coordinates Zn2+, then the divergent N114 in GlyR a2
7 -4 - could be responsible for the differential sensitivity to Zn  as asparagines are poor
7 -4 - coordinating  partners  for Zn  (Auld,  2001).  This  was  examined  by  exchanging 
residues between the GlyR al  and a2 subunits at the equivalent positions of HI07 
(al) and N114 (a2) to generate a lH 107N  and a2N 114H .  This exchange reversed the 
sensitivities of the GlyR al and a2 subunits with regard to Zn2+ inhibition, such that 
aihio7n  230 ± 40 pM, n = 5) was now approximately 8-fold less sensitive to 
Zn2+ compared to a2N 114H  (29 ± 2 pM, n = 4; P < 0.05, Fig 3.35, Table 3.1).  Taken 
together this strongly suggests that HI07 not only forms part of the inhibitory Zn2+  
binding site but also it is largely responsible for the different sensitivities of the GlyR
7  .
al and GlyR al subunits to Zn  inhibition.
GlyR a3 exhibits low sensitivity to inhibition by Zn2+
To  further  establish  the  significance  of HI07  in  the  subtype  sensitivity  to  Zn2+ 
inhibition,  the  GlyR  a3  subunit,  which  possesses  an  asparagine  residue  at  the 
homologous  107 position, was also examined in this regard to its sensitivity to Zn2+  
inhibition.  This  is  of  particular  relevance  as  currently  there  are  no  selective 
pharmacological blockers to  distinguish between the two  adult GlyR subtypes,  al 
and  a3.  Consistent  with  the  data  for  GlyR  a2,  the  potency  of Zn2+  was  also 
substantially reduced on GlyR a3 (IC 50 = 150 ± 10 pM, n = 4).  In accord with GlyR 
a2 subunits, replacing N107 with histidine in GlyR a3 subunits (a3N 107H ) increased 
the potency of Zn2+ mediated inhibition (IC 50 = 26 ± 7, n = 3; P < 0.05, Fig 3.35).
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Figure 3.3 Reversal of GlyR a 
subunit  sensitivities  to  Zn2+  
mediated  inhibition.  A,  GlyR
H107N  ,   ~N114H al  and  GlyR  a2
mutants  and  B,  GlyR  a3  and 
GlyR a3N 107H   Zn2+  concentration 
response  curves  for  modulating 
50  %  maximal  glycine-activated 
currents.  The current peaks were 
compared  for  50  %  maximal 
glycine  responses  in  the  absence 
and  presence  of  varying 
concentrations  of Zn2+  after  15  s 
pre-incubation with an equivalent 
Zn2+  concentration.  Curves  for
wild-type GlyR al  and  GlyR a2
2+
Zn  modulatory  profiles  are 
included  for  comparison  in  A 
(taken from Figure 3.2D).  N = 4 
-  5 for all experiments.
85Mechanism for Zn2+ inhibition on GlyR al and GlyR al subtypes
The proposed mechanism of Zn2+ inhibition has not been fully investigated, although 
glycine  concentration  response  curves  determined  in  the  presence  of  a  single
'7-+-  •  •  •  •  •  •
concentration  of Zn  show  no  depression  in  the  maximum  response  which  is  in 
accord  with  an  apparent  competitive  mechanism  of  inhibition  (Laube  et  al., 
2000;Han and Wu,  1999).  The mode of Zn2+ inhibition was characterised for both 
GlyR al and GlyR a2 subtypes by generating glycine concentration response curves 
in the presence of several inhibitory concentrations of Zn  (Fig 3AA,B).  For both 
GlyR al  and al  subunits the glycine curves were displaced by Zn2+ in a parallel 
manner  without  any  significant  reduction  in  the  maximal  current  elicited  by 
saturating concentrations of glycine, consistent with an apparent competitive mode of 
inhibition.  Due to the relatively high sensitivity of GlyR al to Zn2+ inhibition it was
94- possible  to  pre-incubate  at  several  different  inhibitory  Zn  concentrations  and 
achieve measurable separation between each of the glycine concentration response 
curves.  This  was  not  possible  for  the  less  sensitive  GlyR  a2  subunit  without 
incurring solubility problems due to the high concentrations of Zn2+ required.  This 
series  of  parallel  glycine  curves  were  transformed  into  a  Schild  plot  for  the 
evaluation  of  a  pA2  value  for  Zn2+  as  an  antagonist  at  the  GlyR  al  subtype 
(Fig 3 AC).  The Schild plot slope was not significantly different from one, and the 
constrained slope, with a gradient of 1, provided a pA2 value that was 4.44 ± 0.14, 
yielding a dissociation constant for Zn2+ from the inhibitory site of 27.5 ± 0.87 pM, 
(n = l ).
Rate of onset of Zn2+  inhibition at GlyR al and a2
From the data presented in Fig 3.2, a pre-incubation protocol using  1000 pM Zn2+  
caused a substantial amount of inhibition at both GlyR al  (90 ± 2.4 %, n = 6) and 
GlyR a2 (78 ± 4.4 %, n = 11).  During co-application protocols however, the level of 
inhibition  induced by  1000  pM  Zn2+  was  dramatically  different between  the  two 
subtypes  of receptor (compare  raw  data traces  Fig  3.2C).  To  assess  the  rates  of 
onsets of Zn2+ inhibition at GlyR al and a2, potency matched doses of Zn2+ (40 and 
1000  pM respectively) corresponding to  approximately 70 % inhibition under pre­
incubation conditions, were instead co-applied with 50 % maximal Gly doses for a
94- prolonged 60 s penod to allow Zn  inhibition to reach a steady-state.  A prolonged
8660 s application of Gly alone revealed a directly comparable biphasic desensitisation 
profile  for both  GlyR  al  and  a2,  with  initial  fast  desensitisation  components  of 
4.1  ±  0.2  s,  (n  =  6)  and  5.6  ±  1.3  s,  («  =  5),  and  secondary slow desensitisation 
components  of 45.7  ±  7.8  s,  («  =  6)  and  49.5  ±  7.6  s,  (n  =  5)  respectively (Fig 
3.5A,C).  As observed previously for the co-application protocol, during the initial 
activation phase  for Gly plus Zn2+ responses, the current was in fact enhanced  for 
both al  and a2 due to the rapid onset of Zn  potentiation on GlyRs.  In the case of 
the  slow  activating  GlyR  a2  subtype  (Mangin  et  al.,  2003)  the  initial  Zn2+ 
enhancement caused a significant decrease in the 10 - 90 % rise time to reach steady- 
state from  1.4 ± 0.4 s, (n = 5) in the absence of Zn2+ to 0.5 ±0.1  s, (n = 5) in the 
presence of Zn2+  (P < 0.05; Fig 3.5A,B).  The GlyR al  subtype, however^ shows a
9 -4 - faster  activation  time  in  the  absence  of Zn  compared  to  a2  and  this  did  not 
experience a significant increase in activation rate for the 40 pM dose of Zn  tested 
(Fig 3.5A,B).  The delayed inhibitory component of Zn2+ modulation observed during
9 ^ co-application  of equivalent  doses  of Gly  with  potency  matched  doses  of Zn 
revealed that the rate of onset of inhibition is in fact indistinguishable between the 
two receptors.  In both cases the slow desensitisation phase was completely ablated 
leaving only a fast decaying component.  This fast phase exhibited a modest  1.5 to 
2-fold  increase  in  the  rate  of decay  to  steady  state  compared  to  the  previously
9   i
identified fast desensitisation in the absence of Zn  , from 4.1 ± 0.2 s to 2.8 ± 0.4 s, 
(n = 6) for GlyR al and 5.6 ± 1.3 s, to 3.1 ± 0.3 s, (n = 5) for GlyR a2 (Fig 3.5,4,Q.
9 -4 - The total amount of inhibition after 60 s in 40 and 1000 pM Zn  compared to in the 
absence of Zn2+ was not significantly different between the two receptors.  GlyR al 
was inhibited by 63  ±  7  %,  (n  = 6)  and a2  was  inhibited by 57 ±  13  %,  (n  = 5) 
indicating  that  the  potencies  of  inhibition  were  accurately  matched.  The  data 
therefore suggest that the substitution of al  HI07 with a2 N114 does not interfere
9 +   9 -4 - with the rate at which Zn  can access the inhibitory site,or the rate at which Zn  can 
mediate its effect. (*  Note  that  desensitisation  time  constants  were  measured  by 
fitting decay components with single or double exponential curve fits as appropriate).
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Figure  3.4  Zn2+  exhibits  a 
competitive mode of inhibition at 
GlyR al  and GlyR a2.  Glycine 
concentration response curves  for 
both  al  {A)  and  al  (.B)  GlyRs 
exhibit  clear  parallel  rightward
24-
shifts  in  the  presence  of  Zn
without  any  decrease  in  the
maximum response.  In all cases 
2+  • Zn  was  co-applied  with  the
agonist  glycine  after  a  15  s  pre­
incubation  with  an  equivalent
2+
concentration  of  Zn  .  Glycine 
curves  for  GlyR  al  were 
measured  in  the  absence  and 
presence  of  50,  100,  200  and 
500 pM Zn2+; and for GlyR a2 in 
the  absence  and  presence  of 
500  pM  Zn*.  C,  Schild  plot 
generated from the GlyR al dose- 
ratios  taken  from  the  curves  in 
(A).  A  solid  line  indicates  the 
constrained unity slope with 95 % 
confidence  intervals  assigned  by 
dashed  lines.  All  experiments 
were from an n of 6 -  13.
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Figure 3.5  The effect of co-applied Zn2+  on the decay time constants of 50 % 
maximal Gly responses for GlyR al  and a2.  A, Typical raw data traces showing 
prolonged 60 s application of 50 % maximal doses of Gly in the absence (black) 
and presence (red) of potency matched doses of Zn2+, 40 and  1000 pM for GlyR 
al and al respectively. R, 10 - 90 % rise-times in the absence and presence of the 
same Zn2+  concentrations, highlighted and enlarged in dashed green boxes in (A). 
The time for the slower activating macroscopic current of GlyR a2 to reach steady 
state  is  markedly  reduced  whilst  the  rate  for  al  is  unaffected  by  Zn2+. 
C, Barcharts revealing that GlyR al  and al have comparable desensitisation time 
constants in the absence and presence (red bars) of Zn2".  In the absence of Zn2+  
traces decay with two time constants, fast (4 - 5  s) and slow (40 -  50 s).  In the 
presence of Zn2+  decay with only a fast time constant (approximately 3 s), dotted 
black lines denote the speed of the original fast decay time constant in the absence 
of Zn2+.  N=2>-6.
89Differential sensitivity to Zn2+ inhibition is unaffected by the GlyR p subunit
The 30-fold increased sensitivity of GlyR al over GlyR a2 to Zn2+ inhibition makes 
this  ion  a  potentially  useful  pharmacological  tool.  Whether  this  differential 
sensitivity could be maintained  at native neuronal  GlyR populations was  assessed 
using  recombinant  GlyR  ap  heteromers,  which  are  considered  to  be  the  major 
physiological subtype of the GlyR (Pfeiffer et al.,  1982).  Successful co-assembly of 
GlyR a and  P  subunits was established by measuring a reduction in sensitivity to 
picrotoxin (by approximately 20-fold) compared to homomeric GlyR a subunits as 
previously reported (data not shown; Pribilla et al., 1992;Handford et al., 1996).  The 
GlyR  a2p  heteromers  exhibited  a  subtle  though  consistent  2-fold  increased 
sensitivity to Zn2+ inhibition (IC 50,  180 ± 30 pM, n = 13) compared to the GlyR a2 
homomers (360 ± 40 pM, n = 11; P < 0.05; Table 3.1).  Consistent with the previous 
findings  for  GlyR  homomers,  the  GlyR  a2p  sensitivity  to  Zn  remained 
substantially lower when  compared  with  GlyR  aip,  which retained  a comparable 
sensitivity to the GlyR al homomer (Fig 3.6A,B, Table 3.1).
GlyRs from cultured spinal cord neurones show a low non-al-like sensitivity to 
Zn2+ inhibition
To  evaluate whether a differential  sensitivity to Zn2+  inhibition was  apparent  in  a
•  7 -+-  •  • native environment, the Zn  sensitivity profiles of neuronal GlyRs were assessed in 
embryonic spinal cord cultures and in adult rat acute spinal cord slices.  During early 
embryonic  development  and  in  dissociated  culture,  the  GlyR  a2  appears  to  be  a 
predominant a subtype, with a limited up-regulation of GlyR al during the course of 
culture maturation (Hoch et al., 1989;Hoch et al., 1992).  This becomes more evident 
in  vivo  during  late  embryonic  to  early  postnatal  development  when  neurons 
substantially up regulate the GlyR al  subtype (Becker et al.,  1988;Takahashi et al., 
1992;Watanabe and Akagi,  1995).  Whole-cell recordings from 90 % of rat spinal 
cord  cultured  neurones  responded  to  exogenously  applied  glycine  and  multipolar 
neurones  at  7  days  in  vitro  (DIV)  or  older,  displayed  robust  glycinergic  synaptic 
activity (example recording Fig 3.7A).  The three age groups that were selected for 
study at, 5, 7 and 10-14 DIV, showed an overall low sensitivity to Zn2+ with 5 DIV 
neuronal  cultures  especially exhibiting a pharmacological profile consistent with a
90low sensitivity GlyR subtype in accord with the GlyR a2 subtype (Fig 3.7B, Table
3.1).
Growing spinal cord cultures on an astrocyte monolayer has been shown to enhance 
the  development of GABAergic  and glutamatergic  synaptic inputs during the  first 
week of development (Li et al.,  1999).  We examined whether this co-culture may 
accelerate glycinergic maturation and perhaps drive the development of cultures into 
expressing  al  subunits  as  occurs  in  vivo  (Becker  et  al.,  1988;Takahashi  et  al., 
1992;Watanabe  and  Akagi,  1995).  Astrocytic  co-cultures  did  accelerate  the 
formation of synaptic activity with 5 DIV co-cultures exhibiting both a substantially 
higher frequency of synaptic events and also larger amplitude events, compared to 
5 DIV monocultures.  (5 DIV on astrocytes; mean synaptic amplitude, 450 ± 280 pA, 
frequency = 4.8 Hz:  5  DIV monoculture; mean synaptic amplitude, 250 ± 280 pA, 
frequency =1.8  Hz; Fig 3.8^4).  However,  development of spinal cord cultures on 
astrocyte monolayers failed to produce a noticeable increase in the sensitivity to Zn2+ 
mediated inhibition from 5 DIV to 7 DIV, or when compared to spinal cord cultures 
not grown on astrocytic monolayers (Fig 3.82?, Table 3.1).
This work was directly complemented by following the period during which GlyR 
expression switches in vivo.  To do this, electrophysiological recordings were made 
from neurones in acute spinal cord slices at P0 and PI8.  Whole cell recordings using 
pre-incubation  with  30  pM  Zn2+  exhibited  only  a  partial  inhibition  at  P0,  of 
36 ± 4 %, {n =  19) consistent with a possible mixed GlyR al  and al population; 
however, a profound inhibition, 69 ± 4 %, (n =  13), was exhibited at PI8 in accord 
with  a  progressive  developmental  transition  to  the  adult  GlyR  al  subtype  (Fig 
3.9A,B).  These experiments were performed in collaboration with M.Beato.
91B
c
£
i— 3 0
■ §
1 ■ 4 — l 0
C D 1   1  
0  c
■ f t
O
80 -
40
0
GlyR ct2 
Glycine  +100 Zn2+
GlyR a2p
\ J \J  VJ
1s
160
120
■  GlyR a ip  
O  GlyR a2p 
GlyR a1 
GlyR a2
0.1
Zn2+ concentration (pM)
Figure  3.6  Differential  sensitivity  to  inhibitory  Zn2+  is  retained  in 
physiologically  relevant  recombinant  GlyR  ap  heteromers.  A,  Typical  50  % 
maximal currents evoked by application of an EC50 dose of glycine, on GlyR a2 
and GlyR a2p respectively, in the absence (solid line) and presence (dashed line) 
of 100 pM Zn2+.  This shows there is a modest though not profound difference in 
the potency of inhibitory Zn2+  between the homomeric and heteromeric GlyR a2. 
B, Zn2+  concentration response curves for the modulation of 50 % maximal glycine 
responses  on  GlyR  alp  and  GlyR  a2p  heteromers  in  the  presence  of varying 
concentrations of Zn2+   after  15s pre-incubation with the same concentration  of 
Zn  . For comparison, the Zn  sensitivities of recombinant GlyR al and GlyR a2 
homomers are shown (taken from the curve fits in Figure 3.2D).  N= 3-7.
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Figure  3.7  Native  GlyRs  from  primary  cultures  of spinal  cord  neurones 
exhibit a low  sensitivity to Zn2+ mediated inhibition.  A,  A selected epoch of 
synaptic activity from a 7 DIV neurone demonstrating that they receive robust 
glycinergic  input.  This  was  assessed  by  monitoring  synaptic  activity  in  the 
presence  of  10  pM  bicuculline,  20  pM  AP5  and  10  pM  CNQX  to  inhibit 
GABAA,  NMDA  and  AMPA  receptors  respectively  (left  panel)  and  then 
ablating  this  activity  in  the  presence  of  a  GlyR  selective  inhibitor,  1   pM 
strychnine (right panel).  B,  Native receptors from rat spinal cord cultures at 5, 7 
and  10-14 DIV exhibit a low sensitivity to inhibitory Zn2+  consistent with the 
expected  predominant  presence  of  GlyR  a2  in  the  embryonic  spinal  cord. 
Again, for comparison, the curve fits for the recombinant GlyR al and GlyR a2 
homomers  are  shown (from  3.2D).  The inset raw  data traces illustrate,  on  a 
5  DIV neuron, modulation by 100 and  1000 pM pre- and then co-applied Zn2+  
with a 50 % maximal dose of glycine.  N= 8.
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Figure 3.8  Spinal cord neurones plated on astrocytic monolayers exhibit a low 
sensitivity to Zn2+  mediated inhibition.  A,  Synaptogenesis occurred significantly 
earlier  for  astrocytic  co-cultures  (lower panels),  which  received  robust  synaptic 
input by 5 DIV (up to 2 nA currents; compare with 7 DIV neurones in Fig 2>.1A) 
whilst  5  DIV  spinal  cord  monocultures  (upper  panels)  had  less  frequent  and 
smaller  synaptic  currents  (<  200  pA).  Whole-cell  exogenous  glycinergic 
responses were measured in the presence of 10 pM bicuculline, 20 pM AP5  and 
10 pM CNQX to inhibit GABAA, NMDA and AMP A receptors respectively plus 
TTX  to  effectively  block  all  synaptic  input  including  spontaneous  glycinergic 
events  (right panel).  B,  Despite  accelerated  synaptogenesis  of rat  spinal  cord 
cultures  on  astrocytic  monolayers  these  neurones  retained  a  low  sensitivity  to 
inhibitory Zn2+  at 5 and 7 DIV.  Comparison of inhibition curves for recombinant 
GlyR al  and GlyR a2 homomers are included (from 3.2D).  The inset raw data 
traces illustrate, on a 5  DIV neurone, modulation by 100 and  1000 pM pre- and 
then co-applied Zn2+ with a 50 % maximal dose of glycine.  N= 8.
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Figure 3.9  A switch to the high GlyR al-like sensitivity to Zn2+ mediated
inhibition does occur in rat ventral horn spinal cord neurones in  vivo.  A,  Bar  2+  .  .  2+  
chart of Zn  inhibition following pre- and then co-applied 30 pM Zn  .  This
demonstrates the shift to high sensitivity Zn2+ inhibition in more mature acute
spinal cord slices consistent with an expected shift to the high Zn2+ affinity GlyR
al  subtype  (the  bar  for 5  DIV,  representing  embryonic  stages,  is  taken  from
Fig  3.7B).  B,  The  sample  currents  demonstrate  inhibition  and  subsequent
recovery (after 10 minutes) from modulation by 30 pM Zn2+ for a young PI  and
juvenile PI 8 neurone.  All experiments were from 8 -1 9  cells.  This work was
performed in collaboration with M.Beato.
Identification of the structural elements required for Zn2+ inhibition
Inspecting the aligned primary sequences of GlyR a and p subunits reveals that the 
GlyR p subunit, like the a2 subunit, retains the low affinity asparagine residue at the 
homologous position to the Zn2+ binding GlyR al  subunit HI07.  This is curious 
since co-expression of the p subunit with the GlyR a2 subunit in this study caused a 
modest increase in the sensitivity of this homomer to Zn2+ inhibition.  This suggested 
that perhaps contrary to previous reports, the p subunit may actually contribute to the 
Zn  binding  site.  Such  a  p  subunit  dependent  increase  in  sensitivity  was  not 
observed with the alp heteromer, presumably because the al subunit has the highest 
subtype sensitivity to Zn2+ realised through the presence of its unique residue, HI07. 
A directed comparative scan was therefore made of the a2  and p  subunit primary
95amino  acid  sequences  guided by modelling  the  GlyR N-terminal  domains  on  the 
crystal structure of the homologous acetylcholine binding protein (AChBP; Brejc et 
al., 2001).  This approach identified specific amino acid differences in the predicted 
vicinity of the GlyR al HI 07 and HI 09 based Zn2+ inhibitory binding site.  Of these, 
only two residues differed that might impact on Zn2+  coordination at this  site.  In 
GlyR  a2  subunits,  G112  (al  G105)  and  T140  (al  T133)  are  replaced  in  the 
P subunit by SI28 and SI56, respectively (Fig 3.10,4,2?).  In view of their proximity 
to the Zn2+ inhibitory site, the p subunit residues were switched for their a2 subunit 
counterparts using the mutations, GlyR psl28G  and psl56T, in an attempt to remove 
and  therefore  elucidate,  the  cause  of the  p  subunit  induced  increase  in  GlyR  a2 
sensitivity to Zn2+ inhibition.  However, neither GlyR p8128G  nor pS 156^ removed the 
ability of the p subunit to increase GlyR al sensitivity to Zn2+ inhibition (Fig 3.10C; 
Table 3.1).  In the absence of other suitable p subunit residues capable of interacting 
with the Zn2+ inhibitory site, the effect of the p subunit on GlyR a2 may instead be 
an indirect structural effect.  Such a role has been suggested for T il2 in the GlyR
i
a subunit (Nevin et al., 2003), which also affected GlyR sensitivity to Zn  inhibition 
(Laube et al., 2000).
Further  structural  comparisons  of the  GlyR  al  subunits  revealed  that  the  T133 
residue is located on p strand 6 (according to the nomenclature of Brejc et al, 2001), 
which is predicted to reside directly below HI09 on p strand 5.  Moreover, another 
threonine  in  GlyR  al,  T135,  is  also  located  on  p  strand  6  directly below  HI07 
(Fig  3.10,4,2?).  Since  GlyR  al  T133  and  T135  residues  are  ideally  located  as 
potential coordinating ligands  for Zn2+,  lying just below the putative Zn2+ binding 
HI09  and HI07 respectively, these threonines were assessed for their role in Zn2+ 
inhibition by individual mutation to  alanines.  Although GlyR a lT 135A  exhibited a 
comparable Zn2+ IC 50 (29 ± 2 fiM, n = 3) to the wild-type GlyR al subunit, the GlyR 
a lT 133A  mutation ablated Zn2+ inhibition up to 1  mM (n = 5, Fig 3.10Z), Table 3.1).
96■
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Figure 3.10  Evaluation of potential binding residues in the immediate vicinity of the 
inhibitory Zn2+  site.  A, Two neighbouring GlyR al subunits modelled on the AChBP, 
expanded  in  B,  to  highlight  inhibitory Zn2+   binding  site  residues,  HI07  and  HI09 
(orange)  and  two  newly-identified  potential  Zn2+  binding residues,  T133  and  T135 
(blue). An additional variant residue, in the P subunit SI28, is also shown (red).  In (,4) 
p-strand 5  (green) containing HI07 and HI09 is presented directly above p-strand 6 
(pink) containing T133 and T135.  B, Homologous residues are shown in parentheses. 
For reference, GlyR al El 10 (green) and T112 (pink), previously shown (Laube et al., 
2000) to influence Zn2+   mediated inhibition,  are included and are both predicted to 
face away from the site, suggesting the side chains of these residues could not directly 
coordinate Zn2+.  C,  Assessment of potential p-subunit variants that may induce the 
modest increase in sensitivity to Zn2+  mediated inhibition on the GlyR a2 subtype by 
measuring Zn2+  modulation of 50 % maximal glycine responses (using pre- and then 
co-applied Zn2+) on GlyR a2psl“8tj and GlyR a2psl56T heteromers.  Comparison with 
recombinant GlyR a2  and GlyR a2p  curves (originally from 3.2D and 3.65)  show 
that these substitutions do not account  for the  p-subunit influence on a2.  D, Zn2+ 
concentration response curves for modulation of 50 % maximal glycine responses at 
GlyR a lTlj3A and GlyR a lT 133A  with wild-type GlyR al present for comparison (from 
3.2D). Inset shows raw data traces demonstrating the resistance of glycine responses 
on GlyR a lT 133A  to inhibition by 1000 pM Zn2+.  N= 3-6.
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97Using the GlyR p subunit to investigate functional asymmetry at the inhibitory 
Zn2+ binding site
Although  a  role  for  the  p  subunit  in  coordinating  Zn  has  not  been  favoured 
previously (Bloomenthal et al.,  1994;Laube et al., 2000;Nevin et al., 2003) the data 
presented here suggested that this subunit can influence the potency of Zn  at GlyR 
a2p heteromers.  We addressed the ability of the p subunit to contribute directly to 
the  Zn  binding  site  by  examining  whether  it  could,  if appropriately mutated  at 
homologous positions, compensate for mutated GlyR al  subunits with reduced Zn2+ 
sensitivities.  For  example,  to  compensate  for  the  mutation,  GlyR  a lH 107N ,  with
9 4 - regard to the sidedness of the Zn  binding site, would require co-expression with the 
p  subunit mutation,  pN 130H  (Fig 3.1 IB).  Similarly, the mutant GlyR a lH 109F would 
require a pairing with wild-type P, since this subunit already possesses a homologous 
HI09 (p HI32).  It should be noted that GlyR al  HI09 was mutated to Phe rather 
than the typical Ala usually employed, as a previous report suggested GlyR a lH 109A  
may exert a complicating side effect on Zn2+ potentiation of GlyRs (Harvey et al., 
1999).  The Phe moiety also does not favour chemical coordination with Zn2+ but it 
is more similar in terms of its side chain size and shape to His compared with Ala. 
This  a lH 109F  receptor  still  dramatically  attenuated  the  potency  of Zn2+  mediated 
inhibition  but  maintained  wild-type  levels of responsiveness  to Zn2+  enhancement 
(Fig 3.11R).  Finally, the novel GlyR a lT 133A  mutant could be compensated by the 
psl56T mutation (Fig 3.1 IB).  GlyR al El 10 and T112, previously found to influence 
Zn2+  inhibition  (Laube  et  al.,  2000),  were  not  investigated  in  this  study  as  GlyR 
a lEU0A exerted only a modest 5-fold increase in Zn2+  IC 50  (67 ± 4 pM, n = 3, data 
not shown) and is predicted to face away from the H107/H109 based Zn2+ binding 
site,  whilst  T112  (also  facing  away  from  the  site;  Fig  3A0A,B)  has  properties 
consistent with an indirect effect on binding (Nevin et al., 2003).
For the GlyR al  subunit mutations, H109F and T133A, both of which reside on the 
same  face (nomenclature from Fu & Sine, 1996; Fig 3.1 IB) of the inhibitory Zn2+ 
binding site, no recovery of Zn2+ potency was observed when either of these subunits 
were co-expressed with the compensating GlyR P subunits including either HI32 or 
S156T, respectively (IC 50S > 1  mM, n = 3; Fig 3.11R). Furthermore, we investigated
9 4 -
this face of the Zn  binding site from the perspective of the GlyR al  T133 residue
98and found that co-expression of the wild-type GlyR al  subunit with a psl56A mutant 
also had no effect on the receptor sensitivity to Zn2+ inhibition (IC50 =  17 ± 7 pM, 
n = 3). These data, accrued from one face (-) of the Zn2+ binding site, concur with the 
previously  reported  lack  of  effect  of  co-expressing  GlyR  al  with  pH 132A   0n 
Zn2+ mediated inhibition (Nevin et al., 2003).
By  contrast,  when  the  GlyR  a lH 107N   mutant,  which  is  present  on  the  opposing 
‘+‘ face of the Zn2+ binding site to H109 and T133, was co-expressed with the GlyR 
pN 130H  subunit, a dramatic recovery in the sensitivity to Zn2+ was observed almost 
reaching wild-type GlyR aip sensitivity (IC50 = 24 ± 3 pM, n = 5, Fig 3.11R).  To
2 " b ensure this mutation was not due to the de novo construction of an mtrasubumt Zn 
binding site in the  p  subunit, as this  pN 130H  subunit now contained two juxtaposed 
histidine residues (HI30 and HI32), we co-expressed the pN 130H  subunit with a GlyR 
a lHio7N >   hio9f double  mutant  m d  this  exhibited  no  recovery  to  Zn2+ inhibition 
(IC50 >  1   mM,  n  = 4;  data not  shown).  This strongly suggested the  P  subunit is 
indeed participating in an intersubunit site and that this contribution by the P subunit 
to the Zn2+ binding site can only be donated from the ‘+‘ face of the subunit.
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Figure  3.11  Asymmetry  at  the  GlyR  a  subunit  Zn2+  inhibitory  site  using  p- 
subunit  induced  recovery of a  subunits  with  perturbed  Zn2+  sites.  A,  Raw  data 
traces  illustrating  the  recovery  of sensitivity  to  Zn2+   inhibition  at  the  ‘+*  face 
following  co-assembly  of a  ‘corrected’  pN 1   0H   subunit  with  a  defective  a lH I07N  
subunit.  B,  Schematic  cross  sections of 3  of the  5  GlyR subunits  in  a pentamer 
showing  the  compensatory  p  subunits  required  for  co-expression  with  GlyR  a 
subunits lacking one component of the Zn2+  inhibitory site (HI07, HI09, or T133). 
Black  or  dark  grey boxes  represent  the  residues  mutated  for  al  and  P  subunits 
respectively.  Red boxes occur at the ap subunit interfaces labelled,  *+’  and  to 
highlight Zn^ binding sites where all the binding components under examination 
have  been  restored.  These  sites  would  be  restored  regardless  of whether  the  P 
subunits are portrayed as being separated by an a subunit (shown here) or if the p 
subunits are neighbours.  B, Graph presenting assessment of Zn2+  inhibition in HEK 
cells using  15  s pre- and then co-application of Zn2+ with 50 % maximal glycine 
doses.  All co-expressed heteromeric aip receptors are predicted to reconstitute all 
components of the Zn2+  binding site at the ap subunit interface, however,only in the 
case  of  pN 130H   co-expressed  with  a lH 107N   is  the  sensitivity  to  Zn2+  inhibition 
recovered (as compared to an a 1   wild-type profile, dotted line, originally from Fig 
3.2D).  The inhibition curves  for GlyR a lH 107N , a lH 109F and a lT 133A   subunits are 
included for comparison (data for a lH 107N  and a lT 133A  are taken from Figs 3.3,4 and 
3.10£>, respectively).  N= 3-6.
100Discussion
al HI 07 is responsible for high sensitivity GlyR mediated Zn2+ inhibition
•   2+ This  study  has  identified  a  distinct  difference  in  the  potency  of Zn  mediated
inhibition between the GlyR al  and GlyR al subunits which is also manifest with
the corresponding ap  subunit heteromers.  Comparison of the primary amino  acid
sequences around the previously deduced inhibitory Zn2+ binding site (Harvey et al.,
1999)  revealed  that  a  single  residue,  HI07  in  the  al  subunit,  was  likely  to  be
responsible for the different Zn2+ potencies.  The absence of this residue in the al
subunit substantially accounts for its reduced Zn2+ sensitivity, further supporting the
2+ assertion that this location on the GlyR is probably forming a binding site for Zn 
induced inhibition  (Harvey et al.,  1999;Nevin  et  al.,  2003).  Although  a previous
7 - 4 “ study comparing Zn  potency at GlyR al  and GlyR al subunits did not report any 
differences  in  sensitivity between  these  subtypes  (Laube  et  al.,  1995),  this  could 
reflect the varying Zn2+ application protocols, or possibly the glycine concentration 
chosen  for  study since Zn2+  is  acting as  a competitive  antagonist.  The  ability to 
switch the Zn2+ sensitivities of GlyR al  and a2 subunits simply by point mutation 
(alH 107N  and a2N 114H ) strongly suggested that this differential effect had a molecular 
basis.
Zn2+ inhibition affects the apparent affinity of the GlyR
Despite the differential  sensitivity of GlyR al  and al  subunits to inhibitory Zn2+, 
both  glycine  concentration  response  curves  were  displaced  in  a  parallel  manner 
without any reduction in the maximal glycine-activated current.  This is consistent 
with Zn2+ acting as a competitive inhibitor, however, this does not necessarily imply
9 4 -  •   •   9+ that  Zn  is  directly  competing  for  the  glycine  recognition  site,  since  Zn  could 
interact with the receptor allosteric fashion reducing the ability of glycine to bind to 
its entirely non-overlapping site and possibly vice-versa.  Indeed, this explanation is 
consistent with the current views on the discrete locations of the inhibitory Zn2+  and 
agonist  binding  sites  (Laube  et  al.,  2002b).  Prior  evidence  suggests  that  Zn2+ 
inhibition of GlyRs is largely caused by a reduction in the agonist efficacy (E; Laube 
et al., 2000).  The values of E reported for glycine at GlyR al  vary from,  10-20 
(Laube et al., 2000) and  16 (Lewis et al., 2003), to 40 (Beato et al., 2004)  for the 
higher-liganded GlyR states.  By assuming a sequential ligand binding site model is
101sufficient to explain GlyR activation and using this to simulate glycine dose response 
curves, a reduction in E alone will not produce parallel displacements in the glycine 
concentration  response  curves  of  the  magnitude  observed  in  our  study  without 
significant  reductions  in  the  maximum  response.  For  example,  for  GlyR  al,  E 
would need to be reduced from 40 to 0.19 to increase the glycine EC50 from 24 to 
214  /xM;  however  this  would  cause  the  P0  to  be  reduced  from  0.97  to  0.15,  a 
substantial reduction in maximum glycine current.  Thus, it is highly likely that Zn2+ 
is also affecting the affinity of glycine for its recognition site.  The Schild analysis 
here  provides  the  first  definitive  measurement  of Zn  affinity  for  the  GlyR  al
r
(pA2  of 4.44)  and indicates that Zn  has  a much lower potency (329-fold)  at the 
glycine receptor compared to the classical competitive GlyR antagonist, strychnine 
(pA2 of 7.08, Kb 83.2 nM; Saitoh et al., 1994).
^   I
To further support the mode of Zn  inhibition being the same at GlyR al  and a2, 
these receptors both exhibited comparable macroscopic kinetics for the rate of onset 
of Zn2+ inhibition at activated GlyRs.  The fact that there was an indistinguishable
y,
rate of onset for equipotent concentrations of inhibitory Zn  when co-applied with a
y  I
50 % maximal dose of Gly suggests that the accessibility of the site to Zn  and the 
rate at which Zn2+ mediates its effect is comparable between al and a2.  Under these 
conditions the normal biphasic desensitisation of agonist currents was replaced in the 
presence  of Zn2+  with  a  single  fast  decaying  component.  Unfortunately it  is  not 
possible  to  attribute  this  property to  any  effect  of Zn2+  to  alter the  desensitising 
properties of the receptor as this may simply reflect an independent action of Zn2+ to 
inactivate  the  receptor  via  an  alternative  route.  In  addition  it  is  not  possible  to 
accurately assess the purity of any desensitising effect mediated by inhibitory Zn 
due to the competing and rapid Zn2+ enhancement experienced at these co-applied 
Zn  doses.  This  will  increase  the  height  of the  initial  response  peaks  and  thus 
potentially  increase  the  rate  of desensitisation  as  if the  receptor  were  effectively 
activated by a higher concentration of agonist.
The mechanism of Zn2+ inhibition
Measurements of Zn2+ inhibition using varying application protocols revealed that
y,
pre-equilibration of Zn  with the GlyR and subsequent co-application with agonist
102incurred the highest potency for inhibition.  In agreement with this, prolonged co-
9+   9+ application  of Gly  and  Zn  revealed  a  delayed  onset  of Zn  inhibition,  which 
required  a  significant  5-10  second  time  period  to  reach  steady-state.  These
9+  •  •  .  • observations support a hypothesis favouring Zn  binding to either a closed agonist- 
bound GlyR or a closed agonist-unbound GlyR or both (or the two situations may be 
equivalent).  This dictates that Zn2+ would exert its greatest level of inhibition under
9-j-  •  • •
a pre-incubation protocol as is observed here where Zn  can bind and stabilise the 
closed-bound/unbound receptor prior to the presence of agonist (see Smart,  1992 for 
a similar argument for GABAaRs).  Under co-application conditions a delayed onset 
would be observed as some agonist will activate the receptor before Zn2+ can bind. 
Therefore as Zn2+ cannot bind, or binds less to the open receptor (or perhaps also to 
the closed receptor with agonist bound^it must wait for the receptor to  close and
9   i
possibly for the agonist to  unbind before Zn  can coordinate and inhibit receptor 
reactivation during the course of the remaining agonist application.  This also means
9   i
that the onset of Zn  inhibition will be slower under a co-application protocol  at 
lower  Zn2+  concentrations  because  there  is  an  increased  likelihood  that  after  the 
receptor has shut and/or agonist has unbound that another molecule of agonist will
9-4- bind  and  reactivate  the  receptor  before  the  Zn  can  bind.  This  situation  is 
represented  in  Fig  3.2C,D  where  despite  the  fact  that  under  pre-equilibration 
conditions 100 and 1000 pM Zn2+ exert almost full inhibition at GlyR al, under co­
application (C, example traces) the onset of 100 pM Zn2+ inhibition is substantially
9   I
slower  than  that  of  1000  pM  Zn  .  This  hypothesis  also  supports  the  apparent
9+ competitive mode of Zn  inhibition inferred by parallel dose response curve shifts 
with  unchanged  maximal  agonist  responses.  Under  these  conditions  when  a 
saturating concentration  of agonist  is  applied  the  receptor will  effectively  always 
have  agonist  bound  as  whenever  one  agonist  molecule  dissociates  another  will 
immediately  take  its  place.  Therefore  the  equilibrium  between  open  and  closed 
channels will be biased towards the open state, reducing the prospect of Zn2+ binding 
and causing inhibition.
This observation also has implications for the activation mechanism of the GlyR as it 
suggests that when agonist is bound there is a section of the receptor, encompassing
2 * F " as  far as the Zn  binding  site,  that  is  always  conformationally shifted  as  long  as
103agonist  is  bound.  However  this  conformational  change  is  not  necessarily 
synonymous with opening of the receptor channel.  The reason for this is that single 
channel  studies  clearly  reveal  that  even  in  the  presence  of  saturating  agonist 
concentrations,  i.e.  effectively  agonist  is  always  bound  (especially  for  GlyR 
homomers where 5 molecules of agonist can bind at any one time but only 2-3  are 
required to activate it; Beato et al, 2004) the receptor still flickers between open and 
closed  states  very  rapidly,  with  occasional  long  closures  presumably  due  to 
desensitisation.  Yet Zn2+ does not appear to bind during these closed states as it does 
not  reduce  the  Gly  Im ax  suggesting  part  of the  receptor  is  still  in  an  activated 
conformation preventing Zn2+ binding to its inhibitory site.
Native  GlyRs  retain  the  sensitivity  to  Zn2+  inhibition  of  their  recombinant 
counterparts
This study also revealed that a distinction between GlyR subtypes for Zn  mediated 
inhibition  extends  to  a  native  environment  where  the  sensitivity  of  a  GlyR 
population, that is expected to be predominantly composed of a2 subunits in early 
spinal cord culture, demonstrates an overall low sensitivity to Zn2+ inhibition.  More 
mature  neurons  in  acute  spinal  cord  slices/ however, display a distinctly  enhanced 
sensitivity consistent with the predicted shift to GlyR al  receptor subtypes in adult 
tissues (Becker et al., 1988;Takahashi et al., 1992;Watanabe and Akagi, 1995).  This 
suggests the physiological significance of Zn2+ inhibition is unlikely to be relevant at 
embryonic stages of development since native embryonic GlyRs require greater than
• ji   •
50 pM Zn  before the glycine EC50 response is inhibited.  This result is in keeping 
with a previous report (Laube, 2002a) where 50 pM Zn2+ induced marginal inhibition 
of glycinergic IPSCs in spinal cord cultures.  Our data, in agreement with previous 
immunocytochemistry (Hoch et al.,  1989;Hoch et al.,  1992), suggests that in spinal 
cord cultures the embryonic GlyR a2 remains dominant during culture maturation, 
regardless  of the presence or absence of astrocytes,  as the  sensitivity to  inhibitory 
Zn2+ remains low up to 14 DIV.
104The properties of the P subunit support an asymmetric role for the inhibitory 
Zn2+ site
Previously, the GlyR p subunit has not been shown to exert any detectable influence 
on  Zn2+  mediated  inhibition  at  the  GlyR  (Bloomenthal  et  al.,  1994;Laube  et  al., 
1995;Nevin  et  al.,  2003).  However,  this  report  demonstrates  that  in  the  unique 
instance of the a2 subtype, co-expression with the p subunit revealed an increased 
sensitivity to Zn2+  mediated inhibition.  Although we were unable to  attribute this
■ y ,
effect to a specific moiety in the vicinity of the putative inhibitory Zn  binding site, 
as  a  consequence,  we  identified  GlyR  al  T133,  as  a  pivotal  residue  for  Zn 
inhibition.  When considering the location of the intersubunit Zn2+ binding site, in 
accordance  with  the three-dimensional  GlyR al  model based on the AChBP,  the 
T133 residue is predicted to lie beneath HI09.  This would be an ideal location for 
participation in the putative inhibitory Zn2+ binding site.
Co-expression  of GlyR  a  subunits  with  complementary  p  subunits,  designed  to 
compensate  for  a  subunits  lacking  specific  components  of  the  inhibitory  Zn2+ 
binding site revealed an asymmetry of function between the opposing faces of the 
intersubunit binding site.  Effectively knocking out either GlyR al  H109,or T133, 
both predicted to be on the same  face of the subunit, could not be compensated by 
P subunits mutated to contain equivalent a subunit residues.  This demonstrates that 
the a subunit H107  ‘+‘  face and the mutant p subunit H132/S156T *-*  face cannot
^   I
form  a functional Zn  inhibitory site  alone, when the  a-subunit  face has been 
disrupted by mutation.  In contrast, following knock-out of the GlyR al HI 07 on the 
opposing  ‘+‘  face,  the  attenuated  sensitivity  to  Zn2+  inhibition  was  almost  fully 
restored by co-expression with pN 130H  subunits.  The restoration of Zn2+ inhibition for 
the GlyR al  H107N mutant implies that such inhibition is probably mediated from 
either the  GlyR  al  H109/T133  factor the  p  N130H  ‘+‘  face,  or both  acting 
together.  As  the  wild-type  GlyR  al  subunit  is  able  to  mediate  Zn2+  inhibition 
regardless of the removal of any inhibitory components in the p subunit this supports 
a hypothesis whereby the H109 and T133  face of the binding site is responsible 
for  connecting  Zn2+  binding  to  an  effect  on  receptor  function  (transduction). 
Furthermore,  this  transduction  must  be  driven  through  the  GlyR  al  subunit.  In
105comparison, HI07 can instead be regarded as a pure binding residue, as this can be 
donated from a neighbouring subunit that lacks its own Zn  transduction apparatus
i.e., the p subunit.
A proposed molecular basis for the action of inhibitory Zn2+
The hypothesis of asymmetric transduction from the  face of the GlyR al  subunit
is  in keeping with current perspectives  of proposed  structural rearrangements  that
occur  upon  receptor  activation  of  cys-loop  receptors.  Intermediate  resolution
micrographs  of the  torpedo  nAChR  demonstrate  that  the  conformation  of  each
monomer within the pentamer is equivalent in the agonist-bound conformation of the
receptor (Unwin, 1995).  However, in the absence of agonist the conformation of the
extracellular N-terminus for the principal nAChR agonist-binding a subunits is not
equivalent to the more structural p, y and 8 subunits.  In fact the p, y and 8 subunits
appear  to  undergo  only minor  movements  from  the  conformation  adopted  in  the
agonist-bound  pentameric  state  whilst  the  a  subunits  undergo  a  significant
conformational  change to  adopt  a new position.  Though  direct  structural  data  is
lacking  for  the  GlyR,  the  evidence  suggests  that  the  roles  of the  a  and  p  GlyR
subunits are probably equivalent to those of the nAChRs,  i.e.  the a subunit is the
primary contributor to agonist binding whilst the p subunit acts as structural support.
This is in contrast to GABAa receptors where evidence supports the converse (Amin
and  Weiss,  1993).  Structural  rearrangements  in  GlyRs  may therefore  occur  in  a
similar manner with the agonist binding a subunit undertaking the majority of the
dynamic  conformational  shifts,  at  least  as  far  as  the  extracellular  N-terminus  is
concerned.  Apparent  differences  in  the  resting  conformations  of  the  a  and
P  subunits  has  been  recently  supported  (Shan  et  al.,  2003).  In  this  study  the
reactivity of cys-modifying reagents at the M2-3  linker region, a region critical for
receptor activation, revealed an asymmetric contribution of a and P GlyR subunits to
aP  heteromeric  activation.  Furthermore,  mapping  the  AChBP  onto  the  nAChR
a-subunit in its closed and agonist-bound, presumed open,  conformation, revealed
that the a subunit rotated around a diagonal axis resulting in the greatest movement
across  the  side  of the  subunit  (Unwin  et  al.,  2002).  This  suggests  that  the
GlyR  H109/T133  face  undertakes  a  greater  conformational  shift  in  location
compared to residues on the *+’ receptor face.  Here the ability of Zn2+ to stabilise
106the closed receptor state is determined by whether or not a conformational change in 
response to agonist binding occurs, which would be transmitted as a conformational 
shift primarily across to the  face of the monomer i.e. a transduction route to this 
side of the Zn2+ site.  The ‘+’ HI 07 face by contrast is expected to undergo a smaller 
structural perturbation in response to activation and therefore this residue may still 
remain in a position where it can coordinate Zn2+, thus explaining how the p subunit 
can donate its equivalent N130H, but not its perturbed  H132/S147 face, to a Zn2+  
binding site.
Comparisons with the GABAaR family of inhibitory Zn2+ binding sites
•  9  i
Our current understanding of the molecular components required for Zn  mediated 
inhibition  in  other  cys-loop  ligand-gated  receptors  is  derived  from  the  GABAa 
receptor  family.  A  recent  in  depth  study  of GABAa  receptors  pinpointed  the 
sensitivity for Zn2+  inhibition  to  two  separate  inhibitory sites,  a high potency site 
between two neighbouring p  subunits and a lower affinity site between an a and a 
p subunit, rather than the single location elucidated for GlyRs (Hosie et al., 2003). 
This also revealed that GABAa receptors confer on the pentameric receptor varying
•  •  •  •  •  94 -
levels  of sensitivity to  inhibitory Zn  by replacing  one  of the  two  neighbouring 
p subunits, which form a high potency intersubunit Zn2+ binding site, with a reduced 
sensitivity 8, s or y subunit.  This means that rather than simply varying the potency 
of the site whilst maintaining the same mechanism of action as appears to be the case 
for the  GlyR,  GABAa  receptors  featuring  8,  s  or y  subunits  instead  form  a new 
reliance on the secondary low potency site between the a and p subunits.  However, 
despite  these  initial  differences,  the  GABAa  inhibitory  Zn2+  sites  do  still  retain 
notable similarities to that predicted for the GlyR.  Both the high and low potency 
GABAa receptor Zn2+ sites are proposed to be present as intersubunit sites forming a 
bridge between two neighbouring subunits.  Furthermore both sites contain histidine 
residues,  the most commonly occurring  coordinating partner  for Zn2+  (Vallee  and 
Auld,  1990).  In  the  case  of the  high  potency  site,  two  histidines  from  adjacent 
p subunits are proposed to form part of an intersubunit site, similar to the case for the 
GlyR  a  subunits.  Only the polar hydroxyl  GlyR al  T133  identified here  differs 
from the remaining  components  of the two  GABAa  sites,  all of which  are  acidic 
residues (Hosie et al., 2003).
107In view of the apparent conservation of intersubunit Zn  sites across these receptors 
it is tempting to postulate that the GlyR may share a similar potential mechanism of 
Zn  inhibition  to  its  closest  relative,  the  GABAa  receptor.  Unfortunately, 
alignments  of the Zn2+   sites  in  GABAa  and GlyRs  suggest that though they may 
share certain chemical and structural similarities, the sites are expected to reside in 
different  areas  of the  proteins,  with  the  high  potency  GABAa  site  predicted  to 
occupy a space at the mouth of the ion channel.  In addition to this several studies 
investigating the properties of Zn  inhibition at GABAa receptors suggest that the 
high potency inhibitory component exhibits  a non-competitive mode  of inhibition 
(Smart  and  Constanti,  1990;Legendre  and  Westbrook,  1991;Gingrich  and  Burkat, 
1998),  whilst  the  low potency y-subunit dependent  component  displays properties 
consistent  with  an  apparent mixed  antagonism,  and  also  does not  show  the  same 
dependence as the GlyR for pre-equilibration to ensure a high degree of inhibition 
(Gingrich and Burkat, 1998).
Identification  of residues  required  for  Zn2+  mediated  inhibition  in  other  cys-loop 
receptors  currently  extend  to  a  histidine  residue  reported  to  be  important  for  the 
GAB  Ac  receptor  subtypes  a 1-3  (Wang  et  al.,  1995).  Evidence  to  support 
mechanisms  of actions  at  other  cys-loop  receptors  varies  with  Zn2+  inhibition  of 
GABAa p subtypes 1-3 proposed to be via an apparent mixed antagonism (Chang et 
al.,  1995).  Though there has been no molecular basis of Zn2+ inhibition elucidated 
yet  for  nAChRs  this  process  does  bear  similarities  to  that  of the  GlyR  as  the 
sensitivity is dependent on subunit composition (Hsiao et al., 2001).  In addition,the 
inhibition  requires  pre-incubation  and  due  to  its  voltage  independence  and  an 
apparent  effect  on  the  agonist  affinity  it  has  also  been  suggested  to  act  via  an 
apparent competitive mode either directly or through an allosteric process (Palma et 
al., 1998).
Conclusion
Taken  overall,  this  study  identifies  Zn2+  as  a  useful  pharmacological  tool  to 
distinguish between GlyR al  and a2  or a3  subunits  and identifies  a new  critical 
component in Zn2+ mediated inhibition, GlyR al  T133.  It also provides a rationale
108by which Zn2+ binding initiates the transduction of Zn2+ mediated inhibition resulting 
in  an  effect  on  glycine  binding  to  the  receptor.  This  appears  to  be  propagated 
asymmetrically  from  the  Zn2+  binding  site being  driven  from  the  face.  This 
phenomenon  of  asymmetric  propagation  of transduction  is  quite  likely  to  be  a 
common  feature  characterising  the  binding  of ligands  to  many  different  sites  on 
ligand-gated ion channels.
109GlyR subtype
CHyECsoOiM) W(nA) n Zn2+  IC 5 0 (pM) n
al 24 ±5 4.5 ± 0.5 10 15 ± 2 5
a2 66 ± 6 3.7 ±0.5 13 360 ± 40 11
al & 18 ± 3 4.5 ± 0.9 6 13 ± 2 3
a2 & 51 ±4 5.6 ±0.5 3 180 ±30 13
al“ 24 ±2 5.9 ±0.3 4 230 ± 30 5
a lta* 56 ±5 5.1 ±0.2 3 > 1  mM 3
a jTU JA . 64± 10 4.8 ±0.7 2 * > 1  mM 5
a-p tis--......  - 17 ±2 3.3 ±0.6 3 26 ± 6 3
28 ± 8 4.8 ±0.8 3 24 ±3 5
a jto«>gSis«I 39 ± 4 5.2 ± 1.2 3 > 1  mM 3
a jTin*gilsil 90 ± 16 3.2 ±0.9 3 > 1  mM 3
al 0 ^ 40 5.7 ±0.8 1 17 ± 7 3
......  ■ 58 ±3 4.2 ± 0.7 3 29 ±2 4
a 2 ftsa* 52 ±5 5.0 ± 1.6 3 170 ±20 4
caff3** 52 ±2 5.2 ± 1.2 2 * 210 ± 2 0 5
a3 48 ±3 5.3 ± 1.3 4 150 ± 10 4
a3m O T S 53 ± 12 5.3 ± 0.8 5 26 ±7 3
scDIVS *40 3.1 ±0.3 12 320 ± 50 8
scDIVT *30 4.9 ± 0.7 12 110 ± 10 8
sc IHV10-14 *30 4.3 ± 0.4 8 88 ± 2 1 8
sc astro DIV5 *30 4.3 ± 0.4 8 170 ±50 8
sc astro DIV7 *30 4.3 ± 0.4 8 170 ±50 8
Table 3.1  GlyR sensitivities to glycine and Zn2+.
The  values  indicate  the  glycine  EC50S  for  activating  recombinant  and  native 
GlyRs and also the Zn2+ IC50S  for inhibiting the 50 % maximal glycine-activated 
responses where Zn2+ is first pre-equilibrated with the receptor for 15 s before an
9-4-  • equivalent dose of Zn  is co-applied with glycine. All numbers are means ± s.e. 
from  n  cells.  For the native  GlyR  in  spinal cord (sc) neurons,  the EC50S   were 
estimated from linear segments of the dose-response curves.  Im ax represents the 
maximal glycine-activated current.(*  Due  to  an  n  of 2,  these  errors  represent 
standard deviations).
110Chapter 4
Evidence for an allosteric transduction pathway across the 
extracellular domain of the glycine receptor
Introduction
Evidence so far accrued from three independent studies provides strong support and 
agreement that Zn2+ inhibition appears to be mediated via a discrete site featuring at 
the very least two histidine residues GlyR al HI07 and HI09, which are presented at 
an intersubunit site (Harvey et al.,  1999;Nevin et al., 2003;Chapter 3).  Furthermore 
this  site  appears  to  be  distinct  from  the  agonist-binding  site  as  substituting  these 
residues  with  alternative  moieties  does  not  exert  a  substantial  effect  on  agonist 
potencies or their maximal responses (Harvey et al.,  1999;Nevin et al., 2003;Table
3.1).  These residues also differ from those previously shown to have a substantial 
impact  on  the  agonist  potency  in  a  manner  consistent  with  an  effect  on  agonist 
binding.  Residues implicated in agonist binding include GlyR al D96 to G105 (loop 
A;Han  et  al.,  2001;Vafa  et  al.,  1999),  Y159  to  F161  (loop  B;Kuhse  et  al., 
1990b;Schmieden  et  al.,  1993),  and  Cl98  to  C209  (loop  C;Vandenberg  et  al., 
1992a;Vandenberg et al.,  1992b; Rajendra et al.,  1995b).  The structural homology 
model  (Fig  4AA,B)  predicts  the  agonist-binding  site  and  the  inhibitory  Zn2+  site
74-  •   •   •   • occupy  distinct  non-overlapping  locations  suggesting  Zn  is  unable  to  elicit  its 
apparent  competitive  inhibitory  effect  (Chapter  3)  by  direct  competition  to  block 
access of the agonist to its recognition site.  In addition the predicted location of the 
inhibitory site in relation to the ion channel suggests that Zn2+ is not operating as an
open  channel  blocker  on  GlyRs  (Fig  This  is  also  supported  by  the
•   2+  observation that pre-incubation of the GlyR with inhibitory concentrations of Zn
enhances the  steady-state  inhibition,  suggesting that  Zn2+   can  access  its  site  even
when the channel is closed (Fig 3.1,4 - D).  This is in contrast to an open channel
blocker  such  as  cyanotriphenylborate  (CTB),  which  requires  channel  activation
before it can inhibit the GlyR (Handford et al.,  1996).  Substantial parallel agonist
dose-response  curve  displacements  in  the  presence  of inhibitory  Zn  ,  without  a
reduction in the maximal agonist response, are consistent with this site exerting at
least  some  part  of its  inhibition  in  an  apparent  competitive  mode  to  reduce  the
111affinity of the agonist-binding site.  Given the physical separation of the two  sites 
this would therefore require allosteric communication between the two sites.  From 
the studies in chapter 3 (Fig 3.11) the effect of Zn2+ binding is transduced from the 
H109/T133  face  of the Zn2+ binding  site.  Therefore, to  exert  an  effect  at the 
agonist-binding site would presumably require transmission through, or around, the 
hydrophobic  core  of the  extracellular domain,  as these two  sites  are  on  opposing 
sides of the extracellular domain of the protein (Fig 4.1 A,B).
This chapter aims to  investigate the consequences  of disrupting potential residues 
that  may  reside  on  a  route  for  signal  transduction  across  the  protein  from  the 
H109/T133 Zn2+ inhibitory site  face to the agonist-binding site.  This study is of 
particular interest as to date there are no studies that clearly elucidate transduction 
pathways  through  cys-loop  ligand-gated  receptors  either  in  terms  of  agonist 
transduction to activate the receptor or in terms of the numerous modulator sites that 
are present in this receptor family (Laube, 2002; Lester et al., 2004).  Most likely this 
is a result of the complications that arise from attempting to dissect between whether 
particular  amino  acids  are  important  for  binding,  or  transducing,  or  causing  an 
indirect  structural  effect  on  either  of these  properties.  However,  this  study  has 
several factors in its favour, firstly, through appreciation of chemistry and numerous
74- crystal structures of Zn  binding sites (Auld, 2001), some limitation can be placed 
on  the  number  and  the  type  of residues  directly  contributing  to  Zn2+  binding. 
Secondly,  several  studies  have  already  provided  consistent  support  for  the 
identification of a significant portion of the inhibitory Zn2+  binding site in the form 
of two histidine residues, GlyR al H107 and H109 (Harvey et al., 1999;Nevin et al., 
2003;Chapter 3).  Furthermore, evidence in Chapter 3  suggests that transduction is 
most likely from one side only of this site, the H109/T133  face, giving a starting 
point  for investigating any transduction routes  through the protein  to  the  agonist- 
binding site.  Finally the model of the GlyR based on the AChBP (Brejc et al., 2001) 
gives a structural guide to probing any route through the protein using mutagenesis. 
This  can  also  be used to  then mutate residues  on  either  side  of any transduction 
pathway  to  establish  the  specificity  of  an  effect,  thus  increasing  the  level  of 
confidence  in  whether  it  is  a  genuine  effect  on  receptor  function  rather  than  an 
indirect structural perturbation.
112Figure  4.1  GlyR  model, 
based  on  the  AChBP, 
displaying the  location  of the 
inhibitory  Zn2+  site  viewed 
from  the  inside  face  of  the 
receptor  (A)  and  from  above 
(B),  highlighted  by  the  small 
inset  pictorials  (red).  Two 
neighbouring  subunits  from 
the  pentameric  GlyR  are 
presented  with  the 
extracellular domains in green 
or  yellow.  Transmembrane 
domains  are  included  (blue) 
with the pore lining M2 helix 
in  pale  yellow.  The  agonist 
binding  motifs  (red)  and 
residues  (bubble  chains)  are 
labelled  as  are  the  inhibitory 
Zn2+   binding  site  residues 
(thin  chain).  A  black  and 
white arrow marks  a possible 
route  by  which  the  allosteric 
inhibitory Zn2+  site  face 
may  transduce  its  effect 
downstream  to  the  agonist 
binding site.
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113Other clues as to the genuine contribution of a residue to a transduction pathway can 
also be gleaned from what actually happens to the inhibitory process.  For example in 
the case of neurosteroid modulation of GABAa p receptors,  substitution of an M2 
1307  residue  can  reverse  the  polarity  of a  neurosteroid  effect,  from  inhibition  to 
potentiation (Morris and Amin, 2004: A similar but reverse effect is also seen for the 
Zn2+  potentiation  of GlyRs,  see  Chapter  5).  The  study  presented  here  initially 
compared substitutions of residues at each of the inhibitory Zn  binding site faces to 
ascertain whether these affected receptor properties besides a simple reduction in the 
potency  of Zn2+  mediated  inhibition.  This  in  turn  elucidated  a  novel  receptor 
phenotype whereby Zn2+ itself could directly activate the GlyR from the  face of 
the  inhibitory site and subsequently a hydrophobic  transduction pathway from the 
inhibitory Zn  site to the agonist-binding site was tentatively identified.
Results
Disruption of the GlyR al  face of the Zn2+ inhibition site generates a family 
of low potency Zn2+-activated GlyRs (ZAGs)
During  whole  cell  recordings  from  HEK  cells  transiently  transfected  with  GlyR 
a lTi33A ,  a mutation that impaired Zn2+  inhibition  (Chapter 3) the appearance of a 
persistent but small (less than  10  % of the Gly Im ax) inward current was observed 
upon pre-incubation with a high 1  mM dose of Zn2+.  This unexpected effect was not 
observed during recordings made from cells expressing either al wild-type, a lH 107N , 
a lHi°9F  Qr untransfected cells and therefore appeared to depend on the  location of 
disruption  at  the  inhibitory  Zn2+  binding  site.  To  establish  and  characterise  this 
property further for any possible new information this may reveal about the function 
of the inhibitory Zn2+ site, two sets of mutated al receptors were made representing 
residues  lining  the  vicinity  on  either  side  of  the  intersubunit  site,  i.e.  on  the 
previously  labelled  *+’  and  faces.  The  face,  previously  shown  to  contain 
important  contributions  from  GlyR  al  HI09  and  T133,  was  mutated  with  Ala 
substitutions individually at 5  selected locations.  These included HI09 and T133, 
also  E110  and  T112  previously  implicated  to  influence  Zn2+  mediated  inhibition 
(Laube et al., 2000) and finally an N61 residue that resides on the next ‘rung’ down 
on  P-strand  2,  laying  directly beneath  T133  (Fig  4.2A).  These  a lN 61A ,  a lH 109A , 
a lE110A ,  a lT 112A  and a lT 133A  GlyRs were  first characterised  for their sensitivity to
114Zn2+ mediated inhibition of glycine 50 % maximal responses.  The sensitivities to 
inhibitory Zn2+ were measured by comparing the current after 4 seconds (I4) of co­
applied  50  %  maximal  doses  of Gly plus  1000  pM  Zn2+,  to  the  current of 50  %
^ I
maximal Gly doses applied alone.  A Zn  pre-incubation protocol was not used as 
GlyR a lN 61A ,  a lTU2A  and a lT 133A   all  exhibited significant inward currents  during 
pre-application  of  Zn2+,  and  this  may  partially  desensitise  the  GlyR  causing
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erroneous results.  In the case of al  , al  and al  , inhibition by Zn  was 
completely absent even at the high  1000 pM dose tested leaving only the residual 
potentiating component of Zn2+ modulation on Gly responses apparent (Fig 4.2C). 
GlyR  a lH 109A   and  GlyR  a lE 110A   by  contrast  were  still  significantly  inhibited  by 
33 ± 6 %, (n = 4) and 97 ± 1  %, (n = 3) respectively in response to a high 1000 pM 
Zn2+  dose.  Furthermore,  these two receptors did not display a noticeable  inward 
current during pre-incubation with 1000 pM Zn  and were therefore fully assessed
'j i
for their sensitivity to  Zn  mediated inhibition using the pre-mcubation protocol. 
This surprisingly revealed that a lH 109A  exhibits only a modest 2-fold increase in the 
Zn2+ IC50 to 32 ± 16 pM, (n = 5, P < 0.05) compared to the wild-type al (15 ± 2 pM, 
n = 5) and intriguingly reduces the maximal amount by which Zn2+ can inhibit Gly 
responses to 47 ± 7 %,  (n = 5) compared to  91  ± 7  %,  (n = 6)  for the wild-type 
receptor (Fig 4.2B).  GlyR a lE110A , by contrast, harboured a slightly more significant
94- 4-fold reduced  sensitivity to  Zn  mediated inhibition  (IC50 =  67  ± 4  pM,  n =  3, 
P < 0.05) and did not affect the maximal amount of Zn2+ inhibition (Fig 4.25).
The  persistent  inward  current  observed  during  pre-incubation  of  GlyR  a lN 61A , 
a lT 112A  and a lT 133A  with 1000 pM Zn2+ was possibly due to Zn2+ acting alone as a 
GlyR agonist.  In agreement with the persistent inward current observed during pre­
incubation, dose response curves  for Zn2+  activation on the GlyR a lN 61A ,  a lH 109A  
and a lT 133A  mutants, representing the residues on the aligned rungs of the ladder at 
the  interface, revealed in each case, a significant but low, millimolar potency for 
Zn2+  activation.  This resulted in EC50  values of >  10 mM,  for GlyR a lN 61A   and 
aihio9a  2  respectively)  and  5.4  ±  2.5  mM,  (n  =  5)  for  a lT133A
(Fig 4.3A, C).  Though it was not possible to obtain maximal currents for these dose 
response curves due to the requirement  for higher doses of Zn2+, the curves were
115sufficient to estimate that the Im ax for Zn2+ as a percentage of Gly Im ax (i.e. relative 
efficacy) was greater than 30 % for GlyR a lN 61A  and a lH 109A  and greater than 40 % 
for a lT 133A   (Fig 4.3A,C).  This apparent action of Zn2+  as  an agonist was  termed 
‘Zn2+-Activated  Glycine  receptor’  (ZAG)  activity  in  accordance  with  a  cys-loop
•   " 7 4 -   •   • ligand-gated receptor previously identified as Zn  -activated channel (ZAC) activity, 
though this receptor lacked activation by a battery of agonists tested including Gly 
(Davies et al., 2003).  In comparison, Ala substitution of the nearby El 10 residue, 
which faces away from the site of Zn2+ coordination, yielded a GlyR a lE110A  with no 
discemable  ZAG  activity  up  to  30  mM  Zn2+  (n  =  3).  However,  GlyR  a lT 112A  
produced a high sensitivity ZAG with EC50 = 3.5 ± 1.5 pM and a relative efficacy of 
42 ± 5 % (n = 4; Fig 4.3A,C).  As a control, a wild-type GlyR revealed no noticeable 
ZAG activity at Zn2+ concentrations up to 30 mM, (n = 3).  The Zn2+ current traces 
for all four of the ZAG mutants identified revealed that the Zn2+ activated current 
was relatively slow, whether applied at maximal or submaximal doses, reaching a 
steady-state between 3 and 15 seconds compared to onset times of less than 2 s for a 
submaximal EC50 dose of Gly (Fig 4.3C).  Current-voltage (IV) data accrued for each 
mutant using 50 % maximal responses to Zn2+ revealed a typical linear relationship 
with membrane voltage in keeping with that for Gly currents recorded  from wild- 
type  al  GlyR  (Fig  4.3B).  Due  to  the  small  currents  and  extremely  high 
concentrations of Zn2+ required for activation of a lH 109A  an IV plot was not obtained. 
In addition the reversal potentials for Zn2+ activated currents from a lN 61A , a lT 112A  
and a lT 133A  GlyRs was close to zero (range -4 mV to 7 mV, n = 3), comparable to 
the predicted reversal potential for Cf of around 0 mV.  The data was in accordance 
with  the  Zn  activated  current  eliciting  its  effect  via  the  GlyR  Cl'  channel. 
Furthermore, though the receptors were clearly perturbed in a manner consistent with 
a  disruption  to  the  transduction  apparatus  of the  Zn2+  inhibitory  site,  the  agonist 
activities of the receptor, via the glycine binding site, did not appear to be overtly 
influenced with Gly EC50S  remaining within 4-fold of wild-type values and maximal 
Gly currents not differing significantly (Table 4.1).
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Figure 4.2  Alanine substitutions at the  Zn2+ binding site face disrupt GlyR 
al  Zn2+   mediated  inhibition.  A,  Structural  homology  model  of  GlyR  al 
highlighting potential residues of interest in the  face of the inhibitory Zn2+ 
site, boxed orange.  The orange P-strands represent the three ‘ladder rungs’ upon 
which residues were selected.  B, Zn2^ dose response curves constructed using a 
pre-incubation protocol  to measure modulation of 50  % maximal  Gly-evoked 
responses.  This was carried out for GlyR a lH 109A  and a lE 110A  both of which 
were significantly inhibited by 1000 pM Zn2+. Both receptors revealed a reduced 
sensitivity to Zn2+  mediated inhibition compared to wild-type GlyR al  (dashed 
line)  but while a lE 110A   suffered  a  5-fold  reduced  sensitivity to  Zn2+,  a lH 109A  
instead exhibited a reduced maximal level of inhibition.  C, Current amplitude 
measurements at the 4-second time point (I4) during co-application of 1000 pM 
Zn2+   with  a  Gly  concentration  corresponding  to  50  %  of the  maximal  Gly 
response  (as  a  percentage  of a  Gly  concentration  causing  a  50  %  maximal 
response  in  the  absence  of  Zn2+).  This  demonstrates  that  Zn2+  mediated 
inhibition is completely abolished at this high concentration of Zn2+ for a lN 61A , 
al  ~   and al  .  Due to the discrete Zn2+ potentiation site these receptors 
retain  potentiation  at  this  concentration.  Asterisks  represent  a  significant 
difference from the wild-type receptor (P < 0.05).  N= 3-6.
-   a1
0  a1H 109A  
A  a1E 110A
0.1  1  10  100  1000 
Zn2* concentration (pM)
117B
60 0  a1N 61A
y   a -|H109A
^  40
a1T 133A
0   a1 N61A
V (mV)
1.5
1.0
0.5
■  a1 
O a^ A
A a 1T112A  
o  a1T133A
I /I -6 0 A
a'*— V
-60
O'
&
1   10  100  1000  10000 
Zr£+  concentration (pM)
a  -| H109A a1 T112A
# % 6 .5-°  30  60
- 1.0
-
-1.5J
a -|T133A
M
10000
30000
Figure 4.3  Disruption of the Zn2+ inhibitory site *-* face produces receptors that 
are  sensitive to activation by Zn2+   acting as an agonist.  A, Zn2 +   dose response
r   /-m  t>  1 N 6 IA  1 H I09A  . T112A  ,  . T133A  .  „   ,  .  r curves for GlyR al  , al  , al  and al  plotted as the percentage of 
a maximal response to  glycine  applied  to  the  same  cells.  B,  IV  plots  and  the 
reversal potentials of EC50 Zn2+ activated currents for a lN6lA, a lTll2A, a lTl33A  and 
EC50 Gly activated currents for a wild-type al  GlyR.  Due to the small currents 
and extremely high concentrations of Zn2+ required for activation of a lH l09A  an IV 
plot was not obtained.  C, Typical currents recorded upon Zn2+  activation (black 
traces)  of GlyR a lN6lA,  a lH l  9A , a lTll2A  and a lTl33A.  The time-scale matched 
doses are applied in pM (red bars).  Comparative 50 % maximal glycine induced 
responses are displayed in blue revealing a faster activation profile than the Zn2+ 
activated currents.  The doses applied are in mM (red).  Scale bars represent 1   s 
and 1  nA respectively.  N = 3 - 6.
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118Disruption of the GlyR al  ‘+‘  face of the Zn2+ inhibition  site does not induce 
ZAG activity
9_i
To  further assess this unusual  Zn  sensitive property from the perspective  of the 
residues  surrounding the proposed  inhibitory Zn2+  binding  site,  the  three  residues 
residing on  the  opposing  ‘+*  face  of the  site  were  examined.  These  were  again 
selected from each p-sheet ‘rung of the ladder’ and evaluated for ZAG activity upon 
Ala substitution to generate GlyR a lR 59A ,  a lH 107A   and a lT 135A  (Fig AAA).  Initial 
assessment  of each mutation  for  any  influence  on  the  potency of Zn2+  mediated 
inhibition at the receptor using a pre-incubation protocol revealed, in agreement with 
previous  studies  (Harvey et al.,  1999;Nevin et al.,  2003), that a lH 107A  induces  an 
approximate 15-fold increase in the IC50 of Zn2+ inhibition from a wild-type value of 
15 ± 2 pM, (n = 5) to 330 ± 30 pM, (n = 3; Fig AAB).  In contrast a l1 1 5 ^  failed to 
reduce the potency of inhibitory Zn2+ with an IC50 value of 5.2 ± 0.7 pM, (n = 3) and 
a lT 135A  was previously shown (Chapter 3) not to significantly affect Zn2+ inhibition, 
(IC50 = 26 ± 6 pM, n = 3).  In addition to this, attempts to elicit ZAG activity from 
these  three  receptors  and  also  from  an  a lH 107N   receptor,  all  failed  to  elicit  a 
noticeable current at up to 30 mM Zn2+ (n = 3; Fig A  AC).  Thus H107A seems to 
represent the sole contribution from the *+* face of the inhibitory site and influences 
Zn2+ inhibition in a manner consistent with a role in Zn2+ binding, in support of the 
original asymmetry of function for the two faces proposed for this site (see Chapter
3).
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Figure 4.4  Alanine substitutions at the *+’ Zn +  binding site face disrupt GlyR 
al  Zn2 +  mediated inhibition only at al  HI07.  A , Structural homology model of 
GlyR al highlighting potential residues of interest in the ‘+* face of the inhibitory
^ I   ^
Zn  site, boxed orange.  The orange p-strands represent the three ‘ladder rungs’ 
upon which residues were  selected.  B , Zn2+   dose response curves using a pre­
incubation  protocol  to  measure  the  modulation  of 50  %  maximal  Gly-evoked 
responses.  Of the three residues, R59, H107 and T135, tested, only GlyR a lH 107A  
exhibited  a reduced  sensitivity to  Zn2^  mediated  inhibition with no  shift  in the 
maximal level of inhibition.  GlyR a lR M )A  revealed a modest 2-fold increase in the 
potency of Zn2+  mediated inhibition.  C, Typical currents recorded upon maximal 
activation (blue - 500pM) demonstrating that there is no Zn2+  activated response 
for *+' face Ala substitutions when 30 mM Zn2+  was applied (red traces).  N  = 3. 
Note that GlyR al wild-type (dashed line) and a lT 133A  (small squares) traces were 
taken  from Fig 3.2D and  3.107).  Scale bars represent time of 0.5  s  and current 
amplitude of 1  nA.
120A putative hydrophobic transduction pathway between the Zn2+ inhibition and 
agonist-binding sites
•  •  94*  •  •
So far, these data support the supposition that the  face of the inhibitory Zn  site is 
responsible  for mediating the  downstream  effect  of Zn2+  inhibition  and  sufficient 
disruption of this face causes Zn2+ binding to stabilise the open state of the receptor
94- creating a ZAG.  In the wild-type receptor, Zn  seems to act allostencally to reduce 
agonist potency suggesting there must be a mechanism by which the agonist binding 
and the inhibitory Zn2+ sites interact.  Closer inspection of the GlyR structural model 
does not suggest any obvious route by which this communication could occur as the 
agonist  binding  site  and  the  inhibitory  face  are  almost  diametrically  apposed 
(Fig  4AAJ$).  This  communication  may  perhaps  derive  from  an  electrostatic 
displacement passed around the polar amino  acids on the outskirts of the receptor 
protein, or via a conformational reorganisation directly through the hydrophobic core 
of the protein.  Previously Unwin et al,  (1995) have suggested the ligand-binding 
a subunit of the homologous nAChR does undergo a conformational rearrangement 
upon agonist binding, which is communicated throughout the extracellular domain 
and  so  a hydrophobic communication between the  two  sides  of the receptor may 
represent the most likely routing.
To address this issue, residues representing the most direct route (by eye) across the 
hydrophobic core were mutated to alanine residues.  The rationale for this was that if 
large  hydrophobic  groups  are  required  to  push  against  each  other  and  induce 
conformational change along a pathway through the centre of the protein, then at the 
point of Ala insertion, which is much smaller, there will be no side moiety to induce 
steric pressure  and the communication may break  down.  This presumably would 
lead  to  a reduction  in  the  efficacy  of the  transduction  pathway,  which  would  be 
manifest  by  a  reduction  in  Zn2+  inhibition,  assuming  there  were  no  indirect 
perturbations to the inhibitory site to affect its affinity.  Initially eight hydrophobic 
residues were  selected reflecting their prime locations to drive  signal transduction 
from the agonist binding site to the Zn2+ inhibitory  face; L98, F99, FI00, FI08, 
1132, L134, L156 and F207 (Fig 4.5A,B).  Amino acids L98, F99 and F100 on strand 
p4, LI 56 on p7 and F207 on piO, are spread across P-strands on the agonist-binding 
side of the transduction pathway (nomenclature of Brejc et al., 2001).  FI08 on P5
121and the P6’ LI34 and 1136 are present on P-strands alongside the Zn2+ inhibitory site 
face (Fig 4.5A,B).  These residues can be tentatively ascribed to three domains 
with 1132 present directly on the back of the inhibitory site  face.  FI 00, FI 08 and 
LI 34 are present in the hypothetical linker region in the pathway between the two 
protein domains, as are L98 and LI 56, though these residues are slightly to the side 
(Fig A.5A,B).  All these residues from each side of the meeting point between the two 
domains have their hydrophobic faces opposing each other.  Finally, F99 and F207 
face directly into the agonist binding site and may reflect the initiation point of any 
allosteric communication that is to be transmitted across the protein to or from the 
inhibitory site  face.
Disruption  of the  hydrophobic  pathway  generates  spontaneously  open  GlyRs 
that are dependent on background Zn2+ and protons
The initial proviso was to investigate these residues with the intention of determining 
potential  changes  in  the  maximal  inhibition by Zn  ,  used  as  an  indicator  of the 
efficacy of the inhibitory process.  However initial attempts to record from some of 
these mutant receptors expressed in HEK cells revealed the presence of significant 
background leak currents in the absence of any agonist, which in the most extreme 
cases, declined rapidly over a 5 -  10 minute recording period making it very difficult 
to  measure  dose  response  curves  for  modulators.  These  persistent  background 
inward  currents  could  be  blocked  by  the  application  of the  GlyR  open  channel 
blocker cyanotriphenylborate (CTB; 20 pM) and were therefore initially proposed to 
be spontaneous openings of the mutant receptors.  The extent of spontaneous opening 
was  0.5  ±  0.1  nA  (7.4  %)  for  odL 98A ,  1.4  nA  ±  0.2  nA  (51  %)  for  a lF99\  
0.3 ± 0.1 nA (7.2 %) for a lF108A  and 0.7 ± 0.1 nA (12.4 %) for a lLI34A  where values 
represent the CTB blockable current (Ic t b ) as a percentage of Ic t b  plus the maximal 
Gly response (lay), (« = 4 -  10; Fig 4.6A).  Thus^,percentages reflect the size of the 
leak  current  as  a percentage  of the  maximal  activatable  GlyR current.  All  other 
mutated receptors exhibited a leak current of less than 2 % in the presence of CTB 
(data not shown; n = 4 - 5).  Also a wild-type GlyR al  exhibited only a 0.4 ± 0.1  % 
(n = 4) reduction in leak current following CTB application, suggesting a negligible 
level of spontaneous opening, in accord with single glycine channel studies (Beato et 
al.,  2002;Beato  et  al.,  2004).  Although  these  mutant  receptors  appeared  to  have
122spontaneously open phenotypes, in view of the ZAG channels observed earlier, these 
receptors were also tested  for activation by contaminating background Zn2+ in the 
Krebs, which may be responsible for the observed receptor opening.  Incubation of 
transfected HEK cells with 2.5 mM of the low affinity Zn2+ chelator tricine caused a 
significant reduction  in the basal  leak current  of all  four mutants  a lL98A ,  a lF99A , 
a lF108A  and a lL 134A  (Fig 4.6/1) accounting for between 60 and 80 % of the total leak 
as measured by using CTB.  Studies on a lL 98A  and a lF99A , where the leak current 
was now small  enough (<  0.5  nA)  in the presence of tricine  such  that  it  did  not 
rundown, showed that the remaining leak could be further attenuated by applying a 
more potent Zn2+ chelator, TPEN, presumably by chelating any remaining free Zn2+ 
(Fig 4.6A).  This TPEN solution was applied on the tricine background but did not 
actually contain tricine.  Using previously published Kd values of 10'5  for tricine and 
10'1 5  6 for TPEN (Paoletti et al.,  1997) and assuming the initial contaminating Zn2+ 
concentration in the saline solution was 0.2 pM (Wilkins and Smart, 2002) produced
^ I
final predicted free contaminating Zn  concentrations of 5.42 nM in 2.5 mM tricine, 
reduced to 0.1 atomolar in 100 pM TPEN.  Given the extremely low concentration of 
free Zn  in TPEN it is unlikely that the remaining leak current can be attributed to 
Zn2+.  This residual leak in TPEN was therefore most likely due to activation of these 
receptors by protons.  This assumed that the Zn2+ activation was being mediated by 
the original Zn2+ inhibitory site, HI09, which is also  an important residue  for the 
proton mediated inhibition of GlyRs (Chen et al., 2004) and so protons may now also 
be activating this new set of receptors.  This was supported by the fact that applying 
TPEN  at  pH  8.4,  an  increase  of  1   pH  unit  and  a  10-fold  decrease  in  the  basal 
concentration of protons, from 39.8 nM to 3.98 nM, further reduced the residual leak 
current compared to that with TPEN at pH 7.4.  TPEN at pH 8.4 induced an outward 
current (reduction in leak current) of 2.0 ± 0.8 % of the total GlyR current (measured 
as the Gly Im ax + the leak current inhibited by CTB, Ic t b ) for a lL 98A  and 3.7 ± 0.6 % 
for a lF99A  (n = 4 - 5; Fig 4.6B).  Furthermore, application of TPEN at pH 6.4 on a 
background  of TPEN  at  the  normal  pH  7.4  evoked  a  proton-induced  current  of
5.3  ± 0.7 %, (n = 5) and 7.0 ± 0.6 %, (n = 4) for a lL 98A  and a lF99A  respectively (Fig 
4.6B).  This increased to 10.3 ± 1.7 %, (n - 4), for a lF99A  at pH 6.0 whereas Gly al 
wild-type receptors evoked an inward current of just 0.2 ±0.1  %, (n = 4).  These 
measurements were from proton induced currents at steady-state 4 s time points as
123HEK cells are known to possess an endogenous rapidly inactivating proton induced
sle
current, which dropped to 0.2 ±0.1 %, (n = 4) for wild-type GlyR transfected HEK 
cells in this time (Fig 4.6B).  As  100 pM TPEN was predicted to reduce the Zn2+ 
concentration to at least 10 atomolar across the pH range 6 - 8.4 it is unlikely that the 
induced  currents  responses  at  variable  pH  values  were  due  to  changes  in  the 
efficiency with which TPEN chelates Zn2+.(* Gunthorpe et al., 2001)
Figure  4.5  Mapping  a 
hydrophobic  pathway 
through  the  GlyR  N- 
terminus.  Close-up  GlyR 
structural models showing 
a  potential  hydrophobic 
transduction pathway from 
the  *-*  face  of  the 
inhibitory Zn2+  site to  the 
agonist  binding  site.  A, 
View from the inside face 
and  B,  view  from  the 
outside  face  (see  grey 
pictorials;  Zn2+  site  -  
orange  triangle,  agonist 
site  -   red  square,  white 
arrow shows the direction 
from which the subunit is 
being viewed, black arrow 
shows  the  predicted 
communication  pathway). 
The  *-*  inhibition  site  is 
represented  by  orange  (3- 
strands and an orange box 
where  the  candidate 
binding  residues  are 
presented (not shown here 
for  clarity  but  see  Fig 
4.2/1).  The  agonist 
binding  motifs  are 
presented  in  red. 
Seven  hydrophobic
residues are  shown  as  a 
route  between  the  two 
domains  with  residues
regarded to be at the end of the path in green and residues that are in the centre of 
the path shown in blue and grey.  Note that some extraneous structure on the outside 
face is cut away from B, for ease of viewing.
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Figure 4.6  Zn2+  and H+ basal leak currents in mutated GlyRs.  Experiments to 
remove  leak  currents  from  hydrophobic  mutated  a lL 98A ,  a lF99A ,  a lF108A   and
LI  34A  •  •   2+ al  receptors  were  carried  out  using  Zn  chelators  and  external  pH 
modulation.  A, Leak currents were measured in terms of the background current 
ablated by cyanotriphenylborate (CTB) a GlyR open channel blocker (white bars). 
This  was  measured  as  a percentage  of the  total  current,  which  is  equal  to  the 
amount  of CTB  leak  (Ictb) plus  the maximal  glycine  response  (Ioiy)-  2.5  mM 
tricine (black bars), a Zn2+  chelator, significantly (*; P < 0.05) reduced the leak by 
50 - 80 % (Itricin</IcTB+Iieak as a percentage) and 100 pM of a higher affinity Zn2+ 
chelator TPEN (shaded bars) caused a further reduction.  B,  Lowering external pH 
(pH 6.0 (black) and 6.4 (white)) in the presence of TPEN elicited stable currents in
L98A  F99A al  and al  GlyRs but not in wild-type al.  Removal of protons (pH 8.4 - 
shaded) decreased the leak on a TPEN background.  C, Typical currents induced 
by  increasing  and  reducing  pH,  measurements  were  made  after  4  s  (I4)  to 
inactivate the endogenous H+  receptors of HEK cells (see al  trace).  Scale bars 
represent time of 1  s and current amplitude of 100 pA.  N= 3-8.
125Disruption of the hydrophobic pathway ablates Zn2+ mediated inhibition
In  the  cases where  there was  a  significant  leak  current,  subsequent  recordings  to 
investigate the sensitivity of these receptors to Zn2+  mediated inhibition were carried 
out in  a 2.5  mM tricine background  to  avoid rundown.  Additionally,  due  to  the 
apparent ZAG activity, 1000 pM Zn2+  was co-applied with Gly and the I4 value was 
measured  instead  of using  a  pre-incubation  protocol.  Of the  eight  hydrophobic 
residues  tested  six  of them,  a lL 98A ,  a lF99A ,  a lF100A ,  a lF108A ,  a lI132A   and  a lL 134A  
ablated  sensitivity to  Zn  mediated  inhibition  up  to  1   mM  Zn  co-applied  with 
glycine  concentrations  causing  a  50  %  maximal  response.  This  supports  the 
supposition  that  the  inhibitory site  has  been  converted to  a high  sensitivity ZAG 
mediating site responsible for background leak currents (Fig 4.7A).  Of the remaining 
two  residues,  a lF207A   was  non-functional  {n  =  5)  and  a lL 156A   did  not  exhibit  a 
significantly  shifted  IC50  for Zn2+,  23  ±  6  pM,  (n  =  3;  Fig 4.1  B).  Furthermore 
a lL 156A  did not demonstrate any obvious Zn2+ mediated leak current, nor any ZAG 
activity in response to high 30 mM concentrations of Zn2+ suggesting this residue 
and strand  p7 are not involved in the Zn  transduction pathway (data not  shown, 
n = 3).
Disruption  of the hydrophobic pathway generates a family of high  sensitivity 
ZAG receptors
1
To  assess  and  correlate  the  sensitivities  of these  residues  to  Zn  the  side  chain 
moieties were split into two groups.  One group comprised residues closest to each of 
the binding sites, F99 for the agonist binding site and 1132  for the inhibitory Zn2+ 
binding  site.  The  second  group  included residues  that  are  present  at  the  critical 
bridging region between the two sites, L98 and FI00 from the agonist-binding side, 
and F108, L134 from the inhibitory Zn2+ binding  face (Fig 4.5A,B).  Due to the 
high sensitivities of these receptors to Zn2+ these GlyRs were characterised for the
2“ F   •   • potency of Zn  acting as an agonist alone on a 2.5 mM tricine background to reduce 
the amount of free Zn2+ and control exactly the level of free Zn2+.  Though TPEN 
could remove background Zn2+ more effectively, its high affinity for Zn2+ meant that 
it was unsuitable for regulating the Zn2+ concentration across the range required for a 
dose response curve.  Furthermore, although there will be some small contamination 
from  background proton  activation,  it was  deemed more  appropriate  to  carry out
126these  experiments  out  at physiological  pH,  and with  the  exception  of a lF99A ,  the 
contribution from background protons was small, < 3 %.  Dose response curves for 
glycine revealed that these receptors retained a sensitivity within 4-fold of the wild- 
type glycine E C 50 and did not exhibit significantly different Gly Im ax values with the 
exception of a lF99A , which exhibited an 8-fold increase in  E C 50  from 35  ± 3  pM, 
(n  = 6) to  250 ± 40, (« = 4) and a two-fold reduction in Im ax from 6.8  ±  0.5  nA, 
(n = 6) to 3.8 ± 0.4 nA, (n = 10; Table 4.1).  This is not unexpected as the F99 moiety 
faces directly onto the predicted agonist-binding site (Fig 4.5AJB) and in addition this 
mutant  had  the  largest  leak  currents  suggesting  that  a  portion  of  the  a lF99A  
population may already be in a desensitised state which could account for a reduction 
in the maximal currents attainable.  By comparison to the original  face binding 
site mutations,  the mutated a lF99A  GlyR exhibited a far higher sensitivity to Zn2+ 
activation with an E C 50 of 0.13 ± 0.03 pM, (n = 5) and a higher relative efficacy of 
91  ± 6 %, (n = 5) (Fig 4.8A,C).  GlyR a lI132A  exhibited a lower potency for Zn2+ 
perhaps because it is backed onto the inhibitory  face and could indirectly distort 
the site, however, the relative efficacy was still high at 72 ± 5 %, (n = 5; Fig 4.8A,C). 
In a similar manner to the  face inhibitory ZAG receptors, the 50 % maximal Zn2+ 
activated currents of a lF99A  and a lI132A  also had slower onsets than that elicited by 
an E C 50 dose of Gly (Fig 4.8C).  Current-voltage (IV) relationships again revealed a 
comparable linear voltage dependence to that previously shown for Gly on wild-type 
al  receptors and the reversal potential was close to zero consistent with the ZAG 
current being mediated by chloride flux through the GlyR (Fig 4.8B).  Analysis of 
the residues  representing  the  bridging  region  between  the  two  sites  revealed  that 
these mutated receptors also all exhibited high sensitivities to Zn2+ as an agonist with 
EC50s of 0.26 ± 0.078 pM, (n = 4) for a lL98A , 9.19 ± 0.63 pM, (n = 4) for a lF100A ,
2.3  ± 0.6 uM, (n = 6) for a lF108 and 0.1 ± 0.03 pM, (n = 4) for a lL 134A  (Fig 4.9A).  In 
contrast though, the relative efficacy values compared to Gly for these receptors were 
generally lower at 49  ±  5  %,  (n - 4)  for GlyR a lL98A ,  7.4  ± 3.8  %,  (n  =  4)  for
a lF100A , 25 ± 6 %, (n = 6) for a lF108A  and 18 ± 3 %, (n = 4) for a lL 134A  (Fig 4.9,4).
*  2+   •  • Again  the  rates  of Zn  activation  for the  steady-state macroscopic  currents  were
slower compared to Gly activation, and the Zn2+ IV plots were comparable to those
for Gly obtained for wild-type GlyR al (Fig 4.9B,C).
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Figure 4.7  Ablation of Zn2+ inhibition by substitution of hydrophobic residues 
in the GlyR.  Alanine substitutions of hydrophobic residues lining the transduction 
pathway between the Zn2+ inhibitory site  face and the agonist binding domain
74* ablate GlyR al  Zn  mediated inhibition.  A, Measurements at the 4-second time
2+ point  (I4)  during  co-application  of  1000  pM  Zn  with  a  Gly  concentration 
corresponding to  50  % of the maximal  Gly response  (as  a percentage of a Gly 
concentration  causing  a  50  %  maximal  response  in  the  absence  of  Zn2+). 
Inhibition  is  completely  abolished  at  this  high  concentration  of Zn2+  for  six
I . J   u  j   -J  L98A  . F99A  ^lO O A   . F108A  ,1132a  , hydrophobic mutated residues tested: al  , a l   ,a l  ,a l  ,a l  and
L134A  2+ al  .  Due to the absence of Zn  mediated inhibition these receptors invoke 
currents in the presence of 1000 pM Zn2+ greater than 100 % possibly due to the 
remaining  presence  of Zn2+   potentiation.  *  Asterisks  represent  a  significant 
difference from the wild-type receptor (P < 0.05).  B, Zn2+ dose response curve 
using  a pre-incubation  protocol  to  measure  modulation  of 50  %  maximal  Gly 
evoked responses for the single GlyR a lL156A , which did not exhibit ablated Zn2+ 
mediated inhibition.  N = 4 -6 .  The GlyR al  wild-type (dashed line) trace was 
taken from Fig 3.2D. Bar chart values represent mean ± s.e.
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Figure  4.8  High  relative  efficacy  ZAGs.  Alanine  substitutions  for 
hydrophobic residues marking each end of the transduction pathway between the 
Zn2+ inhibitory site  face and the agonist binding domain produces receptors 
with high relative efficacies that are sensitive to direct activation by Zn2+.  A, 
Zn2+ dose response curves for GlyR a lF99A  and a lI132A  plotted as the percentage 
of the maximal response to glycine applied to the same cells.  B, Current-voltage 
(IV) relationships and the reversal potential of EC50 Zn2+ activated currents for
F99A  I132A al  and al  .  These IVs are comparable with the Gly IV plot from a wild- 
type  GlyR  al  (dashed  blue  line).  C,  Typical  currents  recorded  upon  Zn2+ 
activation  (black)  of GlyR a lF99A  and a l1 1  2A .  The time-scale matched doses 
applied are in pM (red bars -  this represents the longest application required as 
the  low doses took  longer to reach  steady-state).  50  % maximal  Gly evoked 
responses are also included (blue) as a comparison and reveal a faster onset rate 
than the response matched Zn2+ currents.  Scale bars represent  1   s  and  1   nA. 
N= 4-5.
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Figure  4.9  High  sensitivity,  low  relative  efficacy  ZAGs.  Alanine 
substitutions for hydrophobic residues in the bridging region between the Zn2+ 
inhibitory  site  face  and  the  agonist  binding  domain  produce  receptors 
sensitive  to  activation  by  Zn2+  with  low  relative  efficacies.  A,  Zn2+  dose
r   /-Mr*  1 L98A  , F100A  ^lO S A   ,  .L134A  ,  „   , response curves  for GlyR al  ,  al  ,  al  and al  plotted  as  the
percentage of the maximal response to  Glycine applied to  the  same cells.  B, 
Current-voltage  (IV)  relationships  and  the  reversal  potential  of  EC50  Zn2+
/ >   F99A  H32A activated currents  for al  and al  .  These IVs are comparable with the
EC50  Gly  IV  plot  from  a  wild-type  GlyR  al  (dashed  blue  line).  C,  Typical 
currents recorded upon Zn2+ activation (black) of GlyR a lL98A , a lFl00A, al  l08A 
and a lIl32A.  The time-scale matched doses applied are in pM (red bars -  this 
represents  the  longest  application  required  as  the  some  doses  took  longer  to 
reach  steady-state).  50  %  maximal  Gly  evoked  responses  are  also  included 
(blue)  as  a comparison  and reveal  a  faster onset  rate  than  the Zn2+  activated 
currents.  Scale bars represent 1  s and 1  nA.  N= 3-6.
130ZAG receptors require binding components of the Zn2+ inhibitory site
The  concomitant  observations  that  a lL 98A ,  a lF99A ,  a lF100A ,  a lF108A ,  a lI132A   and 
ai li34a receptors aj-g activated by protons and that the inhibitory Zn2+ site no longer 
functions, suggests that this ZAG activity is derived from the original inhibitory Zn2+  
binding site.  However, it also appears that there are at least two different types of 
ZAG  site present;  a high affinity site that appears in response to the hydrophobic 
core  disruptions  and  a  low  potency  site  that  occurs  upon  disruption  of  the 
inhibitory binding face.  The low potency ZAG site formed from the inhibitory 
face  disruptions  can  be  explained  by  the  fact  that  these  receptor  mutants 
potentially suffer disruption to the Zn2+ coordinating partners in the ZAG reducing 
the affinity of the site.  In the case of the high affinity sites though the potencies for 
Zn2+ are as low as 0.1  pM compared to the potency for Zn2+ inhibition at wild-type 
receptors of approximately 20 pM, suggesting this site may have changed chemically 
to produce a higher affinity for Zn2+.  To test this hypothesis two mutated receptors, 
a  1 Ti33A  to represent the low potency ZAGs and a lF99A  to represent the high potency 
ZAGs,  were  compared  for  their  dependence  on  residues  forming  the  original 
inhibitory Zn2+ binding site, namely HI07, HI09 and T133.
GlyR a lT 133A , which had a low sensitivity to Zn2+, possibly due to the loss of T133 
as  a  coordinating partner,  lost  almost  all  ZAG  activity when  an  extra  H107A, or 
H109F (which unlike HI 09A had no ZAG activity of its own; data not shown, n = 3) 
were incorporated, with 30 mM Zn  evoking currents, as a percentage of the Gly 
W ,  of only  1.8  ± 2.2  %, (n = 3)  for a lT133A ’ H 107A  and  1.4 ± 0.2  %,  («  = 3)  for 
a jTi33A, H 109F  ^0A).  gy contrast, introduction of substitutions at HI 07 or HI09
on the a lT 133A  receptor only slightly affected Gly potency (Fig 4.1 OR, Table 4.1).  As
^ I
a further test of the criticality of HI07 for Zn  coordination and induction of ZAG 
activity this residue was  also mutated to  an alternative Zn2+ binding moiety,  Asp. 
The a lT 133A ’ H 107D  receptor retained a similar Gly potency to a lT133A , but the Zn2+ 
potency  was  still  significantly  reduced  almost  to  the  extent  of  a lT133A ,H 107A  
suggesting  that  the  exact nature  of the residue  at position  107  is  critical,  though 
whether this requirement is structural, chemical,or both,is unclear (Fig 4.10A,B).
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Figure  4.10  Shared  Zn2+ 
binding  components  between 
Zn2+  inhibition  and  low 
potency  ZAGs.  The  low 
potency Ala  substituted  ZAG 
receptors  formed  by 
disruption at the  face of the 
inhibitory site still require the 
Zn  binding  residues  of the 
inhibitory site  for direct  Zn2+ 
activation.  A,  Zn2+  dose 
response curves plotted as the 
percentage  of  a  maximal 
response to Glycine applied to 
the  same  cell.  For  GlyR 
a lT 133A   based  mutants,  the 
introduction  of  extra 
disruptions  to  the  putative 
Zn2+  binding  residues,  HI07 
and  HI 09,  introduces 
substantial  reductions  in  the 
potency of Zn2+. (The a lTl33A 
Zn2+  dose  response  curve  is 
taken  from  Figure  4.3  A). 
B,  Gly dose response  curves 
for  GlyR  a lT 133A   based 
mutants  showing 
introduction  of
that 
extra
disruptions  to  the  putative 
Zn2+  binding  residues,  HI07 
and  HI09,  introduces  only 
modest  shifts in Gly potency. 
N= 3-5.
132riAA *  A i
For al  , mutation of the inhibitory Zn  site residue, HI09 caused a significant 
10-fold reduction in the Gly potency but more substantially, virtual ablation of ZAG 
activity, such that a 1   mM Zn  induced a current of only 2.4 ± 2.8 %, (n = 5) for 
a l F99A,  H109F  Qf the Qly  (Fig 4 ^  Intriguingly,  a lF99A ’ H 107A   and  a lF99A ’
T133A ,  induced  similar  10-fold  reductions  in  Gly  potency,  but  they  only  exerted 
modest  3  to  5-fold decreases  in the  sensitivity to  Zn2+  activation with Zn2+  EC50 
values increasing from 0.13 ± 0.3  pM, (n = 5) for a lF99A  to 0.4 ± 0.1, (n = 5) for
a l F99A, H107K ^   t()  Q J $   ±   Q ^   ^   =   ^   f o r  a l F99A, T133A  4  U B y   ^   k e e p i n g   w it h
the consistent reductions in ZAG sensitivity of these mutated receptors the level of
* y  I
spontaneous Zn  dependent leak was also reduced, evident from the block induced 
by both CTB and tricine (Fig 4.11C).  This suggests these two residues do not have 
the  same  degree of importance  as  HI09  for the high potency ZAG  site.  Further 
studies to  attempt  to  elucidate  alternative Zn  coordinating partners  for the  high 
potency  ZAG  site  did  not  reveal  any  obvious  candidates.  The  nearby  residues 
selected  were  a lF99A ’ D 97A ,  a lF99A ’  E 103A ,  a lF99A ’   D 114A   and  a lF99A ’   E 157A   from  the 
‘+*  face and a lF99A ’  E 110A  and a lF99A ’ T 112A  from the  face, all of which failed to 
reduce the potency of Zn2+ at an a lF99A  based ZAG (Fig 4.124^5).  An a lF99A ,D 57A  
receptor was also tested but this proved non-functional (n = 5).
133L
e
a
k
 
(
%
 
o
f
 
I
c
t
b
 
+
 
1
^
)
 
0
 
Z
n
2
*
 
l
m
a
x
 
(
%
G
l
y
 
l
m
a
x
)
 
C
D
 
%
 
G
l
y
c
i
n
e
 
I
H107K
,  H109F
, T133A
100  1000  10000 
Gly co nee ntration (pM)
■ a1F99A
0   a lF99A, H107K 
^  a lF99A, H109F
A a1F99A 'T133A
0.01  0.1  1   10 100 100010000 
Zn2+ concentration (pM)
70
60
50
40
30
20
10
0
F99A F99A
H107K
F99A
H109F
F99A
T133A
II
o   .£
A?
Figure 4.11  Dependence  of 
high  nM  sensitivity  ZAG 
receptors  on  Zn2+  binding
residues  of  the  original
2+ inhibitory  site  for  direct  Zn 
activation. A, Gly dose response
FQQA
curves  for  GlyR  al  based 
mutants  showing  that 
introduction of extra disruptions 
to  the  putative  Zn2+  binding 
residues, H107, H109 and T133, 
introduces a consistent ten-fold 
reduction  in  the  sensitivity  to 
glycine.  B,  Zn2+ dose response 
curves plotted as the percentage 
of  a  maximal  response  to 
glycine applied to the same cell.
FQQA
For GlyR al  based mutants, 
the  introduction  of  extra 
mutations  to  the  Zn2+ binding
residues,  HI 07  and  T133,
introduces  a  comparable
reduction  in  sensitivity  to  the 
agonist  Zn2+.  However, 
introduction  of  an  H109F
mutation  introduces  a  near 
complete  ablation  of  ZAG 
activity.  (The a lF99A   Zn2+  dose 
response  curve  is  taken  from 
Figure 4.&4). C, In keeping with 
the  lower  Zn2+  sensitivity  of 
these  a lF99A   receptors  the  leak 
current  measured  as  a 
percentage  of the  total  current, 
(Ictb  plus  the  maximal  Gly 
response  (Iciy))  is  significantly 
reduced  (*;  P  <  0.05,  white 
bars)  and  could  be  further 
reduced  by  2.5  mM  tricine 
(black bars).  N = 4 - 5.
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Figure 4.12  Acidic residues residing in the vicinity of the inhibitory Zn2+ site 
do not mediate Zn2 +  binding for the high Zn2+ potency ZAG receptors.  The ZAG 
sensitivity was analysed on the high sensitivity ZAG a lF)9A  background in terms 
of the  size  of the  leak  currents  (A)  and  the  %  maximal  current  evoked  by  a 
submaximal 0.3 pM dose of Zn2+ (B).  A, Leak currents measured as a percentage 
of  the  total  current,  Iqjq  plus  the  maximal  Gly  response  (Ioiy)  were  not 
significantly reduced  in  any of the  six  potential  Zn2+  coordinators  tested  when 
measured as the CTB blockable current (white bars) or the 2.5 mM tricine reduced 
current (black bars).  B, In keeping with this, the percentage current induced by 
0.3 pM Zn2+  (shaded red bars) was also not significantly reduced compared to the
F 99A
al  background when recorded as  a percentage of the maximal  Gly evoked 
response or, in cases where Gly was not the most efficacious agonist (black bars),
2“ F as a percentage of the Zn  1 ^   (red bars) in the same cell.  N = 3-4.
135The formation  of high  sensitivity ZAG receptors  is  specific to  residues  of the 
hydrophobic transduction apparatus
•  94- From  the  group  of residues  tested  for their ability to  compromise  Zn  mediated 
inhibition  all  but  one,  a lL 156A ,  resulted  in  formation  of  a  ZAG.  Therefore  to 
demonstrate  that  this  ZAG  transduction  pathway  was  in  fact  specific  to  these 
residues, several other hydrophobic amino acids in the surrounding region were also
94- mutated  to  Ala  and  tested  for  an  influence  on  Zn  mediated  inhibition.  GlyR 
aim  154A  g.om ^  p7 strand as well as GlyR a lI130A  and GlyR a lL 136A  were selected 
as the closest hydrophobic residues surrounding the hydrophobic bridging  section. 
Also, and a lA 101L and a lN 102A , immediately adjacent to the DLFF motif, were also 
tested.  These mutations failed to induce any ZAG activity with 30 mM Zn2+ (n = 3). 
Furthermore  these mutated  GlyRs  all  exhibited biphasic  dose response  curves  for
    7 1   VII  A      * >  I
Zn  modulation (al  not tested) when Zn  was pre-applied and then co-applied 
with a 50 % maximal dose of Gly and the IC50 values were all within 2-fold of that 
for the GlyR al wild-type (Fig 4.13^4,5).
Both  low  and  high  sensitivity  ZAG  receptors  exhibit  a  slower  rate  of 
macroscopic current activation
The  evidence  so  far  provides  strong  support  for  the  presence  of a  hydrophobic 
transduction pathway stretching across the extracellular domain from the inhibitory
94- Zn  binding  site  to  the  glycine  recognition  site.  In  the  wild-type  receptor  this 
pathway presumably mediates  the  effect  of Zn2+inhibition  on  the  agonist-binding 
site.  Howevei^ from the data presented so  far it is not obvious what function this 
pathway performs upon the actual binding of agonist and subsequent activation of 
the receptor.  The Gly EC50S,  and Im ax values  for both the  low  and high  potency 
ZAGs  do  not  show  any  obvious  patterns  of disruption  relative  to  the  wild-type 
receptor  (Table  4.1).  It  could  be  that  this  pathway  exists  simply  to  mediate  a 
modulatory  effect  from  Zn2+  during physiological  processes.  However  it  is  also 
possible that this conformational transition from one side of the extracellular domain 
to the other also fulfils some other purpose in terms of receptor function.  To address 
this issue the shapes of the macroscopic traces were analysed to measure any effects 
on  the  extent  of glycine  induced  desensitisation,  which  inhibitory  Zn2+  has  been 
shown to influence in the NMD  A receptor (Zheng et al., 2001), and also to measure
136the  activation  rates  of the  receptors.  In  a  comparable  manner  to  the  effects  on 
glycine potencies, the desensitisation studies did not reveal any obvious disruption to 
this process in the ZAG receptor mutants with the wild-type receptor desensitising by 
45  ±  2  %,  (n  =  7)  during  a  10  s  supramaximal  10  mM  glycine  application 
(Fig 4.14,4,5).  Only GlyR a lL 98A , a lT 133A  and a lL 134A  displayed modest increments 
in the extent of desensitisation with Igiy reducing to 36 ± 3  %, (n = 3), 44 ± 3  %, 
(n =  7)  and 41  ± 2  %,  (n = 3) of the peak  current,  respectively under the  same 
conditions (P < 0.05; Fig 4.144,5).
In contrast to the extent of desensitisation, when a single exponential was fit to the 
upper phase of 50 % maximal Gly currents, a significant increase in the time constant 
to  reach  steady-state was  measured  for  all  high  and  low potency ZAGs  with  the 
exception of GlyR a lF99A  (P < 0.05; Fig 4.15A,B).  This increase in the time constant 
to  reach  steady-state peaked  for the hydrophobic  residues  located  in  the bridging 
region  with  a lF100A ,  a lF108A   and  a lL 134A   having time  constants  of 250  ±  30  ms, 
(n = 8), 220 ± 30 ms, (n = 11) and 210 ± 60 ms, (n = 5) respectively, compared to 
GlyR al  wild-type of 100 ±  10 ms, (n = 7).  For the low potency ZAGs, the time 
constants  were  even  slower with  a lT 133A   exhibiting  the  slowest  time  constant  of 
450 ± 80 ms, (n = 6).  To demonstrate that this effect on receptor macroscopic rates 
of  activation  was  specific  to  the  ZAG  mutants,  four  other  nearby  non-ZAG 
mutations,  the hydrophobic  a lI130A ,  a lL 136A  and a lL 156A  mutants  and the  ‘+*  face 
mutation a l1 1 5 ^  were tested.  All failed to induce any change in the rate of activation 
values (Fig 4.15,4,5).  It should be noted that these estimations of activation rates 
were carried out using doses  of Gly giving 50 % maximal responses in 0.25  mM 
tricine  to  remove  contaminating background  Zn2+,  which  is  sufficient  to  activate 
many of these receptors  to  a  certain  degree  with  a  slower  onset  rate,  potentially 
interfering with the rates of onset presented here.  However a lF99A  the most sensitive 
and efficacious ZAG did not exhibit slower onset rates suggesting this possibility of 
Zn  interference was unlikely.
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Figure 4.13  Demonstration of the specificity of the hydrophobic transduction 
path from the inhibitory Zn2^ site  face to the Gly binding site.  A, View from 
the outside face (see grey pictorial; Zn2+ site - orange triangle, agonist site -  red 
square, black arrow shows the viewing angle, white arrow - predicted transduction 
pathway)  showing  the  green  and  blue  hydrophobic  residues  previously 
demonstrated to mark a pathway between the  inhibition site (orange p-strands 
and orange box) and the agonist binding motifs (red).  Residues labelled in pink 
are hydrophobic residues that lie just outside the predicted path of the transduction 
domain. Some extraneous structure is cut away for ease of viewing.  B, Zn  dose 
response  curves  using  a  pre-incubation  protocol  for  the  modulation  of  50  % 
maximal  Gly  evoked  responses  demonstrates  that  Ala  substitution  of  these 
residues  failed  to  reduce  the  sensitivity  to  Zn2+  mediated  inhibition  when 
compared to the wild-type al GlyR.  N= 3.
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Figure 4.14  Variations in the extent of macroscopic desensitisation do not show 
any  obvious  correlation  with  mutations  that  induce  the  formation  of  ZAGs. 
A, Mean values for the extent of desensitisation of macroscopic currents measured 
in terms of the current amplitude after  10 seconds of supramaximal  10 mM Gly 
application (Iio) as a percentage of the peak amplitude of the same current (Ipeak)* 
Mutated GlyRs were compared to the wild-type al  receptor (black bar) and were 
separated into categories as follows; mutated receptors that did not form ZAGs - 
white bars; low potency ZAGs formed through disruption of the  inhibitory Zn2+ 
binding site face - orange shaded bars; high relative efficacy ZAGs - green shaded 
bars; and high potency, low relative efficacy ZAGs -  blue shaded bars. Asterisks 
depict  mutated  receptors,  which  reached  a  significantly  different  extent  of 
desensitisation  compared  to  the  wild-type  al  receptor  (P  <  0.05).  B,  Typical 
currents  showing  the  extent  of desensitisation  during  10  s  applications  of  a 
supramaximal 10 mM dose of Gly.  Scale bars represent 1  s and 1  nA.  N = 3 -7 .
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Figure  4.15  Rate of glycine current activation measured  in terms  of the  time 
taken  to  reach  steady-state,  is  correlated  with  mutations  that  generate  ZAGs.
A, Mean values for the rate of onset measured by fitting a monoexponential curve fit 
from the current onset to the time taken to reach steady-state of 50 % maximal Gly 
evoked responses.  The wild-type al  receptor (black bar)  was  compared to non- 
ZAG mutated receptors  (white  bars)  and  ZAG  receptors  with;  low  Zn2+  potency 
formed by disruption of the  inhibitory Zn2+  binding site face (orange bars); high 
relative efficacy (green bars);  and high potency,  low relative efficacy (blue bars). 
Asterisks  depict  a  significant  increase  in  the  time  constant  (a  decrease  in  the 
activation  rate)  compared  to  that  for  the  wild-type  al  receptor  (P  <  0.05).
B, Typical 50 % maximal Gly evoked currents highlighting (dashed box) the region 
over which the monoexponential curve fit was determined (faint blue overlay over 
the black trace).  Scale bars represent 1  s and 1  nA.  The currents presented here are 
timescale matched for ease of comparison.  N =3-11.
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The  data  presented  here  describe  the  identification  of  a  hydrophobic  pathway, 
predicted  from  a  structural  model,  to  travel  through  the  hydrophobic  core  of the 
protein from the  inhibitory Zn2+ site face across to the agonist binding domain.  In 
addition  these  data  also  support  the  previous  hypothesis  from  Chapter  3  that 
transduction from the inhibitory Zn2+ site occurs initially through the  H109/T133 
face of the Zn2+ binding site.
Evidence favouring an asymmetric function of the Zn2+ inhibition site
Mutagenesis studies introducing Ala substitutions to amino acids predicted to reside 
on the three rungs of the (3-sheet ladder at the *+* face of the inhibitory site revealed 
that a lH 107A   attenuated the  sensitivity to  inhibitory Zn2+.  In keeping with  a pure 
binding role for this residue, Zn2+ potency at the Ala mutated receptor was reduced 
without any evidence  for the generation of a ZAG.  Two  other mutated receptors 
a l1 1 5 ^  and a lT 135A  that reside on the  *+’  face failed to induce any effect on Zn2+ 
mediated  inhibition  demonstrating  that  the  *+’  face  donates  only  HI07  to  the 
inhibitory Zn2+ site, and this occurs in a manner consistent with an involvement in 
Zn2+ binding.  By contrast,  Ala substitution of residues predicted  to  reside  at the
9 -1 - face  yielded  receptors  with  unexpected  phenotypes  in  response  to  Zn  , 
suggestive of an important transduction role for this side of the site.  Of these amino 
acids, only disruption to an El 10 residue produced an a lE 110A  receptor phenotype in 
keeping with a possible pure binding role for this amino acid as the mutant exhibited 
a  modest  5-fold  decreased  sensitivity  to  inhibitory  Zn2+  without  affecting  the
9 -4 - maximal limit of Zn  mediated inhibition.  According to the model this residue is 
predicted to  face away from the Zn2+ binding site precluding a direct role in Zn2+ 
binding, however this model is not capable of predicting the exact side chain position 
based  on  such  a  low  primary  sequence  homology  (approximately  20  %)  and 
therefore  in  the  real  protein  structure  it  may  be  that  binding  at  El 10  can  be 
accommodated, or that an El 10A substitution simply introduces an indirect structural 
perturbation.  The other four mutated receptors, a lN 61A , a lH 109A , a lT 112A  and a lT 133A  
all yielded either an attenuated maximal level of inhibition by Zn2+, as was the case 
for a lH 109A , or ablated Zn2+ mediated inhibition.  Furthermore, these receptors were 
now  susceptible  to  direct  activation  by  Zn2+  acting  as  an  agonist,  with  relative
141efficacies,  compared to  glycine,  of between  20  and  50  %.  Consistent  with  Zn2+ 
acting as an agonist, receptor activation was concentration dependent, in a voltage- 
independent manner relying on transmembrane  chlonde  flux,  indicating Zn  was 
eliciting anionic flow via the GlyR chloride channel.
A simple hypothesis to explain ZAG formation
If Zn2+, by binding to the inhibitory site, is causing channel activation in the mutated 
receptors, it suggests that ZAG activity involves a reorganisation of the ‘-‘ face of the 
inhibitory site, altering the transduction machinery of the receptor such that Zn  now 
activates  rather than  inhibits  the  receptor.  Though  it  is  not  possible  from  these 
studies  to  understand  exactly  how  such  an  apparently  substantial  phenotypic 
conversion  could  have  occurred,  the  most  likely  explanation  is  potentially  quite 
simple.  Previous evidence (Nevin et al., 2003, Chapter 3) supports the supposition 
that  Zn  exerts  its  inhibitory effect by  forming  a  ‘bridge’  between  two  adjacent 
a subunits, stabilising a closed conformation of the receptor.  Therefore, in order to 
switch this site to elicit activation, all that is needed is a disruption to the  face 
such that the bridging residues, primarily H109/T133 of the  face and HI 07 of the
' j ,
*+’ face, are now better aligned for Zn  coordination when the receptor is activated,
rather than when it is closed.  This will have the resultant effect that application of
2+
Zn  to the receptor can induce activation by drawing the two faces together through 
coordination  and  subsequently,  in  principle,  the  receptor  may  activate.  This 
reorganisation  might  not  necessarily  even  require  a  substantial  disruption  of the
face as it is dependent on the size of the movement that would normally occur at 
this location during activation.  As was previously discussed (Chapter 3) under the 
hypothesis  that  the  nAChR  a  subunit  (and  therefore  quite  probably  the  GlyR 
a subunit also) undergoes a twist during activation (Unwin, 1995), we would expect 
the  H109/T133  region  to  move  relative  to  the  *+’  H107  residue  on  the 
neighbouring subunit (Unwin et al.,  2002) such that Zn2+ can no  longer bind.  So 
then, disruption to move the ‘-‘face out of alignment could be sufficient to induce the 
ZAG  phenotype.  Though  it  is  speculative,  based  on  the  relatively  non-specific 
structural data currently available for GlyRs and their movements during activation, 
a  schematic  model  displaying the  basic  tenets  of such  a process  and the  relative
142simplicity by which it might arise in the context of what is expected for cys-loop 
receptors is presented in Fig 4.16A,B.
A.  Wild-type B.  ZAG
Fig  4.16  Schematic  model  presenting  a  simple  mechanism  for  ZAG 
formation.  A,  Wild-type  GlyR al  can bind inhibitory Zn2+  (blue circle)  to 
stabilise  the  closed  state  but  not  when  the  receptor  activates  (bottom). 
B, Disruption of the *-* face of the inhibitory Zn2+ site prevents Zn2+ binding in 
the closed state (top) but enables Zn2+ binding in the activated conformation 
(bottom) creating a ZAG receptor.
The data discussed here do, of course, assume that the Zn2+ site eliciting activation is 
in fact derived from the original Zn2+ inhibition site.  This does seem to be the case 
as  for  all  the  ZAG  receptors  generated,  Zn2+   mediated  inhibition  is  ablated 
suggesting this functionality has been replaced by the ZAG property.  Furthermore, 
mutation of either of the principal histidine Zn2+ binding residues, HI 07 or HI09, to 
non-Zn2+ binding groups on a ZAG a lT 133A  background, removed the ZAG activity 
suggesting this novel phenotype is still derived from the original H107/H109 based 
inhibitory site.  Given these observations the Zn2+ potencies measured for the  face 
disrupted ZAGs reveals information about the nature of the residues in terms of their 
function at the inhibitory Zn2+  site.  Both a lN 61A , a lH 109A  and a lT 133A  all  formed
143very low potency ZAGs, suggesting the site had been disrupted such that the affinity
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was also reduced.  However, at al  , Zn  had a much higher potency for causing 
activation with an EC50 of similar magnitude to the original IC50 for Zn  mediated 
inhibition, yet its relative efficacy was similar to that for Zn2+ on a lT133A .  Though 
this  means  T112  can  clearly  affect  the  transduction  from  the  site  it  may  not  be 
affecting  the  potency  and  therefore  is  unlikely  to  have  a  role  in  binding,  which 
concurs with its predicted location facing away from the inhibitory site (Nevin et al., 
2003;Chapter 3).  One potentially confusing issue remaining is the fact that a lH 109A  
which  forms  a  very  low  potency  ZAG  also  retains  sensitivity  to  Zn2+  mediated 
inhibition although with a decreased maximal inhibition.  This most likely reflects a 
situation where disruption to the  face of the site is more subtle and this allows 
Zn2+ to compete for two conformations of the site, one which stabilises the closed 
state and one which stabilises the open state.
Evidence supporting the hydrophobic pathway as a transduction pathway
n 1
The evidence so far supports an asymmetric role for the inhibitory Zn  site with the 
face mediating the initial downstream transduction process.  This hypothesis  is 
further  strengthened  here  by  the  identification  of  an  apparent  hydrophobic 
transduction  pathway  leading  selectively  from  this  face  of the  inhibitory  site 
across to the agonist binding site.  Though it is not always possible from mutagenesis 
studies alone to  ascribe the exact function of amino  acids within the  context of a 
binding-transduction role there are  several  factors  elucidated here that  support the 
assertion that this hydrophobic pathway could be a genuine transduction pathway. 
First and foremost is the availability of a structural model for the GlyR, which shows 
strong agreement with the hydrophobic residues identified here lining up to form a 
path between the agonist binding site and the inhibitory Zn2+  face.  This structural 
evidence is also supported by a previous study investigating the putative p4-strand in 
the  homologous  GABAa  receptor  P-subunit.  The  use  of a  cysteine  accessibility 
reagent  revealed  access  to  residues  in  this  domain  were  consistent  with  them 
adopting a p-strand structure and also  showed that the GABAa receptor p  subunit 
residue equivalent to GlyR F99 was predicted to face into the agonist binding site. 
This  means  that  GlyR  L98  and  FI00  are  predicted  to  face  into  the  receptor 
hydrophobic  core  (Boileau  et  al.,  2002).  Secondly,  the  consistent  phenotypic
144exchange upon distortion of the transduction pathway to create ZAGs is supportive 
of a transduction role since if these residues are part of a chain, as is predicted here, 
then  disruption  to  any one residue  within  the  linear  chain  should  elicit  the  same 
phenotype.  In addition to this, the substitutions introduced do not simply ablate site 
function,  which would then preclude  the  dissection  of whether the  corresponding 
residues are important for transduction, binding or are causing an indirect structural 
perturbation.  Instead, these phenotypic disruptions still retained a high potency for 
inhibitory Zn2+ suggesting that though the residues clearly influence the potency of 
the  site  they  also  clearly  influence  signal  transduction  from  the  site.  As  these 
residues are predicted to reside in the hydrophobic core of the receptor and are not 
considered likely Zn  binding residues, it seems reasonable to ascribe to them a pure 
transduction role.  The only ZAG to have a low Zn2+ potency was I132A, which was 
located directly on the back of the  face inhibitory site.  It is the best located of 
those hydrophobic residues to elicit a secondary indirect effect on the structure of the 
Zn2+ binding site to reduce the Zn2+ affinity and therefore the potency.  In further 
support of the hydrophobic chain hypothesis was the demonstration that generation 
of these ZAGs was not a general side effect of disrupting the GlyR global structure. 
It was instead selective to the hydrophobic residues in question, as was verified by 
the absence of any ZAG phenotype when nearby hydrophobic residues, lying just off 
the hypothetical pathway, were similarly substituted with an Ala moiety.
Reliance of Zn2+ binding residues at the high  and low potency ZAGs  and the 
original Zn2+ inhibition site
As mentioned previously this transduction pathway also relies on the tenet that ZAG 
activity is still derived at least in part from the original Zn2+  inhibitory site and again 
this does appear to be the case.  Each of the hydrophobic Ala substitutions ablated 
the previous Zn2+  mediated inhibition and replaced it with ZAG activity rather than 
creating  a  receptor  with  both  properties  as  has  been  observed  previously  for  a 
mutated  nAChR  (Palma  et  al.,  1998).  Secondly,  and  most  critically,  the 
incorporation  of an  H109F  mutation  into  GlyR  a lF99A   ablated  the  ZAG  activity 
demonstrating  that  this  activity  still  has  a  critical  reliance  on  the  face  HI 09 
inhibitory site residue.  Interestingly the potency of Zn2+  activating the channel is 
high, reaching nanomolar sensitivity compared to the original micromolar sensitivity
145for Zn2+  inhibition.  The  incorporation  of H107K  and  T133A mutations  into  the
a lF99A  background introduced a far more modest reduction in Zn2+ potency for ZAG
•  •  2+ activation  compared  to  the  substantially  reduced  sensitivity  to  Zn  mediated 
inhibition that is induced by removing these residues.  However it cannot be ruled 
out  that  these  residues  do  have  critical  requirements  for  the  high  potency  ZAG
7   •  •  •  •
receptors but upon substitution another Zn  coordinating residue can step in to take
their place, a point that has been raised previously (Traynelis et al., 1998) and which
2+ could not be discounted here.  Though a scan of additional  capable Zn  binding 
moieties within range of the putative ZAG site did not reveal any obvious candidates 
for the high sensitivity a lF99A  based ZAG.  This relatively modest influence from 
substitutions at HI07 and T133 on an a lF99A  background was perhaps not surprising 
as  reorganisation  of the  inhibitory site  face,  so  that  it now  favours  activation, 
would be expected to at least induce a partial shift in the emphasis placed on each of 
the  binding  residues.  This, however, does  not  appear to  be  the  case  for  the  low 
potency ZAGs generated upon disruption to  the inhibitory site  face as a lT133A
7 4 - retained a heavy reliance on both HI07 and HI09.  Thus the Zn  binding residues of 
the  high  and  low potency ZAGs  appear to  differ in nature,  though  they  do  both 
require HI09.
Consequences  for  the  hydrophobic  transduction  pathway  in  determining 
macroscopic rates of receptor activation
Under the  assumption that  reorganisation  of the hydrophobic pathway,  elucidated 
here, does indeed represent a valid transduction pathway between the agonist-binding 
site and the  face of the GlyR, then this process may represent more than just a 
mechanism  for  allosteric  modulation  in  response  to  Zn2+  mediated  inhibition. 
Though this study investigated this pathway in the context of Zn2+ induced allostery, 
basic characterisation of mutated receptor properties suggested that this transduction 
process may be able to exert an effect over the rate of activation for the GlyR.  In 
contrast there was no  obvious  correlations with the varying agonist potencies  and 
modest  effects  on  desensitisation  measured  from  these  Ala  substituted  receptors. 
This important influence over the rate of receptor activation could have important 
physiological  consequences  as  it has  been  suggested  that  the  slower macroscopic 
activation of the  GlyR a2  subunit may reduce  its  efficiency as  a rapid  inhibitory
146mediator at  synapses  (Mangin  et  al.,  2003).  Though  the  molecular basis  of this 
slower rate  of activation  at  the  GlyR  a2  subunit  has  not  yet  been  dissected  the 
pathway identified here could represent one way in which this  GlyR subtype may 
alter  its  activation  rate.  This  may  also  extend  more  generally  to  the  variable 
activation rates observed throughout the cys-loop family of receptors.
The significance of related studies on ZAC formation
Unfortunately the data depicted here and the hypotheses put  forward do  not have 
much previous evidence, or prior studies to draw on.  Investigations tend to steer clear 
of perturbations  to  the  hydrophobic  core  due  to  problems  with  interpreting  the 
specificity of any downstream consequences, something that could be addressed here 
due to the fortuitous ZAG effect.  A low potency Zn2+ activated channel (ZAC) has 
previously been reported (Davies et al., 2003) and further structure-function studies 
of this receptor may reveal a resemblance to the low potency ZAGs identified here, 
as this ZAC has a comparable low sensitivity and also retained a slow onset profile 
for  Zn2+  induced  currents.  Though  the  site  itself will  not  bear  direct  chemical 
comparison to that of the mutated GlyRs in this study, the ZAC does possess acidic 
residues at equivalent predicted locations to GlyR HI07, El 10 and T133 suggesting 
the  site may be  analogous  (alignment not  shown).  Also  of interest  is  a previous 
report  identifying  an  M2  nAChR  a lU47T  mutant  that  exhibited  a  very  high 
nanomolar sensitivity for Zn2+ activation (Palma et al.,  1998).  However subsequent 
structure-function studies to elucidate the nature of this phenomenon have not been 
forthcoming.  Furthermore  such  studies  may be  of limited relevance  to  the  ZAG 
receptors discussed here as this mutation appeared to create a novel Zn2+ binding site 
rather than changing the function of a pre-existing site, as Zn2+ mediated inhibition 
was also retained in this receptor.
The rate of progress: As measured by the NMD  A receptor
The data presented in this study represent a significant contribution to understanding 
Zn2+  modulation  of GlyRs.  As  a  comparison,  the  most  intensely  studied  Zn2+ 
mediated  process  at  a  ligand-gated  ion  channel  is  that  of Zn2+  inhibition  of the 
NMDA receptor.  This receptor exists as heteromers of NR1 and NR2 subunits, with 
inclusion of the NR2B subunit introducing a low affinity site, with sensitivity around
14710  -  100  pM,  and  inclusion  of the NR2A  subunit providing  a high  affinity Zn2+ 
inhibitory  site,  with  sensitivity in  the  range  10 -   100  nM  (Paoletti  et  al.,  1997). 
Though the low affinity inhibitory site remains unreported the location of the high 
potency  site  has  been  the  subject  of  several  studies  (Choi  and  Lipton, 
1999;Fayyazuddin et al., 2000;Paoletti et al., 2000).  Candidate residues, as well as 
their positions, have been identified using site directed mutagenesis and a structural 
homology model in a similar manner to that reported here for the GlyR.  Though 
these  studies  have  not  yet  proposed  any  molecular  basis  for  the  transduction
^ I
apparatus responsible for mediating the effects of the inhibitory Zn  binding site. 
Also, this unrelated receptor (to the GlyR) has not been reported to exhibit any ZAC 
properties despite extensive mutagenesis of potential Zn2+ binding site residues (Choi 
and Lipton,  1999;Fayyazuddin et al., 2000;Paoletti et al., 2000).  This could perhaps 
be  a  consequence  of the  fact  that the identified voltage-independent  high  affinity
9 4 - Zn  binding site of the NMDA-R is believed to act by reducing the ability of the 
receptor  to  gate  rather  than  by  reducing  agonist  binding  (Christine  and  Choi, 
1990;Legendre  and Westbrook,  1990).  In the case of the Zn2+  inhibitory process 
reported  here  for the  GlyR,  it  appears  the  communication  is  an  intrinsic  process 
specific to a single globular domain of the receptor and this reduces the affinity of 
the  protein  for the  agonist  glycine.  However  in  the  case  of the  NMDA-R  each 
subunit  is  split  into  several  separate  modular  domains,  of which  the  so  called 
leucine/isoleucine/valine-binding protein (LIVBP) domain, that carries the identified 
high  affinity voltage-independent  site,  is  predicted  to  feed  its  transduction  effect 
across  to  the  gating  and  agonist  binding  modules  to  disrupt  the  communication 
between these two, a process which, if true, is vastly different to the unrelated GlyR 
(Paoletti et al., 2000).  Previous studies have not attempted to discern whether Zn2+ 
inhibition elicits an effect on desensitisation in the GlyR and the studies in chapter 3, 
though  demonstrating  that  Zn2+  can  accelerate  the  rate  of  decay  during  co­
application, which might be construed as an effect on desensitisation, are insufficient 
to  support  such  a  proposition.  Most  evidence  supports  an  interaction  of 
desensitisation with the GlyR ion channel domain (Breitinger et al., 2002;Breitinger 
et al.,  2001) while Zn2+ inhibition appears to interact with the agonist-binding site 
(Chapters 3 and 4).  By contrast, recent studies on the NMDA receptor suggest the 
main mechanism by which the high affinity Zn2+ inhibition site acts is by introducing
148a very rapid desensitisation component into glutamate activation of NMD  A receptors 
(Zheng et al., 2001).  The two receptors are clearly separate in terms of how Zn 
exerts inhibition, both in molecular and mechanistic terms, but the  ability to  now 
draw such comparisons demonstrates the progress that has now been made in these 
two fields of research.
Conclusion
The data here present a strong case for the presence of a hydrophobic transduction 
pathway across the N-terminus of the GlyR from the  face of the Zn  inhibition 
site  to  the  p4  strand  of the  agonist-binding  domain.  Though  the  extent  of the 
relevance of this communication route cannot be exactly pinpointed in the context of 
this work, the evidence strongly suggests that this path at the very least marks the
9 4 - route of allosteric communication between the inhibitory Zn  site and the agonist- 
binding site.  Under this hypothesis agonist binding transmits a reorganisation to the
9 4 - face  of the  GlyR  at the  location  equivalent to  the Zn  inhibitory site  via the
94* hydrophobic pathway such that Zn  can no longer bind and stabilise the closed state 
of the GlyR.  From the reverse perspective, Zn2+ binding presumably stabilises the 
interface  between the  and  *+’  faces  of the  GlyR preventing  the  agonist  from 
binding  and  inducing  reorganisation  of  the  hydrophobic  pathway  to  allow  the 
receptor to open.  Furthermore, due to a consistent reduction in the activation rates of 
the  resultant  ZAG receptors,  this  pathway may represent  an  important  regulatory 
process by which cys-loop receptors can determine their intrinsic activation rates.
149EC50 (pM)
Glycine
W n A ) ft
"z?*
EC50 (pM)
Agonist
Im ax
(% Gly Im ax)
n IC5o(hM)
Inhibition
U(%) n
Zn2 +   face 
al 35 ±3 6.7 ± 0.5 6 No Activation 4 15 ± 2 9 ± 7 5
alN 6 1 A 95 ± 18 6.2 ± 0.8 4 > 10 mM > 25 % 5 None — 4
alH 1 0 9 A 21 ±2 5.9 ±0.7 4 > 10 mM > 20 % 3 33 ± 16 53 ±7 5
alE ll0A 24 ±4 6.0 ± 1.5 3 — No Activation 3 67 ±4 4 ±   1 3
alT 1 1 2 A 19 ±6 5.0 ±0.6 4 3.5 ±  1.5 42 ±5 4 None ___ 4
alT 1 3 3 A 133 ±32 5.4 ±  0.7 5 5400 ±  2500 >  45 % 5 None ___ 4
a jT133A,H107A 100 ±28 4.9 ±0.3 3 >   10 mM > 2 % 3 n.e n.e n.e
a jT133A,H107D 53 ± 15 4.4 ± 0.7 3 > 10 mM > 12 % 3 n.e n.e n.e
a jT133A,H109F 180 ±28 5.7 ±0.8 3 > 10 mM > 2 % 3 n.e n.e n.e
Zn2 +  ‘+‘ face 
alM 9A 52 ±5 7.3 ±0.7 3 No Activation 3 5.2 ±0.7 3 ± 3 3
alH 1 0 7 A 56 ±9 7.2 ± 0.3 3 ___ No Activation 3 330 ± 30 12 ± 3 3
alT 1 3 5 A 17 ±2 3.3 ± 0.6 3 --- No Activation 3 26 ±6 5.8 ±0 3
Hydrophobic pathway
alL 9 8 A 35 ±6 6.4 ± 0.5 6 0.26 ± 0.08 49 ±5 4 None 4
alF 9 9 A 250 ±8 3.9 ± 0.4 4 0.13 ±0.03 90 ±6 5 None — 4
a jF99A,H107K 4200 ± 1700 3.5 ±0.6 5 0.4 ±0.1 53 ± 12 5 n.e n.e n.e
a |F99A,H109F 3400 ± 330 0.5 ± 0.2 5 n.e > 2 5 n.e n.e n.e
a jF99A,Tl33A 3300 ± 700 4.9 ± 0.9 4 0.75 ± 0.22 65 ±4 4 n.e n.e n.e
a lF 100A 117 ±21 4.5 ±0.7 6 9.19 ±0.63 7 ± 4 4 None — 4
a lFI08A 14 ±3 4.5 ±0.5 5 2.3 ± 0.6 25 ±6 6 None — 5
alI1 3 2 A 96 ± 15 6.1 ±0.7 6 140 ± 60 72 ±5 5 None — 4
a lL,34A 83 ± 17 6.0 ± 0.3 7 0.1 ±0.03 18 ± 3 4 None — 4
Table 4.1  Summary table presenting sensitivities for the agonist Gly and where appropriate for Zn2+ acting as 
an agonist or antagonist of glycinergic currents.  Values presented as means ± s.e.  Definitions: n.e - not evaluated,
‘—’ could not be evaluated as property is not present, none -  property not present.ECso(pM)
Glycine
Imax (nA) n
Zn
ICso(pM)
Inhibition
Imin (% ) n
Non ZAG receptors 
al 35 ±3 6.7 ± 0.5 6 15 ± 2 9 ± 7 5
alA ,0 1 L 430± 113 6.5 ±0.8 3 18 ± 5 0.3 ± 0.3 3
alI,3 0 A 3.4 ± 0.9 6.4 ± 0.7 4 38 ±6 3 ±0.9 3
alL 1 3 6 A 16 ±0.6 6.8 ± 0.8 3 22 ±4 4 ± 0 3
a jM I54A 99 ± 14 4.4 ± 1.4 3 27 ±6 1.8 ±0.8 3
alL 1 5 6 A 105 ±2 6.7 ± 0.7 3 23 ±6 0.1 ±0.1 3
Table 4.2  Summary table presenting sensitivities for the agonist Gly and the 
antagonist Zn  acting on GlyRs without the ZAG phenotype.  Values presented as 
means ± s.e.Chapter 5
Identification of a Zn2+  potentiation site in GlyRs and a mechanism 
of action involving the cys-loop gating domain
Introduction
The  cys-loop  family of receptors,  most  notably comprising  nAChRs,  GABAaRs,
GlyRs  and  5-HT3RS  are  all  susceptible  to  Zn2+  mediated  inhibition  with  varying
*
degrees  of sensitivity  and  selectivity  (Hsiao  et  al.,  2001;Hubbard  and  Lummis,
2000;Chang et al.,  1995;Smart et al., 2004).  In some instances these receptors have
•  2+   • also been shown to exhibit a more complicated biphasic modulation by Zn  , with 
enhancement  of  agonist  responses  occurring  at  low  Zn2+  concentrations  and  a 
secondary  inhibitory  phase  initiating  at  higher  doses,  as  is  the  case  for  GlyRs, 
5-HT3RS  and  certain  nAChR  subtypes  (Bloomenthal  et  al.,  1994;Hubbard  and 
Lummis, 2000;Hsiao et al., 2001).  Current research regarding inhibitory Zn2+ sites 
has  identified  discrete  locations  on both  GABAa  (Hosie  et  al.,  2003)  and  GlyRs 
(Harvey  et  al.,  1999;Chapter  3),  but  there  have  been  no  clear  candidate  sites 
elucidated for Zn  potentiation.  An understanding of the molecular components and 
the dynamic interactions that occur during potentiation by Zn2+  is of importance for 
two reasons.  Firstly, understanding the mechanism of Zn2+ potentiation at cys-loop 
receptors provides insight into how drugs can exert a positive influence on receptor 
function and this may be relevant to a number of other pharmacologically relevant 
potentiators  including  anaesthetics,  barbiturates,  benzodiazepines,  ethanol  and 
neurosteroids.  Secondly, in  cases where Zn2+ potentiation has been reported,  this 
process occurs with higher potency than Zn2+ mediated inhibition and therefore may 
be of more relevance physiologically, where the concentrations of Zn2+ at a synapse 
are  currently considered to reside in the range,  0.01  -  5  pM  (Frederickson  et al., 
2000). (* Gill et al., 1995).
A previous study by Laube et al, (1995) identified a GlyR al D80 residue, which as 
well as being capable of binding Zn2+ also produced a receptor insensitive to Zn2+ 
enhancement  of glycine-evoked  responses  when  substituted  with  an  Ala  residue. 
However, a subsequent study by Lynch et al, (1998) demonstrated that GlyR a lD 80Aablated  potentiation  only  of glycine  mediated  currents  and  not  those  elicited  by 
taurine,  another  agonist  of the  GlyR  that  is  also  thought  to  bind  to  the  glycine 
recognition site (Schmieden et al., 1993).  This suggests either there is more than one 
Zn2+ enhancement site for each agonist, a seemingly unlikely proposition given that
94- both agonists bind to the same receptor region and Zn  has the same potency for 
causing potentiation of both  agonist-activated  currents,  or that  D80A  is  having  a 
complicated action on the Zn2+ potentiation site in a manner unrelated to the direct 
coordination of the cation.  The study by Lynch et al, (1998) also identified a number 
of other residues all within the extracellular TM2-3 loop that attenuate Zn2+ induced 
enhancement when substituted with alanine; however the chemical nature of these
9 4 - residues  is  not  consistent  with  Zn  coordination.  Studies  of  other  positive 
modulators of cys-loop receptors locate the GABAa potentiating benzodiazepines in 
the N-terminal extracellular domain (Sigel and Buhr,  1997), whilst anaesthetics and 
ethanol have been suggested to interact with the cys-loop receptor transmembrane 
domains  (Mihic  et  al.,  1997).  Thus  from  current  studies  there  are  no  definitive 
candidate regions to begin a search for a discrete Zn2+ potentiating site in the GlyR.
This study took advantage of an observation in chapter three that GlyR al  and a2 
appear to have subtly different sensitivities to Zn2+ potentiation of glycine-evoked 
responses  (Fig  3.1 A-C).  An  initial  comparative  scan  of the  GlyR  al  and  a2 
N-terminal  domains  was  therefore  made  and  substitutions  to  swap  potential  Zn2+ 
binding  residues  between  the  two  receptor  subtypes  identified  a  candidate  Zn2+ 
binding  residue  responsible  for  this  differential  sensitivity.  This  study  used  this 
information  in  combination  with  the  AChBP  structural  model  to  characterise  a 
discrete  site  for  Zn2+  potentiation.  Furthermore,  it  also  identified  an  important 
regulatory element, which  appeared to  control the  ability of this  site  to  influence 
receptor function and attempt to explain how the site may exert a modulatory role on 
receptor efficacy via the cys-loop gating domain.
153Results
GlyR al and a2 exhibit distinct sensitivities to Zn2+ mediated potentiation
The sensitivity of the GlyR al  and a2  subtypes to Zn2+ mediated potentiation of 
50 % maximal Gly responses was compared using whole-cell recordings from HEK 
cells.  To accurately maintain low concentrations of Zn  the buffering agent tricine
9 -4- was  used  to  remove  interference  from  Zn  contamination  in  the  external  saline 
solution  (Suwa et  al.,  2001).  Consequently,  in  the  presence  of 10  mM  tricine  a 
significant  15-fold  increase  in  the  potentiating  Zn  EC50  was  observed  from 
13.9 ± 3.4 nM, (n = 4) for GlyR al to 203 ± 68 nM, (n = 5) for GlyR a2 (P < 0.05; 
Fig 5.1 A,C).  This  distinct  difference was not  affected by co-expression with the 
GlyR  ancillary  P-subunit  (Fig  5.15),  whose  faithful  incorporation  to  form  ap 
heteromers  was  ratified  as  before,  by  an  approximate  20-fold  shift  in  picrotoxin
9  1
sensitivity (data not shown; Pribilla et al.,  1992).  The Hill slopes for Zn  mediated 
potentiation  varied  between  1.2  and  1.5  suggesting  more  than  one  Zn2+  ion 
coordinates to each receptor oligomer.  To identify the determinant(s) responsible for
•   2“ P   •  •   • differential Zn  sensitivity the extracellular domain was scanned for residues that 
differed  between  GlyR  al  and  a2  by  concentrating  on  classical  Zn2+  binding 
substituents; Cys, Asp, Glu, and His (Auld, 2001).  Three locations were identified 
(Fig 5.15)) and upon individual reconstitution of the GlyR al  variations into a2, an 
a2E 2°iD  substitution  was  found  to  be  solely  sufficient  to  recover  al  levels  of 
sensitivity to potentiating Zn2+ (Fig 5.1A,C) with no influence observed for a2L178Q ’  
si79E, di8oq Qr a2E 187D  mutated receptors (data not shown).
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Figure 5.1  Zn2+ potentiation of 50 % maximal Gly responses for GlyR al and a2 
in 10 mM tricine from whole-cell recordings in HEK cells.  A, GlyR a2 recovers al 
levels of sensitivity to potentiating Zn2+ when reconstituted with the homologous 
residue to al  D194, to generate a2E201D .  B,  GlyR al(3 and a2p heteromers retain 
differential Zn2+ potencies for potentiation.  C,  Raw data traces of 50 % maximal 
glycine responses in the presence and absence of 30 nM Zn2+ for GlyR al, GlyR a2 
and GlyR a2E201D .  D,  Amino acid sequence alignment of GlyR al  and GlyR a2 
displaying  the  region  of  the  N-terminal  extracellular  domain  that  harbours 
differences  in  potential  Zn2+  binding  residues  (bold,  underlined).  A  grey  box 
highlights the residue responsible  for the differential  sensitivity to  Zn2+  mediated 
potentiation between al and a2.  N= 4-6.  Maximal potentiation was normalised to 
140  %  at  the  1   -  3  pM  Zn2+  measurement  for  ease  of comparison,  though  the 
maximal  potentiation  did not  differ  significantly between  any individual  receptor 
subtype (data not shown).
155GlyR  al  El92,  D194  and  H215  are  all  essential  for  high  sensitivity  to 
potentiating Zn2+
The discovery that a residue equivalent to GlyR al  D194, a potential Zn2+ binding 
residue,  is  capable  of influencing  the  potency  of Zn2+  potentiation  suggests  this 
moiety may be an a direct contributor to Zn2+ binding at the potentiation site.  To test 
this hypothesis  it is necessary to remove the Zn2+ binding power of the  Glu  side 
chain  by  mutation  to,  for  example,  an  inert  alanine.  Unfortunately  due  to  the 
biphasic  nature  of Zn2+  action  at the  GlyR,  where  Zn2+ potentiates  at  low  doses 
(0.1-10  pM)  and inhibits  at doses greater then  10  pM  (Bloomenthal  et  al.,  1994; 
Chapter 3), any attempts to measure substantial reductions in the sensitivity to Zn 
enhancement  will  be  masked  by  the  onset  of the  contaminating  Zn2+  mediated 
inhibition.  To  partially  alleviate this  effect,  all  experiments  to  identify the  Zn 
potentiation binding site were performed using an H107N background  (defined as 
Reduced Inhibition - RI) GlyR, which exhibits a dramatically attenuated sensitivity 
to  inhibitory Zn2+  without overtly affecting other receptor macroscopic  properties
i
(Table 5.1).  However, it was not possible to completely remove the interfering Zn 
mediated inhibition component as all other candidate residues for the inhibitory site 
have significant side effects on general receptor properties (as discussed in chapters 
3 & 4).  To further reduce the sensitivity to Zn2+ mediated inhibition all recordings 
were made using a co-application protocol for Gly plus Zn2+ as this favours the rapid 
onset of Zn2+ potentiation over the delayed onset of Zn2+ inhibition (Chapter 3).  This 
resulted in  an  IC50  for Zn2+  inhibition  at RIGlyR al  of >3000  pM.  In  addition, 
potentiation was measured for two agonists, glycine and taurine, as residues that are 
not part of the presumed sole potentiating Zn2+ site have been identified that knock 
out enhancement of currents activated by one agonist but not the other, presumably 
due to an indirect affect on some downstream transduction mechanism (Lynch et al.,
^ 1
1998).  However, Zn  potentiation of both glycine and taurine EC50 responses can 
be  ablated,  as  demonstrated  for  the  RI  a lD 194A   (Fig  5.2A,B).  As  an  apparent 
consequence  of  removing  Zn2+  enhancement  the  sensitivity  to  competing  Zn2+ 
inhibition increased from > 3000 pM to 270 ± 50 pM (n = 3; Table 5.1).
To elucidate further residues capable of interacting with the putative al D194 based 
binding  site,  alanine point mutagenesis  was  carried out on  classical  Zn2+  binding
156residues  selected  from  motifs  predicted  to  be  structurally  close  to  D194  in 
accordance with a GlyR structure modelled on the AChBP  (See methods  and Fig 
5.2C;  Brejc  et al.,  2001).  This  strategy identified two  further residues,  E192  and 
H215 that may contribute to Zn2+ potentiation for both Gly and taurine currents.  The 
mutant  RIGlyR  a lE 192A   entirely  ablated  Zn2+  potentiation,  whilst  RIalH 215A  
dramatically reduced the potency of Zn2+ enhancement such that the Zn2+ EC50 for 
potentiation of 50 % maximal glycine responses was increased from 0.8 ± 0.2 pM, 
(n = 4) for RIGlyR al to 22 ± 4 pM, (n = 4) for the mutant (P < 0.05; Fig 5.2A,B). 
The results for other Ala substituted acidic residues had no effect on the potency of 
Zn2+  enhancement  (Table  5.1).  By removing, or reducing, Zn2+  enhancement  the 
sensitivity to competing Zn2+ inhibition increased for both RIalE 192A  and RIalH 215A  
(Fig 5.2A, B\ Table 5.1).  All three of these RI mutants, a lE 192A , a lD 194A  and a lH 215A  
did not shift the maximal responses evoked by the agonist and only RIaD 194A  exerted 
a modest 3-fold shift upon the agonist EC50 (Table 5.1) suggesting these mutations 
selectively affected the  Zn2+  potentiation binding  site  and do  not  exert  a  general 
perturbation on receptor function.  Importantly, with regards to the potential of these 
residues  to  form  the  core  of  a  Zn2+  binding  site,  the  GlyR  homology  model 
(Fig 5.2C) predicts each of these residues, El92, D194 and H215 to reside in close 
proximity to one another and to all face the same direction pointing out into solution 
from the outside face of the N-terminal extracellular domain.  This is in accord with 
the  site being accessible  to  Zn2+.  To  highlight the  localised nature  of this  small 
domain to Zn  potentiation, alanine mutagenesis was carried out on other residues 
facing out into  solution,  selecting those residues immediately to  either side of the 
putative Zn2+ binding site.  These RI a lK 190A , a lR 196A , a lR 213A  and a lE217A  mutated 
receptors did not have any significant shifts in Gly, taurine or Zn2+ EC50S or in the 
size of maximal Zn2+ potentiation or maximal Gly currents (Table 5.1).  In addition, 
co-expression of a GlyR RIalE 192A  with the p-subunit did not recover Zn2+ mediated 
potentiation  suggesting  the  p-subunit  is  not  an  important  contributor  to  Zn2+  
enhancement (data not shown; n = 3).
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Figure  5.2  Zn2+   dose response curves  for the modulation of 50 % maximal 
responses of Gly or taurine to screen for residues important in Zn2+  potentiation. 
All  experiments  were  performed  on  a  reduced  sensitivity  to  Zn2+   inhibition 
background (reduced inhibition -  RI) GlyR a lH 107N .  A,  Gly and B,  taurine both 
exhibit equally attenuated sensitivity to Zn2+  enhancement for all three candidate 
residues identified, RlGlyRalD 194A , RIalE 192A  and RIalH 215A  compared to Rial. 
Insets represent typical raw data traces for the Rial  background and mutants in 
the  absence  and  presence  of  10  pM  Zn2+,  scale  bars  represent  1   nA  by  1   s. 
C, Amino acid motifs in the extracellular GlyR al  domain and homologous GlyR 
a counterparts that reside in close proximity to the identified a lD 194A ; based on the 
AChBP.  Potential  Zn2+   binding  residues  are  in  bold  and  underlined,  whilst 
identified, important residues are highlighted in grey boxes.  N = 4-8.
158Asymmetry of function at the putative Zn2+ potentiation site
To  further  strengthen  the  evidence  in  support  of these  residues  as  direct  Zn2+ 
coordinators  at  a  localised  site  it  is  necessary to  demonstrate  that  this  domain  is
i
accessible to water, a vital requirement of any dynamic Zn  binding site.  To test 
this, individual Cys substitutions of al  El 92, D194 and H215 were created to assess 
the  site  for  accessibility to  the covalent  Cys  modifying  reagent,  MTSEA.  If this 
agent modifies the potentiation site, it will introduce a positive charge to the binding 
site that should attenuate Zn2+ mediated enhancement of Gly EC50 drug applications. 
Pre-application of 3  mM  MTSEA  for  1   minute to  non-Cys mutated Rial  did not 
have any observed effect on Zn2+ potentiation or Gly sensitivity (Fig 5.3A).  Upon 
individual  replacement  of El92,  D194  or  H215  with  Cys,  another  capable  Zn2+ 
coordinator,  receptors were  generated which  exhibited  similar sensitivities to Zn2+  
potentiation  (Table  5.1).  Significantly  though,  when  these  receptors  were  pre­
incubated with 3 mM MTSEA for 1  min, Zn2+ potentiation (assessed before and after 
in the same cell) was ablated in the cases of RIalD 194C  and RIalH 215C  as would be
' y ,
expected  if a  Cys  binding  Zn  was  occupied  with  a positively charged  MTSEA 
substituent (Fig 5.3B,C).  In the unique case of RIalE192C  no significant effect was 
observed after chemical treatment, perhaps suggesting that this part of the site is not 
directly  accessible  to  MTSEA  (Fig  5AA).  However,  in  contrast  to  the  results 
obtained  with  the  Rial  background,  a  consistent  reproducible  increase  in  Gly 
potency was observed after MTSEA treatment on RIalE192c even in the total absence 
of Zn2+, with the 50 % maximal glycine response being potentiated by 45 ±  12 %, 
(n  -  4; Fig 5.4R).  This suggests the El92  location is  accessible to MTSEA,  as it 
affects the sensitivity of the receptor to Gly, but that the glutamate side chain moiety, 
unlike D194 and H215, is probably not necessarily a direct or major contributor to 
Zn2+ coordination.
The data  so  far clearly demonstrate  that al  El92,  when perturbed by substitution 
with  an  Ala  residue,  exerts  a  strong  influence  on  Zn  mediated  potentiation  but 
unlike D194 and H215 it does not exhibit properties that are entirely consistent with 
direct binding to Zn  via its side chain moiety.  This raises the possibility that the 
effect  elicited  by  El92  may  be  in  response  to  a  perturbation  of the  P-strand 9
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Figure  5.3  Covalent
modification  experiments  using 
MTSEA  to  measure  the 
accessibility of the candidate Zn2+ 
potentiation site.  A-C,  Zn2+ dose 
response curves for modulation of 
50  %  maximal  Gly  responses 
were measured  for the sensitivity 
to Zn2+ enhancement on Rial  and 
receptors  mutated  to  incorporate 
Cys  mutations  at  putative  Zn2+ 
binding  residues.  This  was 
assessed  before  and  after 
incubation  of  HEK  cells  with 
3  mM  MTSEA  for  1   min. 
A,  RIGlyR  al  background  does 
not  exhibit  any  perturbed 
sensitivity  to  Zn2+  mediated 
potentiation  in  response  to 
MTSEA  treatment,  whilst 
complete  ablation  of  Zn2+ 
enhancement  is  observed  after 
RIalD 194C   (.B)  and  RIalH 215C  (C) 
have  been  exposed  to  the  Cys 
covalent modifying reagent.  The 
insets  present  example  raw  data 
recordings  from  HEK  cells 
showing  EC50  Gly  responses 
±  10  pM  Zn2+,  before  and  after 
MTSEA  incubation,  for
,   D194C  ,   H215C  X T   , Rial  or  Rial  .  N =  4 
for all experiments.
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Figure  5.4  GlyR  al  El92  is 
unlikely to directly coordinate Zn2+ 
via  the  glutamate  side  chain. 
A,  50  %  maximal  Gly  responses 
recorded from HEK cells reveal that
E192C Rial  shows  only  minor
attenuation  of  sensitivity  to  Zn2+ 
enhancement  in  response  to 
MTSEA  treatment.  B,  Bar  chart 
and  raw  data  traces  demonstrating 
that  RIalE192c  does  appear  to  be 
modified  by  MTSEA  treatment  as 
an  increase  in  sensitivity  of  the 
receptor  to  the  agonist  Gly  is 
observed.  C,  Further evidence that - y _ L
El92 may influence Zn  mediated 
inhibition  in a manner independent
of  its  side  chain  moiety.
Replacement  with  a  Pro  residue, 
typically  considered  to  introduce 
rigidity  to  the  protein  backbone  is 
incapable  of  supporting  Zn2+
coordination  via  its  side  chain. 
Zn2+ dose response curves on 50 % 
maximal  Gly  responses  for
El  92P Rial  produced  a receptor that 
retained  a  high  sensitivity  to  Zn2+  
enhancement  only  5-fold  less 
sensitive than the Rial background 
(Table 5.1).  N= 3-4.
Zn2-"  concentration (pM)
161backbone  (nomenclature  of Brejc  et  al.,  2001)  in  this  region,  either  because  the 
backbone indirectly disrupts the nearby Zn2+ potentiation site, or because the polar 
peptide backbone is directly contributing to Zn2+ coordination at this position.  To 
address  this  issue  an  RIalE192P  GlyR  was  generated  to  replace  glutamate  with 
proline, an amino acid associated with introducing an increased level of rigidity to 
the peptide backbone (Chou and Fasman,  1974;Yohannan et al., 2004).  This might 
therefore  prevent  the  same  apparent  disruption  of the  peptide  backbone  that  is 
observed for RIalE192A .  In this unique circumstance, potentiation was not ablated 
and the receptor merely experienced a subtle, reduced potency for Zn2+ potentiation 
from 0.8 ± 0.2 pM, (n = 4) for Rial to 4.2 ± 0.8 pM, (n = 3) for RIalE192P (P < 0.05; 
Fig 5.4C; Table 5.2).  As the proline side chain is considered to be a poor donor for 
Zn  coordination this suggests that this region must retain a specific conformation at
'y ,
the backbone of El92 in order to retain Zn  mediated potentiation.  As a control, the
I
mutation of D194 to a Pro was found to still ablate Zn  mediated potentiation, the 
expected outcome if it is indeed the side chain moiety that is contributing to Zn2+  
coordination at this position (Table 5.2; n = 3).
Comparative influence of GlyR al  El92 and D194 on (3-strand 9 with H215 of 
p-strand 10
9 - + - In all three point mutations where Zn  potentiation is attenuated or ablated there was 
always an increased sensitivity to the competing Zn2+ inhibition. This could simply 
reflect  an  enhanced  ability of Zn2+  to  exert  inhibition  from  the  inhibitory  site  as 
competition,  when  the  Zn2+  potentiating  component  has  been  removed.  In  this 
simple case, removal of a further residue at the Zn2+ inhibitory site should cause a 
direct rightward shift to reduce the sensitivity profile for inhibition of the RIalE192A , 
RIalD 194A   and  RIalH 215A   mutants.  In  turn  this  may  allow  for  more  accurate 
assessment of the extent by which Zn2+ enhancement was ablated for RIalE 192A  and 
RIalD 194A  where any low sensitivity enhancement remaining is masked by the onset 
of inhibition.  Introduction of an RIalH 109F mutation, originally identified by Harvey 
et  al,  (1999),  further  reduced  the  sensitivity  of Zn2+  mediated  inhibition  without
*   2 i affecting Zn  potentiation or overt disruption of other receptor properties (Fig 5.5A, 
Table  5.2).  Evaluation  of RIalH 109F’   H 215A   did  indeed  generate,  as  predicted,  a 
modest rightward shift to reduce the sensitivity profile of the inhibitory component
162of this mutant (Fig 5.55).  However for both RIctlH 109F >  E 192A  and RIalH 109F’  D 194A  
there was not the expected reduction in potency of inhibitory Zn2+, with RIalH 109F’  
D 194A  actually exhibiting evidence for a novel biphasic inhibition, suggestive of two 
separate inhibitory sites each with differing potencies (Fig 5.5C,D).
This could reflect a situation whereby the RIalE192A  and RIalD 194A   are exerting a 
more complicated effect on the potentiation site, which has resulted in a reversal of 
the sites polarity to switch a high potency potentiation site into a novel low potency 
inhibitory site.  Thus further ablating the original low potency inhibitory site based 
on HI07 and HI09 would not affect the receptors inhibitory profile as the inhibition 
now arises largely from the reversed potentiation site.  To elucidate the nature of the 
actions of El92 and D194 on Zn  mediated potentiation more thoroughly, each of 
these  residues  was  instead  mutated  to  a  non-Zn2+  binding  residue  with  an  extra 
carbon atom in the side chain, as is present on the Glu and Asp side chains, to ensure
7+ this  complicating  side effect of apparently converting the Zn  potentiation  site to 
one that mediates inhibition was not specific to alanine substitution.  In the case of 
RIalE192K , potentiation was still ablated, but consistent with the previous evidence 
suggesting this residue exerts a more complicated effect on the potentiation site not 
directly  correlated  with  the  properties  of the  side  chain  moiety,  an  even  clearer 
biphasic inhibitory profile was now observed (Fig 5.6A, Table 5.2).  This  supports 
the supposition that disruption of El92 to an Ala residue was indeed reversing the 
polarity of the potentiation  site  to  generate  two  separate  inhibitory Zn2+  sites,  the 
novel  E192K based  inhibitory site and the original H107/H109 based  low potency
inhibitory  site.  Conversely,  the  RIalD 194K   receptor,  which  also  exhibited  ablated
2+  2+  Zn  potentiation,  revealed  less  of  an  increased  sensitivity  to  inhibitory  Zn
compared  to  its  RIalD 194A   counterpart  and  did  not  result  in  a biphasic  inhibitory
profile,  raising the possibility that  introduction  of a Lys  at D194  had perhaps  not
reversed  the  polarity of the  potentiation  site  (Fig  5.65).  The  modest  increase  in
sensitivity to Zn2+ mediated inhibition for RialD 194K  may simply reflect the removal
7 -4- of Zn  enhancement  therefore  allowing  the  H107/H109  based  inhibitory  site  to 
manifest its effect with a monophasic profile.  This was validated by evaluation of an 
RIalH 109F’   D 194K   receptor,  which  demonstrated  a  monophasic  rightward  shift  to
7 -4- reduced  sensitivity  for  inhibitory  Zn  (Fig  5.65)  comparable  to  that  seen  for
163RIalH 109F’   H 215A   (Fig  5.5B).  Therefore  in  agreement  with  the  MTSEA  studies 
suggesting that D194 is a genuine Zn2+ coordinator at the binding site, there was no 
detectable  functional  side  effect  for  an  RIalD 194K   disruption  on  the  transduction 
process, such as a polarity reversal of the potentiation site.
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E192A  and a lD 194A  do not exhibit pure effects on Zn2+ binding 
Introduction  of  an  H109F  mutation  to  attenuate  the
Figure 5.5 GlyR al 
at  the  potentiation  site.
sensitivity of the H107/H109 based Zn2+ inhibitory site results in a clear rightward 
shift of the inhibitory curves for A, RIalH 109F and B, RIalH 109F’H 215A  compared with 
Rial, demonstrating that Zn2+ inhibition at Rial  and RIalH 215A  is derived from the 
H107/H109 site.  C,  Introduction of an H109F mutation to create RIalH 109F’  E 192A  
does not produce any further shift of the inhibitory profile suggesting Zn  inhibition
E1Q2A  . at  Rial  is  no  longer derived  from  the  H107/H109  inhibitory  site  and that  a 
novel  inhibitory  site  is  probably  responsible  for  inhibition.  D,  In  the  case  of 
Rial  ’   a  rightward  shift  of the  lower  phase  of the  inhibitory  profile  is 
evident creating a biphasic inhibition curve (arrow), supporting the presence of two 
inhibitory  sites  each  with  differing  potencies,  one  derived  from  the  H107/H109 
based site and another novel inhibitory site.  Most likely, El92A and D194A have 
reversed the  ‘polarity’  of the potentiation site.  The data for the non H109F based 
mutants, represented by dashed lines, are taken from Fig 5.2A.  N= 4 -  8.
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Figure  5.6  GlyR  a lD 194K   exhibits  properties  consistent with  a pure  effect  on 
Zn  binding at the potentiation site. Zn  dose response curves were evaluated for
E192K the modulation of 50 % maximal glycine responses.  A, GlyR Rial  exhibits a 
clear biphasic inhibitory profile consistent with this receptor ablating potentiation 
and generating an additional inhibitory site, most likely by reversing the polarity of
D194K the  original  potentiating  site.  B,  GlyR  Rial  shows  a reduced  increase  in 
sensitivity to Zn2+ mediated inhibition compared to its D194A counterpart (dashed 
line,  from  Fig  5.2A) but  still  ablates the Zn2+ potentiation of glycine responses. 
Furthermore, introduction of H109F to disrupt the original H107/H109 inhibitory 
site decreases the sensitivity of this receptor to inhibitory Zn2+.  This suggests Zn2+
D194K mediated inhibition in the Rial  receptor is derived from the H107/H109 site, 
thus D194K has not reversed the polarity of the potentiation site and may not be 
interfering with transduction from the Zn2+ site but rather is having an effect on 
binding at the potentiation site. N= 3-6.
165GlyR al T151 is a critical control element for Zn2+ potentiation
A  previously  generated  chimera,  (Laube  et  al.,  1995)  where part  of the  GlyR  al 
subunit was replaced by the ancillary p receptor, including a section of the cys-loop 
region  investigated  here,  was  reported  to  ablate  Zn2+  potentiation.  The  two  Asp 
residues,  D141  and D148  of the  Cys  loop,  mutated in this  report,  did not  exert  a 
selective effect on Zn  potentiation with D141A having no discemable affect and 
D148A ablating receptor function, consistent with a previous report (Schofield et al., 
2003;Table  5.1).  One  potential  unexplored  candidate  residue  is  T151,  which  is 
chemically capable of interacting with Zn  through its hydroxyl group, and is also 
replaced  by  an  Arg  in  the  p-subunit.  An  alanine  substitution  was  therefore 
introduced at al  T151  to generate an Rial1151A  GlyR.  Subsequent examination of
- j i
the Zn  enhancement of 50 % maximal Gly and taurine evoked responses revealed 
no detectable potentiation by Zn2+ (Fig 5.1  A J$).  Intriguingly, although the lack of 
potentiation was clear,  there was  also  an unusual  additional  effect revealed  in the 
form of a novel biphasic sensitivity to Zn2+ inhibition, with high (IC50 1.6 ± 0.6 pM, 
n = 5) and low potency components (IC50  1040 ± 290 pM, n = 5; Table 5.3).  This 
biphasic profile was directly comparable for taurine (IC50 = 3.2 ± 0.8 pM, n = 5 and 
2840 ± 820 pM, n = 3; Fig 5.IB).  The potency for the high sensitivity inhibitory 
component  is  comparable  to  the  original  Zn2+  IC50  (0.8  ±  0.2  pM,  n  =  4)  for 
potentiation of Rial  (Table 5.1) raising the possibility that the a lT 151A  substitution 
converted  the  Zn2+  potentiation  site  to  a  high  sensitivity Zn2+  inhibitory  site.  In
t i ci *  r i  a
support of this hypothesis the Rial  ’  mutant, designed to disrupt the original 
potentiating  site,  reduced  the  sensitivity  of the  high  potency  component  of the 
biphasic  curve  (Fig  5.7.4;  Table  5.3).  Whilst  removal  of the  H107N  background 
mutation to recover the original inhibitory Zn2+ site gave an a 11151A  receptor with an 
increased sensitivity for the lower potency component (Fig 5.1  A,B\ Table 5.3).
To  further characterise the role of T151,  this residue was mutated to  its  P-subunit
counterpart,  RIalT151R ,  which  ablated  Zn2+  mediated potentiation  at  GlyR  al  and
also  generated  a  biphasic  sensitivity  to  inhibitory Zn2+  (Fig  5.1C).  In  this  case,
whilst the sensitivity of the high potency component was still comparable to the Zn2+
potentiation  EC50  of Rial  (RIalT151R   IC50  =  3.6  ±  0.4  pM,  n  =  4)  the  maximal
contribution  of  the  high  sensitivity  inhibitory  component  on  glycine  evoked
166responses was reduced to 39 ± 3 %, (n = 4), from 73 ± 8 %, (n = 4), for RIalT 151A  
(Fig  5.7C,  Table  5.3).  Threonine  151  was  further  mutated  to  the  5-HT3A R 
counterpart, Asn, as this homologous receptor is also potentiated by Zn2+; however, 
Zn2+ mediated potentiation was still abolished  for this mutated RIalT 151N  receptor. 
Again,  though  the potency of the  high  sensitivity  inhibitory component  remained 
similar  to  the  original  Zn2+  potentiation  EC50  of  Rial  (RIalT 151N  
IC50  =  1.6  ±  0.7  pM,  n  =  4)  but  the  maximal  contribution  of this  high  potency 
inhibitory site was now even less at just 6.5 ± 0.3 %, (n = 4; Fig 5.7C, Table 5.3).
The  5-HT3A R Zn2+  potentiation  site  does  not  operate  through  its  GlyR T151 
homologue
The  data  for  GlyR  a lT151N   demonstrated  that  this  receptor  was  not  amenable  to 
potentiation by Zn2+ suggesting that this residue may not form part of the apparatus 
required for Zn  enhancement of the homologous cys-loop 5-HT3A R.  To validate 
this  assertion  a  wild-type  5-HT3A R  and  a  5-HT3A RN 170A   were  each  assessed  for 
sensitivity  to  Zn  mediated  potentiation  of  50  %  maximal  serotonin  induced 
currents.  Serotonin in the presence or absence of Zn  was co-applied to receptors 
without Ca2+ or Mg2+ present as these cations compete with Zn2+ for potentiation of 
5-HT3A Rs, (Hubbard and Lummis, 2000; though Ca2+ and Mg2+ were still present in 
the background saline solution to maintain the health of the cells).  Serotonin dose 
response curve analysis showed that the sensitivity of each receptor to serotonin was 
directly comparable (wild-type EC50 = 0.86 ± 0.11  pM, n = 3 and 5-HT3A N 170A  EC50 
= 1.05 ± 0.25 pM, n = 3; Fig 5.85).  Furthermore, in agreement with the supposition 
that N170  does  not  play  an  equivalent role  in  the  5-HT3A R to  the  GlyR  T151  as
^ 1
regards  Zn  potentiation,  both  serotonin  receptors  exhibited  biphasic  profiles  in 
response  to  Zn2+  modulation  with  the  sensitivity  to  potentiating  Zn2+  and  the 
maximal enhancement remaining indistinguishable (Fig 5.8C, n = 3).
167A  Rla1T151A   B  Rla1T151A
Glycine  +10Zn2+  Taurine  +10 Zn2+
c
£
L_ 3 0 
*D   0)
1
0 0 3 1
< D C
£
O
Glycine  +10Zn2+
■   a1T 1 5 1  
o  Riot 1T151A
A  RU1T151A,
n m m   < \   -m m m
Zn2"" concentration (pM)
a1T 1 5 1
Rla1T 1 5 1 A
1.01  0.1  1   10 100100010000 
Zn2"- concentration (pM)
4 0
■ Rla1T151A 
A  Rla1T151R
O  R |a 1 T151N
m  n 1  1  in   inn 1
Zn2 -" concentration (pM)
Figure  5.7  Zn2+ potentiation  of 50  % maximal  Gly or taurine responses  is 
abolished  in  al  T151  mutated  receptors  and  replaced  with  a  novel  biphasic 
inhibition.  RIalTl5lA exhibits biphasic inhibition for^f, Gly and B, taurine.  The 
lower potency component can be shifted to the left when the low sensitivity site 
residue N107 (RI) is reconstructed (N107H) to create a l n51A.  Introduction of 
El92A  to  perturb  the  original  Zn2+   potentiation  site,  by  contrast,  induces  a 
reduction in the sensitivity of the high potency inhibition component of the curve 
on RIalT151A .  C,  RIalTl5IN or R ialII5lR also ablate Zn2+  potentiation of 50 % 
maximal Gly responses and introduced biphasic inhibition curves.  Notably the 
potency  of the  two  phases  remains  comparable,  but  the  maximum  inhibition 
(dashed  red  lines)  for  the  high  potency  component  is  reduced  in  the  order 
RialT L >lA  > RialTl51R  > Rja ]1  l5 lN   £>  GlyR al  extracellular domain based on 
AChBP, highlighting T151  (yellow) within the putative cys-loop gating domain 
(grey) and its proximity to another important determinant in gating, the TM2-3 
linker region (pink; Lynch et al, 1997). N = 4-6.
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As T151  resides in the cys-loop, recently implicated as important for agonist gating 
in the cys-loop based ligand-gated ion channel superfamily (Kash et al., 2003), each 
of  the  T151  mutations  was  assessed  for  altered  agonist  potencies.  All  three 
mutations,  either  a lT 151A   or  RIalT151A ,  RIalT151R   and  RIalT151N ,  resulted  in  a 
progressive  reduction  in  sensitivity  to  both  Gly  and  taurine  with  Rial1151N  
demonstrating  an  11-fold  and  23-fold  increase  in  EC50  for  Gly  and  taurine 
respectively (n = 4-5; Fig 5 . 9 T a b l e  5.3).  Consistent with a gating effect, the 
percentage Im ax for taurine (compared to maximal glycine responses in the same cell, 
termed ‘relative efficacy’), which has a lower absolute efficacy than Gly at GlyR al 
(Lewis et al., 2003) decreased from  100 %, (n = 4) and 97 ± 4 %, (n = 4) of Gly 
maximal currents in Rial  and R ial7151A  respectively to 93 ± 3 % for Rial7151R  and 
to 46 ± 6 % for RIal7151N.  Additionally in the case of RIalT 151N  the Gly maximal 
current  also  dropped  significantly  (P  <  0.05)  from  wild  type  responses  of 
4.5  ±  0.4 nA to  2.9 ± 0.5  nA (Fig 5.9A-D,  Table  5.3).  Though this reduction in 
maximal Gly current amplitude is consistent with a reduction in the efficacy of the 
receptor  it  cannot  be  ruled  out  that  the  receptor  may  instead  be  less  efficiently 
expressed at the cell surface i.e.  the receptor may carry an assembly or trafficking 
defect.  However, such an explanation does not explain the taurine data.  In further 
support of an effect by these mutations on gating there was no appreciable shift in 
sensitivity  to  the  competitive  antagonist  strychnine  (Fig  5.10,4,5)  suggesting  the 
ligand-binding  region  was  not  substantially  distorted  (Vandenberg  et  al., 
1992a;Vandenberg et al., 1992b).
To investigate further the chemical properties required by the residue at position 151 
e.g.  polarity  and  side  chain  volume,  five  other  T151  mutants  were  generated 
including:  GlyRal7151c, a l7151D , a l7151E, a l7151F and a l7151s.  Glycine and taurine 
dose response curves  for the a l715ic,  a l7151E,  and a l715is  receptors  all  showed  a 
significant  (P  <  0.05)  but  small  2 - 4   fold  increase  in  E C 50  for  both  agonists 
(Fig 5.10C,A Table 5.3) compared to the wild-type receptor.  This was comparable 
to  the  a l7151A   receptor  despite  the  fact  that  these  new  mutations  retained  polar 
electronegative  moieties  at  this  position.  Furthermore  introduction  of  a  large 
hydrophobic  side  chain  at  this  position  in  the  form  of a l71517  did  not  cause  a
170significantly  greater  (P  >  0.05)  perturbation  to  agonist  potencies  than  any  of the 
previously  inserted  polar  substitutions  (Fig  5.10C,A  Table  5.3).  Even  more 
intriguing  was  that  a lT151D ,  which  introduced  another  polar  electronegative  side 
chain, produced a receptor with maximal currents less than 20 pA (n = 10).
GlyR al  T151  and residues in  the proposed Zn2+ potentiation  site region  can 
interact in mutated receptors
The  mutation  of GlyR  al  T151  to  an  Ala  followed by  an  Arg  and  then  an  Asn
9 -4- resulted in a progressive reduction in the ability of Zn  to interact with the receptor 
via the Zn  potentiation site.  As the function of the potentiation site was reversed to 
instead  elicit  inhibition  this  progressive  reduction  was  measured  as  a  decreasing 
contribution  of the  high  sensitivity  inhibitory  component  to  the  total  amount  of 
inhibition in the biphasic inhibition profile (Fig 5.7Q.  This same series of mutations 
also resulted in an apparent progressive deterioration in receptor gating, in the same
order  ofT151A  <  T151R  <  T151N,  suggesting  that  there  may  be  a  direct  link
2+ between  the  Zn  potentiation  site  and  domains  involved  in  receptor  gating.  To 
further demonstrate  a potential  influence  of the  Zn2+  potentiation  site on receptor 
gating  via  T151  the  agonist EC50S   of Gly  and  taurine  along  with  their  maximal
/.  r>T  -T151A,  El 92 A  T151A,  D194A  i T151A,  H215A  . responses were compared  tor Rial  ,al  ,al  to  the
R ial7151A  receptor.  Whilst the presence or absence of H107N does not affect agonist 
potency at a lT 151A  mutant receptors (Fig 5.9CJ), Table 5.3) and E192A, D194A and 
H215A  mutations  alone  introduce  minimal  disruption  to  receptor  function 
(Table  5.1),  addition  of these  mutations  to  an  Rial7151A   background  did  cause  a 
synergistic  disruption  to  receptor  gating.  Introduction  of  El92A  to  RIal7151A  
reduced agonist potencies in a manner consistent with a change in channel  gating. 
Gly  and  taurine  EC50S  were both  10-fold  higher  and  the  taurine  maximum  was
reduced from  100 %  (n = 4) to 65 ± 4.3  %, (n = 7) of the Gly maximal response.
Again the maximal Gly responses were also reduced from 4.0 ± 0.4 nA, (n = 5) for 
RIal7151A  to  1.9 ± 0.5 nA, (n = 7) for RIal7151A ’ E192A ?  consistent with a decrease in 
the efficiency of channel gating, assembly or trafficking.  The strychnine sensitivity 
remained  at  wild-type  levels  suggesting  the  agonist-binding  site  retained  the 
characteristics required for agonist binding (Fig 5.10,4,5).  In comparison to the dual 
mutation of T151  and El92, the  strongest candidates  for direct Zn2+ coordination,
171RIalT151A ’ D 194A   and RIalT151A ’  H 215A   showed a more dramatic phenotype with Gly 
currents significantly reduced to  150 ± 70 pA, (n = 8 from 27) for RIalT151A ’ D 194A  
and 40 ±  10 pA, (n = 7 from 23) for RIalT151A ’H 215A  (Fig 5.1 IA-Q.  Once more the
    'T1  c 1   a  r  i q* ) *
Gly EC50 increased significantly in a comparable fashion to Rial  ’  with a 
14-  and  24-fold  increase  to  220  ±  20  pM,  (n  =  4  from  24)  and  370  ±  30  pM, 
(n  =  2  from  23)  for RIalT151A ’ D 194A   and a lT151A ’ H 215A  respectively.  The relative 
efficacy of taurine was also substantially reduced to 33 ± 6 %, (n = 3  from 24) for 
RIalTI5IA’D 194A  and 40 ± 10 %, (n = 7 from 23) for RIalT151A ' H 215A  (Fig 5.11A-Q.
” 7 4 - Thus  D194  and  H215,  the  strongest  candidates  for Zn  potentiation binding  site 
residues,  also  have  the  strongest  influence  on  receptor  function  when  mutated  in 
combination with T151A.
Further  studies,  mutating  residues  immediately  surrounding  the  proposed  Zn2+  
binding site and which are presented on the same side of the p-strands, revealed that
alT151A, K190A, alT151A, R196A, ^TISIA, R213A ^  al T151A, E217A ^  exacerbated ^
properties of the RI a lT 151A  mutation  in a comparable way to the RIalT151A ’  E 192A  
mutation.  This is despite the fact that individually these K190A, R196A, R213A and 
E217A mutations do not influence GlyR agonist properties (Table 5.1).  The Gly and 
taurine EC50S were increased in each case, whilst the maximal glycinergic response 
was  reduced  and  taurine  was  reduced  to  a  partial  agonist  with  maximal  taurine 
currents  varying  between  30  and  85  %  of  the  maximal  glycine  response 
(Fig 5.11A-C, Table 5.3).  This synergistic disruption to receptor function, especially 
at the core of the proposed Zn2+ potentiating binding site (D194 and H215), suggests 
this region is capable of interacting with T151.
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Figure 5.9  T151 mutated GlyR al receptors exhibit altered agonist activation 
properties  consistent  with  changes  to  channel  gating.  Representative  raw  data 
traces showing maximal evoked responses to A,  Gly, and then in the same cell 
B, taurine revealing the maxima for both agonists was reduced in RIalT 151N  and
T151A E192A Rial  ’  though  to  a  greater  degree  for  the  less  efficacious  and  potent 
agonist taurine.  C,  and D,  Corresponding dose response curves to demonstrate 
decreased  potency of agonists  in  a  series  of al  T151  mutants;  al  »  Rial  >
, T151A  OT  1 T l5l A  .  OT  - T151R  .  n T   -T151N  ,1 1 5 1 a ,E192A  ,  r al  » Rial  > Rial  > Rial  » Rial  are  shown  for
Gly  (C)  and  taurine  (D).  Taurine  lm 2 iX   data  were  always  measured  as  a 
percentage of the maximal Gly response in the same cell.  N= 4 - 11.
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Figure  5.10  Further  studies  on  T151  mutated  GlyR  al  receptors.  A, 
Sensitivity  to  inhibition  by  the  competitive  antagonist  strychnine  of  50  % 
maximal  Gly  responses  remained  comparable  across  a  series  of  al  T151 
mutants.  B,  Typical  50  %  maximal  glycine  responses  in  the  absence  and 
presence of 10 nM  strychnine (St) and after recovery for Rial  and RIalT151N . 
Further characterisation of the effect of T151 mutated receptors on dose response
r   ^   i  •  j   •   r   ,11510  , T151E  ,T151F  ,  ,T151S curves  for  C,  glycine and D,  taunne  for al  ,  al  ,  al  and al
T151C mutated  GlyRs.  Despite  retaining  polar  electronegative  groups  at  al
T151E  T151S al  and al  , all three receptors exhibited a 2 - 4 fold increase in EC50 for 
both  agonists  and  a  minor  reduction  in  taurine  relative  efficacy,  assessed  in 
comparison  to  the maximal  Gly response  in  the  same  cell.  Introduction of a 
large  hydrophobic  group  in  the  form  of an  a lT151F  did  not  cause  a  further 
increase  in  agonist  EC50s  relative  to  its  polar  electronegative  counterparts. 
N = 3-4.
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Figure  5.11  Agonist  properties  for  Gly  and  taurine  activating  Rial1151A  
receptors carrying additional mutations in the nearby potentiating Zn2^ binding site 
region.  A,  Gly EC50 values  increased and taurine efficacy B,  and Gly maximal 
currents  C,  were both  decreased  when  mutations  from  the Zn2+ binding region 
were  introduced  into  R ial1131A .  The  greatest perturbation  to  receptor  function 
coincided with the axis of the predicted Zn2+ binding site with R ial1151A ’D 194A  and 
Rial n51A' H 215A  producing effectively non-functional receptors with Gly maximal 
currents less than 200 pA. Asterisks (*) denote significant (P < 0.05) divergence in 
receptor property from RIa 11151A .  N= 4-7.
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Evidence for a discrete Zn2+ potentiation site in GlyR al
The Zn2+ potentiation site elucidated here in the form of GlyR al  D194, H215 and
" ? + El92  fits the criteria for a Zn  binding site.  Each of these residues is chemically 
adept at interacting with Zn2+, and the structural GlyR al  model, based on AChBP, 
predicts these three residues are in close proximity and ideal  for presentation in a
“ 7+  •   •  •   • Zn  binding site.  In addition, alanine substitution of these residues equally reduced 
Zn  potentiation  of currents  activated by two  different  agonists,  Gly and taurine, 
strongly suggesting that these residues exert their effect from a single source or site 
of action such as a binding site.  Finally, experiments using MTSEA demonstrate that 
this  site  is  accessible  to  water  and  therefore  also  to  Zn  via  all  three  residues. 
Moreover, the analysis of an a lE192p mutated receptor suggested that El92 may be 
exerting  its  effect  on  Zn2+  binding  through  the peptide backbone.  This  site  only 
requires a fourth coordinating point to complete the Zn2+ binding site and in the case 
of catalytic  sites,  this  is  predominantly provided  by  an  activated  water  molecule 
(Auld, 2001).
Comparison of the GlyR al inhibition and potentiation sites
This potentiation site features a histidine residue as a likely Zn2+ coordinating partner 
and thus has some similarity with the GlyR inhibitory site.  However, even without a 
precise atomic structural guide for the potentiating site it is still possible to predict 
that  the  exact  chemical  nature  and  structural  properties  of this  site  will  be  quite
different  from  the Zn2+  inhibitory  site.  This  is because  the  other main  candidate
•   2+ residue for Zn  coordination features an acidic carboxylic acid group donated by an
Asp, a residue not present in the inhibitory site.  In addition there may be an unusual 
•  •  2+ contribution to Zn  coordination, at the potentiation site, from the peptide backbone, 
the  organisation  of which  is  important  for  Zn2+  sensitivity.  These  coordinating 
groups  could  account  for  the  higher  sensitivity  of the  potentiation  site  to  Zn2+ 
(EC50 « 1  pM) compared with the inhibitory site (IC50 « 20 pM), as acidic groups are 
stronger Zn2+ coordinators than polar hydroxyl groups such as those of the inhibitory 
site, e.g. al  T133 (Auld, 2001).  Finally, this potentiation site differs critically from 
the inhibitory site in that its predicted location suggests the site exists as a discrete 
unit  on  each  subunit  rather  than  as  a  cross-bridge  between  adjacent  subunit
176interfaces.  This means that in contrast to the mechanism of action of the inhibitory 
site,  which  could  act  by  stabilising  communication  between  two  neighbouring 
subunits  and preventing the  subunits rotating to  activate the receptor (Chapter  3), 
each potentiation site must communicate its effect initially within the confines of a 
single  subunit  before  any  downstream  global  consequences  on  receptor  function 
could be imposed.
Transduction roles for residues at the GlyR al Zn2+ potentiation site
Although the three residues identified here, GlyR al  El92, D194 and H215, are all 
potential contributors to the potentiating Zn2+ site, it appears that the contribution of 
these residues to the site is not equal,  as was previously shown to be the case for 
residues  at the  GlyR  al  inhibitory  site  (Chapter 3-4).  In the  case  of an  H215 
substitution,  an  Ala  residue  attenuated  but  did  not  ablate  the  sensitivity  to 
potentiating Zn2+.  The a lH 215A  receptor also did not have any obvious effect on the
' S i
maximum  level  of Zn  enhancement or alter the function of the potentiating site. 
This suggested that H215 may contribute a pure binding role to the potentiating site.
In contrast, introduction of Ala at either El92 or D194 produced a receptor with no
2+ detectable Zn  enhancement.  Furthermore these substitutions appeared to create an 
extra  Zn2+  inhibition  site  suggesting  this  region  could  influence  the  function  and 
transduction  of  potentiation.  However,  in  accord  with  a  role  in  direct  cation 
coordination for El92 and D194 the potency of Zn2+ at the new inhibitory site was 
always  of  the  order  15-50  fold  less  than  at  the  original  potentiation  site. 
Substitution of the prime Zn2+ coordinating candidate D194 with a Lys residue, also 
a non-Zn2+ binding moiety but of larger volume than Ala, still ablated potentiation 
but did not induce any secondary functional effects.  It is conceivable that the effect 
of a lD 194A  on transduction may simply be due to the insertion of an alanine at this 
position.  In  the  case  of El92  this  residue  does  appear to  be  able  to  specifically 
influence  the  transduction  that  is  induced  from  the  potentiating  site.  The  data 
support the supposition that the organisation of the backbone at this locus is critical 
both for the potency of the site and also for the polarity of the site.  In order for Zn2+ 
to bind and potentiate glycine currents, it must increase the propensity of the receptor 
to open in response to agonist binding.  From the evidence presented here and given 
that  the  region  surrounding  the  E192/D194/H215  site  did  not  influence  Zn2+
177potentiation, it can be speculated that the movement required is most likely linked to 
the  backbone  region  at  El92,  though  this  cannot  be  validated  without 
thermodynamic and structural data.
A  link  between  the  GlyR  al  Zn2+  potentiation  site  and  the  channel  gating 
domain
In  addition to those residues thought to  line the Zn2+ binding site,  T151  was  also 
identified as a vital  ‘control element5   for this site.  Threonine  151  appears to be an 
important transduction component since its replacement by other residues altered the 
phenotype of the potentiation site reversing its polarity to create a high sensitivity 
inhibitory  site.  More  profoundly,  the  sensitivity of the  novel  inhibitory  site  was
94- comparable to that of the original potentiating site for Zn  , suggesting this residue 
was not affecting the affinity of the site.  Instead the alternative residues inserted at 
position  151  varied the extent of inhibition in agreement with a transduction role. 
Threonine  151,  located  in  the  critical  cys-loop  gating  domain  (Kash  et  al., 
2003;Schofield et al., 2003;Schofield et al., 2004), was also important in determining 
agonist potencies since mutation to Ala, Arg and Asn reduced the GlyR sensitivity to 
agonists.  This clear dual function of T151  suggested a mechanism of action for the 
Zn2+  potentiation  site.  The  effect  of  Zn2+  binding  appears  to  communicate 
downstream to T151 to increase the efficacy of the agonist-induced channel opening. 
This  is  supported  by mutations  introduced  in  the  extracellular  domain  outer  face 
around the Zn2+ binding site, which compounded the effect on agonist potencies of 
a lT 151A   mutated  receptors,  even  though  these  mutations  alone  were  innocuous. 
Importantly,the putative Zn2+ binding locus, El92, D194 and H215, when replaced 
with  Ala  residues,  all  strongly  reduced  agonist  relative  efficacies  on  the  a lT 151A  
background.  This  supported  the  supposition  that  for the wild-type  receptor,  Zn2+ 
binding at this location could induce a downstream effect onto the cys-loop at T151 
enabling  potentiation.  In  accordance  with  Zn2+  potentiation  increasing  agonist 
efficacy, the partial agonism of taurine on GlyR al  in oocytes is enhanced to nearly 
a  full  agonist  by  potentiating  doses  of Zn2+  (Laube  et  al.,  2000).  Furthermore, 
residues  located in the M2-3  extracellular loop, which  are predicted to  be  closely 
opposed  and  to  interact  with  the  cys-loop  gating  domain  (Brejc  et  al.,
1782001;Miyazawa et al.,  2003), also  affect Zn2+ mediated potentiation  (Lynch et  al., 
1998) as would be expected if there is interplay between these two domains.
Recently  it  has  been  shown  that  in  the  case  of anaesthetics  operating  on  GlyRs 
perturbation  of a  selection  of residues  in  the proposed cys-loop  domain,  not  only 
reduced  glycine  potency  but  also  diminished  the  potentiation  caused  by  certain 
anaesthetics  (Schofield  et  al.,  2004).  Though  T151  was  not  one  of the  residues 
concerned,  the  authors  did  replicate  a  reduction  in  agonist  potency  for  a  GlyR 
a lT 151A  mutation  as  is  reported  here.  This  supports  a potential  scheme  in which 
positive modulators that increase the receptor efficacy may operate by feeding into 
the critical receptor gating domain comprising the cys-loop and M2-3  loop, even if 
originally  the  input  is  derived  from  distinct  sources  such  as  the  extracellular  or 
transmembrane domains.  Also of interest is the recent observation that when 1307 in 
the  TM2  domain  of the  GABAa p  receptor is  substituted with  a  Gin residue the 
polarity of an inhibitory 5P-pregnane-3a-ol-20-one neurosteroid is reversed to now 
induce potentiation (Morris and Amin, 2004).  This is comparable to the reversal of 
the Zn  potentiation  site polarity observed here upon perturbation of al  El92  or 
T151  suggesting that modulation site polarity reversals may be a common side effect 
of interfering with the transduction machinery of a binding site.
Implications for Zn2+ potentiation at other GlyR subtypes
The structure-function study reported here focused primarily on determinants of Zn2+ 
mediated potentiation in GlyR al.  However the implications for properties of Zn2+  
enhancement at GlyR a2-4, GlyR p and the 5-HT3A  receptor were also investigated. 
Accurate comparisons of the potency of potentiating Zn2+  at GlyR al  and a2  and 
their respective heteromers revealed that both receptors have a submicromolar high 
sensitivity to Zn  enhancement, though the potency is 10 -  fold less for a2 due to a
•n  i
subsitution  at the Zn  binding residue,  al  D194,  with  another acidic  moiety,  al
E201.  The remaining two residues al El92 and H215 as well as the control element
T151  all  remain  the  same  in  a2  (Fig  5.2Q  suggesting  the  properties  of  Zn2+
potentiation at the al  subtype have the same molecular basis.  Though no  studies
were carried out to measure the potency of Zn2+ enhancement at GlyR a3 and 4 these
two  receptors  retain  the  exact  same  molecular  composition  as  al  for  Zn2+
179potentiation and are therefore likely to retain comparable properties, an assumption 
supported by a significant potentiation of GlyR a3 by 1  pM Zn2+ (Chapter 3).
Studies  to  investigate  a  contribution  from  the  p-subunit  to  Zn2+  potentiation 
suggested  its  role  is  unimportant  in  this  process.  Incorporation  of the  P  subunit 
forming heteromeric GlyR alp and a2p did not in any way influence the potency of
^  i  a
Zn  enhancement and co-expression of the p-subunit with an al  mutant devoid 
of Zn2+ potentiation  did not  enable the recovery of a positive  allosteric  action by
^ I  ^ i
Zn  .  The molecular basis of this apparent lack of sensitivity to Zn  enhancement 
by the p-subunit could be attributed at least in part to the identification of a variant 
residue  at the  equivalent position to  al  T151.  Introduction of the corresponding 
p-subunit residue, an Arg, into the GlyR rendered the a 11151R  mutant insensitive to 
Zn2+ enhancement such that the potentiating site now seemed to support an inhibitory 
influence.  This  is supported by a previous observation where an al  chimera that 
suffered  a  partial  replacement  of the  region  encoding  the  cys-loop  and  therefore 
T151  with the p-subunit sequence also generated a GlyR al  subunit insensitive to 
Zn2+ potentiation (Laube et al., 1995).
Implications for Zn2+ enhancement of §-HT3A Rs and nAChRs
Characterisation of the 5-HT3A R for modulation by Zn  has also previously revealed 
a biphasic profile with comparable sensitivities for Zn2+ potentiation and inhibition to 
those measured for the GlyR (Hubbard and Lummis, 2000).  The possibility though 
that these two receptors  share the same molecular basis  for Zn2+  potentiation now 
seems unlikely as replacing GlyR al  T151  with the Asn present in the 5-HT3A R did 
not retain Zn2+ potentiation at the GlyR.  In addition substitution of the 5-HT3A R Asn 
residue  with  an  Ala,  which  when  introduced  to  create  GlyR  a lT 151A   ablates 
enhancement, did not cause any apparent effect on Zn2+ potentiation at 5-HT3A Rs. 
Though the other specific molecular correlates of the GlyR al  binding site El92, 
D194 and H215 did align with potential Zn2+ binding partners in the mouse 5-HT3A R 
variant tested here (Fig 5.&4), alignment analysis with the human 5-HT3A R did not 
provide the same results (data not shown).  As the regions around the actual Zn2+  
binding site residues are poorly conserved between GlyRs and the 5-HT3A R it was 
not possible to gage whether these acidic residues in the 5-HT3A R were homologous
180to those of the GlyR and an in depth structure-function study to investigate this was 
not undertaken.  Overall the evidence presented here suggests that the  5-HT3A R is
9 ^ unlikely  to  possess  a  homologous  Zn  potentiation  site  compared  to  that  of the 
GlyR.  This is further supported by the fact that the 5-HT3A R does not maintain the 
same degree of specificity for cation enhancement (Hubbard and Lummis, 2000).  At 
5-HT3A Rs the Zn2+ enhancement effect can be displaced by other cations including 
Ca2+ and Mg2+ making it necessary to carry out the Zn2+ modulation curves in the 
absence of these ions, which is not required when measuring Zn2+  enhancement at 
the GlyR.
^ I
There is also no molecular basis for the potentiation by Zn  of some subtypes of the 
nAChR  (Hsiao  et  al.,  2001).  Though  it  may be  possible  that  nAChRs  retain  a 
comparable  site  for Zn  enhancement to  the  GlyR, the properties  of this nAChR 
site(s), are likely to be quite different.  Whilst Zn2+ potentiation of GlyRs is a very 
robust process occurring with comparable sensitivities and maximal enhancements 
across GlyR a 1-3  and their respective ap  heteromers, Zn2+ potentiation at various 
nAChRs  is  more  complex.  Both  the  subtype  of the  a  and  p-subunit  are  able  to 
influence  the  extent  and  maximal  level  of Zn2+  mediated potentiation  at nAChRs 
(Hsiao  et  al.,  2001).  Furthermore  the  sensitivity to  Zn2+  enhancement  in  normal 
saline across all these nAChR variants, a2-4 and p2 and P4, was substantially lower 
with EC50S in the range 15-100 pM compared to the 0.8 pM value reported here for 
GlyR al.
The nAChR potentiation site does however share a higher level of selectivity like the
9+ GlyR  (Laube  et  al.,  1995)  when  compared  to  the  5-HT3A R,  with  significant  Zn 
potentiation occurring even in the presence  of Ca2+  and Mg2+   ions and only Cd2+ 
being able to partially compensate  for Zn  enhancement  (Hsiao  et al.,  2001).  A
9  1
study using chimeras has demonstrated that the most important contribution to Zn 
mediated potentiation in nAChRs comes from the extracellular N-terminal domain of 
the receptor similar to the GlyR.  However, there are no obvious correlates between 
the GlyR residues,  T151,  El92,  D194 and H215,  in the nAChR a and  p  subunits 
(alignment not shown) that could account for Zn2+ modulation.
181Physiological significance of GlyR Zn2+ potentiation
The high sensitivity to Zn2+ enhancement reported here for homomeric al  and 2 and 
heteromeric  al(3  and a2p  GlyRs,  along with  the rapid  onset of Zn2+  potentiation 
previously reported  (Chapter  3),  make  Zn2+  an  ideal  endogenous  co-modulator  at 
glycinergic synapses.  This is relevant especially as Zn2+ is concentrated into selected 
nerve terminals and packaged into  synaptic vesicles throughout the CNS  including 
those present within glycinergic boutons of the spinal cord (Birinyi et al., 2001 ;Jo et 
al., 2000;Velazquez et al.,  1999;Wang et al., 2001).  Additionally, Zn2+ ions may be 
released  into  the  synaptic  cleft  or  from  a  thin  Zn  veneer  following nerve  fibre 
stimulation  (Assaf and  Chung,  1984;Howell  et  al.,  1984;Kay,  2003)  resulting  in 
multiple  effects  on  neuronal  excitability by modulating  ligand-gated  and  voltage- 
operated ion channels (Smart et al., 1994;Harrison and Gibbons, 1994).  Experiments 
measuring  zebrafish  glycinergic  IPSC  kinetics  in the presence  and absence  of the 
Zn  chelators, tricine and TPEN, revealed that these synaptic receptors are sensitive 
enough  to  be  potentiated  even  by  Zn2+  contamination  in  the  extracellular  saline 
solution (Suwa et  al.,  2001).  Thus it would appear likely that GlyRs can at least
^ I
undergo a basal level of modulation by released Zn  though whether this extends to 
the specific action of Zn  as a rapidly released and removed synaptic co-modulator 
will require further studies.
Conclusion
^ I
I  report  here  the  identification  of the  Zn  potentiation  site  for  the  GlyR  and  a 
possible mechanism of action for Zn  potentiation via the cys-loop channel-gating 
domain.  This site has a high sensitivity to Zn2+, with the EC50 estimated at less than 
1   pM, well within the current range of estimates for putative physiological levels of 
released  Zn2+  (Frederickson  et  al.,  2000).  Importantly,  this  mutagenesis  study 
supports  the  supposition  that  the  AChBP  is  a  powerful  model  for  use  in  GlyR 
structure-function studies and strengthens the recent precedent linking the GlyR cys- 
loop region to channel gating (Kash et al., 2003;Schofield et al., 2003;Schofield et 
al., 2004), by identifying a novel regulatory component in GlyR function in the form 
of T151.  This study provides novel insight into the function of a cys-loop ligand-
^ 1
gated ion channel Zn  binding site.
182Glycine
Max current  EC5 o (pM) 
(nA)
n EC5 o  (pM)
Taurine
t%GlyI™*)
n ECS 0  (pM)
Zni+ (on Gly)
Max(%)  IC50(pM) 
increase*
n
Zn2 +  binding residues
al 4.5 ±0.5 16 ± 2 5 90 ± 10
i
©
o 5 0.8 ± 0.3 39 ±8 20 ±5 4
Rial 5.9 ± 0.3 25 ±4 4 130 ±30 -100 4 0.8 ± 0.2 42 ±6 >3000 4
RIalE 192A 3.6 ±0.7 19 ± 4 3 190 ±60
i
©
o 3 None None 710± 100 7
RIalDl94A 4.8 ± 0.4 48 ±4 3 310 ±70 -100 3 None None 270 ± 50 3
Rlal**21^ 3.7 ±0.2 21 ±3 3 100 ±30
i
©
o 3 22 ±4 28 ± 12 1320 ±210 4
Acidic non-binding residues
RIalD 141A 2.9 ± 1.1 46 ±7 2 240 ± 80
©
o 2*1 0.5 ± 0.2 41 ±21 >3000 3
RIalD 148A <0.04 — 10 --- __ 3 — — — —
RIalE19,A 4.8 ±0.6 22 ±5 3 190 ±40 -100 3 0.8 ± 0.4 80 ±50 >3000 3
Residues surrounding Zn2 +  binding site
Rial 4.5 ±0.3 9 ± 2 3 80 ±20
i
©
o 3 0.9 ± 0.7 29 ±6 n.e 3
RIalR 196A
— .  - D O H A 5.0 ±0.5 27 ±6 4 150 ±50
I
©
o 4 0.6 ± 0.1 34 ±7 n.e 4
Rial 5.3 ± 0.2 9 ± 7 3 60 ± 10 -100 3 0.5 ± 0.3 58 ±30 n.e 3
RIalE2,7A 4.2 ±0.8 21 ±5 3 120 ±50 -100 3 0.9 ± 0.3 37 ±3 n.e 4
Cys mutated receptors
RIalE 192C 5.8 ±0.8 110 ± 10 4 n.e n.e 1.9 ±0.2 59 ± 15 -  1000 4
RIalD 194C 5.6 ±0.8 99 ±24 4 n.e n.e 3.6 ± 0.6 40 ± 12 2000 ± 300 5
RIalH 215C 4.0 ± 0.6 71 ± 10 3 n.e n.e 0.44 35 ±8 1100 2
^ja jEt92C, H 215C < 0.1 6 — __ __
RIa 1D,94C .H 215C < 0.1 — 6 — — — — — —
Table 5.1  Agonist potency data and Zn2+ modulation data for mutagenesis studies to elucidate the Zn2+  potentiation site of
GlyR al.
Definitions:  n.e. -  not evaluated, ‘—’ represents receptors where maximal Gly currents were too small to accurately evaluate Zn2+  
modulation, none - denotes circumstances where the attribute under evaluation was not present.
* The maximum percentage increase of a 50 % maximal agonist induced response. ** _ This error is a standard deviation.Max current 
(nA)
Glycine
ECsoCpM) n EC50 (pM)
Znz+ (on Gly)
Max (%)*  IC50 (pM) 
increase
n
H109F mutated receptors
Rial 5.9 ±0.3 25 ±4 4 0.8 ± 0.2 42 ±6 >3000 4
RIalH 109F 5.1 ±0.2 28 ±5 3 ~1 67 ± 14 >10000 7
RIalE,92A 3.6 ±0.7 19 ± 4 3 None None 710± 100 6
RIalH ,09F*  E 192A 6.0 ± 0.5 51 ±4 4 None None 660 ± 90 4
W al“ ,SA 3.7 ±0.2 21 ±3 3 22 ±4 28 ± 12 1320 ±210 4
RIalH l09F*  ®15A 1.2 ±0.3 150 ± 15 3 40 ± 11 34 ± 11 3200 ± 600 4
Pro &  Lys mutated receptors
RIalE,92P 7.0 ± 0.2 48 ±4 3 4.2 ±0.8 50 ± 11 > 1000 3
RIalD 194K 6.4 ± 0.8 140 ±30 6 None None 640 ± 80 6
RfcjHlWF. D194K
1.9 ±0.5 200 ± 30 3 None None 1270 ±110 6
Zn2+ IC50A*1 IC50A Max*2 Znz+ IC50B*3 n
(pM) (%) inhibition W )
H109F mutated receptors (biphasic inhibition)
Rial 4.8 ± 0.4 48 ±4 3 270 ± 50 100 n.a. 3
j^ j HIWF.DIWA
2.5 ±0.6 290 ± 70 3 79 ±28 45 ±4 820 ± 80 4
Pro & Lys mutated receptors (biphasic inhibition)
Rial 7.0 ± 0.2 60 ± 6 3 32 ± 14 52 ±8 1000± 100 3
RIalD,94P 5.2 ±0.9 43 ±9 4 8.2 ± 1.3 42 ±7 150 ±28 3
Table 5.2  Agonist potency data and Zn2+ modulation data for mutagenesis studies to determine 
effects on transduction from the Zn2+  potentiation site.
Definitions:  n.a. - not applicable as this receptor exhibited only one distinguishable inhibitory phase, 
none - denotes circumstances where the attribute under evaluation was not present.
* The maximum percentage increase of a 50 % maximal agonist induced response.
i  ^
*  First high sensitivity IC50 component, *  Maximum achievable percentage reduction by the first 
inhibitory component of 50 % maximal Gly responses, *3  Second low sensitivity IC50 component.Max current 
(nA)
Glycine 
EC 50 (pM) n EC 50 (pM)
Taurine
itn tx
(%GlyUJ
n Zn2+
IC 50A* 1
(pM)
Zn'+ (on Gly)
IC 50A  ZnJ* ICjoB*3 
Max*2 (%)  (pM) 
inhibition
n
Agonist and Znl+  transduction T151 residue mutations
a l T15.A 4.7 ± 0.6 53 ±9 4 330 ± 60 -100 4 2.9 ±2.0 68 ±7 160 ±60 4
RIalT,51A 4.0 ± 0.4 63 ± 12 5 380 ± 80 97 ±4 4 1.6 ±0.6 73 ±8 1040 ±290 5
RIalT15,N 2.9 ± 0.5 180 ±30 7 2060 ± 230 46 ± 6 5 1.6 ±0.7 7 ±0.4 1410 ± 210 4
RIalT 151R 3.8 ± 0.9 95 ±7 3 560± 130 93 ±3 4 3.6 ± 0.4 39 ±3 710 ± 130 4
T151 combined with residues both within and surround ng the Zn2 +binding site
R I(x1T.51A.K«90A 0.4 ±0.1 180 ± 10 4 1810± 140 32 ±3 4 n.e n.e n.e
RIalT!51A *E,92A 1.9 ±0.5 170 ± 10 7 960± 160 65 ±4 7 16 ± 3 32 ±4 390 ± 60 3
R I a l T15IA.Dl 94A 0.15 ±0.07 220 ± 20 20 n.e 33 ±6 20 n.e n.e n.e
R I a l T151A.Rl96A 1.2 ±0.3 130 ± 10 4 1810 ± 450 35 ±7 4 n.e n.e n.e
Rlfll^^A1  R213A 2.1 ±0.8 52 ± 10 5 400± 120 85 ±2 5 n.e n.e n.e
R I a l T151A.H215A
0.1 ±0.04 380 ± 30 15 n.e 40+10 15 n.e n.e n.e
R I a l T15JA.E217A
1.2 ±0.4 120 ±6 4 900 ± 70 71 ±3 3 n.e n.e n.e
Further T151 residue mutations
RI<xlT,5,c 4.6 ± 1.6 52 ±8 3 370± 130 94 ±4 3 n.e n.e n.e
RIalTl5lD <0.05 n.e 10 <0.05 n.e 10 n.e n.e n.e
RIalT,5IE 5.0 ± 1.5 50 ±7 3 390 ± 70 94 ± 1 3 n.e n.e n.e
RIalT,5,F 5.7 ± 0.6 100 ±20 4 600 ± 240 88 ±5 4 n.e n.e n.e
RIalT151s 5.3 ±0.8 73 ±7 3 620 ± 190 90 ±4 3 n.e n.e n.e
Table 5.3  Glycine, taurine and Zn2+  potencies for GlyR al carrying mutations at threonine 151.
Definitions:  n.e. - not evaluated, ‘—’ represents receptors where maximal Gly currents were too small to accurately 
evaluate Zn2+  modulation. i  •   •   •««  2  ,  ,
*  First high sensitivity IC50 component, *  Maximum achievable percentage reduction by the first inhibitory component of 50 % 
maximal Gly responses, *3  Second low sensitivity IC50 component.Chapter 6 
Summary and Final Thoughts
The  1960s  represented  a  critical  landmark  in  the  optimisation  of techniques  to 
elucidate  protein  structure.  This  holy  grail  was  of  fundamental  importance  as 
scientists believed that knowledge of a protein’s structure was key to its functional 
secrets.  Clearly,  since  the  deduction  of  crystal  structures  such  as  insulin  and 
haemoglobin, this has proved to be  an unfounded assumption,  largely because the 
structure of a protein is not the sole source of functional information.  Another vital 
component  is  also  required,  that  of protein  dynamics.  In  contrast  to  structural 
techniques,  such  as  NMR  and  X-ray  crystallography,  there  is  as  yet  no  formal 
process for obtaining the dynamic information possessed by a protein.  Strategies to 
monitor  real-time  equilibrium  fluctuations  within  a  protein’s  structure  and  to 
measure  the  movements  that  are  undertaken  in  response  to  ‘stimuli’,  i.e.  binding 
events,  will  be  key to  determining  this  information.  The  standardisation  of such 
techniques,  however, is most  likely decades  away and in the mean-time  functional 
diagnoses rely predominantly on covalent modifications, whether this be in the form 
of site-directed mutagenesis or covalent labelling strategies.
The work described in this thesis demonstrates that with appropriate interpretation, 
covalent modification is remarkably powerful at determining the locations involved 
in binding events and even at elucidating potential mechanisms of communication 
between different protein domains.  The data presented reveal that an unequivocal 
picture  of amino  acid  function  is  almost  never  forthcoming.  This  supports  the 
assertion  above that  a protein  is  not  merely a  static  image where residues  can be 
pigeon-holed  into  their  specific  functional  roles,  but  that  instead  a  protein  is  a 
dynamic  structure,  constantly  in  a  state  of  physical  flux,  where  amino  acids 
contribute to  multiple processes  and work together as  an inseparable team.  Even 
attempts to assess the importance of residues at potential Zn2+ binding sites, where 
the coordinating moieties can be chemically predicted and might be expected to have 
a fairly specific role in coordination, proved remarkably complex with a wide range 
of functional consequences for the GlyR.  The functional interpretations of such data
186are beyond that which can be determined from the structural model alone and instead 
require an appreciation of, as yet, completely absent dynamic information.
Previous studies on GlyR al pointed to four residues with a potential involvement in 
Zn2+ coordination at the inhibitory Zn2+ binding site, HI07 from the subunit ‘+* face 
and HI09, El 10 and T112 from the  face of a neighbouring subunit (Harvey et al., 
1999;Laube  et  al.,  2000;  Fig  6.1).  The  work  here  identifies  two  further  polar 
residues exposed at the surface of the GlyR al  Zn2+ inhibitory  face, which also
influence Zn2+ mediated inhibition, N61  and T133 (Fig 6.1).  All these residues are
2+
predicted to reside in the same region and therefore may influence Zn  coordination 
at the predicted inhibitory site, either directly or indirectly.  The primary sequence 
arrangement for the original three identified residues on the Zn  inhibitory site 
face means that these residues are all spatially close to one another.  However given 
that HI09 marks the end of the predicted  p-sheet 5  with its  immediate neighbour 
El 10 marking the start of a loop region it is unlikely that the peptide psi bond angles 
would  permit  both  residues  to  be  similarly  orientated  to  contribute  to  Zn2+ 
coordination  (Auld,  2001;Vallee  and  Auld,  1990).  Such  a  situation  where  two 
neighbouring residues on a P-strand contribute to Zn2+ coordination of the same ion 
has not yet been reported (Auld, 2001;Vallee and Auld,  1990).  Furthermore, GlyR 
al N61 and T133, which from a structural perspective are predicted to reside on two
* y ,
separate nearby loops ideal for contributing to Zn  binding, represent relatively less 
favoured Zn2+ binding moieties  (Auld,  2001;Vallee  and Auld,  1990).  The results 
from the functional site-directed mutagenesis studies were also not unequivocal.  The 
evidence for HI07 as a direct binding partner in the site is the strongest, as ablation 
of the Zn  coordination property of this residue gives a dramatic reduction in the
‘ ji
potency  of  Zn  inhibition  without  affecting  the  efficacy  (maximal  level  of 
inhibition)  or  inducing  other  Zn2+  related  phenomena  such  as  ZAG  activity. 
Furthermore, only the residue at the equivalent position to HI 07 can be donated from 
what  is  considered  to  be  a  neighbouring  non-functional  P-subunit  and  return 
functionality  to  the  inhibitory  site.  The  data  suggest  that  this  is  because  the 
inhibitory  signal  can  then  be  mediated  through  the  a  subunit  face,  therefore 
suggesting  that  the  ‘+*  face  HI07  is  required  for  binding  but  not  transduction. 
Perhaps also of consequence, the data presented here reveal that the HI 07 equivalent
187is  also  responsible  for  differential  sensitivity  to  Zn2+  inhibition  between  GlyR 
subtypes.  From  an  evolutionary  perspective,  if  it  were  desirable  to  select  for 
receptors with varying sensitivities to Zn2+ then it would be most effective to target a 
residue with a pure role in Zn2+ coordination so as not to induce other effects on the 
properties of the receptor.
Concerning  the  residues  residing  on  the  inhibitory  Zn2+  site  face  it  is  more 
difficult to distinguish specific roles for each moiety.  Previous data and the evidence 
presented in this report favours Zn2+ binding at the intersubunit interface, between 
the  *+’  and  subunit domains, to  stabilise the receptor in a closed conformation 
(Nevin et al., 2003).  From this standpoint HI09 and El 10 chemically represent the 
strongest  candidates  to  mediate  the  Zn  binding  process  at  the  interface. 
However alanine substitution of El 10 induced a relatively small 5-fold reduction in 
the potency of Zn2+ mediated inhibition, while an a lH 109A  mutated GlyR has an even 
smaller reduction in potency, just 2-fold, and also affects the efficacy of this process 
by reducing the maximal amount of inhibition that Zn  can induce.  The structural 
model  of  the  GlyR  presents  HI09  in  a  more  favourable  orientation  for  direct 
coordination with Zn2+ across to HI07.  However the AChBP has a low sequence 
homology with GlyRs (approximately 20 %) and the region for HI09 and El 10 falls 
across the start of a peptide loop within the receptor, which classically retains the 
least structural similarity between homologues.  Therefor^, it is not possible to place
• " y  1
complete  confidence  in  this  prediction  that  HI09  is  the  primary  face  Zn 
coordinating partner.  The remaining three  residues,  N61,  T112  and T133  do  not 
represent  classical  Zn2+  coordination  partners,  though  these  moieties  have  been 
reported  as  binding  partners  in  some  instances  (Auld,  2001).  All  three  of these 
residues, along with HI09, can clearly influence Zn2+ transduction when substituted 
with alanines, as Zn2+ mediated inhibition is ablated and ZAG activity is conferred. 
Plus  these residues  exert other complicating effects on GlyR properties,  including 
some modest reductions in the potency of glycine and a decrease in the macroscopic 
activation rates by non-saturating doses of glycine.  The clear similarities exhibited 
between these residues, despite their discrete locations along the primary sequence, 
demonstrates  the  usefulness  of  the  structural  model  as  a  reliable  predictor  of 
approximate  amino  acid  positions.  It  is  also  worth  mentioning  that  alanine
188substitution at N61, HI09 and T133 generated low potency ZAGs but at T112, high 
potency  ZAG  activity  was  induced,  not  dissimilar  in  sensitivity  to  the  original 
potency of Zn  mediated inhibition.  As the evidence suggests the ZAG induced by 
disruption at the subunit  face, relies on the same Zn2+ binding components as the 
original  Zn2+  inhibitory  site  this  implies  that  disruption  at N61,  HI09  and  T133 
affects the site potency whilst disruption at T112 affects only the transduction.  This 
would agree with previous studies where substitutions of Til 2 have induced effects 
on the relative efficacy of partial agonists and so T112 may have a general role in 
multiple aspects of GlyR  function  (Schmieden et al.,  1999), rather than a specific 
role in Zn2+ coordination.
i
This  report  also  identified  a  novel  site  for  Zn  potentiation.  The  evidence  for
'j ,
residues specifically involved in direct coordination of Zn  at this location is clearer 
perhaps due to its predicted intrasubunit nature.  Site directed mutagenesis studies 
identified a discrete region, composed of three residues, GlyR al  El92, D194 and 
H215  (Fig  6.2)  that  when  substituted  with  alanine  either  ablated, or  reduced, 
sensitivity to Zn2+  enhancement.  Other potential Zn2+ coordinating amino acids in 
the  vicinity  and  neighbouring  residues  did  not  exert  any  influence  over  Zn2+  
potentiation  when  substituted,  demonstrating  the  specificity  of  this  location. 
Furthermore, the evidence that two of these residues, D194 and H215, were direct
^ I
coordinators  of Zn  was  strengthened by demonstrating their apparent  accessible 
nature at the surface of the protein using a cys-modifying reagent, a requirement for 
any dynamic Zn2+ binding site.  As with the studies on the Zn2+ inhibitory site, the
94- results were not always unequivocal.  The alanine substitution at El92 ablated Zn
94- potentiation but  also  induced  the  formation of a  low potency Zn  inhibition  site. 
The evidence indicated that this occurred through a reversal of the function of the 
potentiation  site  suggesting  El92  can  influence  transduction  from  this  site.  The 
inhibition was also of a lower potency than the original potentiation implying that 
manipulation  of El92  also  reduced  the  affinity of the  site,  though  decreasing the 
efficiency of transduction can  also  cause  such an  effect.  Interestingly,  side  chain 
modification  of El92  using  a  cys-modifying  reagent  did  not  ablate  potentiation. 
Furthermore  substitution with  a proline,  known to  influence the peptide backbone 
geometry (Chou and Fasman, 1974;Yohannan et al., 2004), also retained the capacity
189for Zn2+ potentiation with only a modest reduction in potency.  This suggests it is the 
trajectory  of  the  backbone  at  this  loci  that  is  of  vital  consequence  for  Zn2+ 
potentiation rather than the side chain identity.  It was not possible from these studies 
to  determine if the peptide backbone is  involved directly in binding, but dynamic 
Zn2+ binding sites are predicted to retain at least three coordinating residues and an 
activated water molecule  (Auld,  2001).  As  there  are no  other obvious  candidate 
binding residue for the third coordinating partner in this region, then currently, the 
peptide backbone presents the most plausible explanation.
The  mutagenesis  experiments  presented  in  this  report  not  only  investigated  the 
relatively simple prospect  of dissecting true components  of Zn  binding but  also 
attempted to divulge possible mechanisms by which the two sites could propagate 
their  effects.  This  strategy  proved  surprisingly  powerful  in  divulging  useful
^ i
information  regarding  such  transduction  mechanisms.  In  the  case  of  Zn 
potentiation,  an  element  in  the  cys-loop  gating  domain  of the  GlyR,  T151,  was 
isolated that could determine the extent by which the potentiation site was able to 
exert  an  effect  on  receptor  function.  This  suggested  that  Zn  might  exert 
potentiation  by  acting  on  the  gating  process,  a  hypothesis  also  supported  by  the
synergistic  effect  that  disrupting  the  gating  element,  T151,  in  combination  with
•   •   •   * ) +   •   •   residues in the vicinity of the Zn  potentiation site had on reducing the efficacy of
agonist  action.  Such  synergy was  not  observed  between  T151  and  HI07  at  the
'y ,
inhibitory site suggesting this effect is selective to the region of Zn  enhancement.
A previous study in oocytes also showed that Zn2+ increased the relative efficacy of
the partial agonist taurine (Laube et al., 2000).  Furthermore, certain residues in the
M2-3 loop, an important component of the gating process (Lynch et al., 1997) ablate
Zn2+   potentiation  (Lynch  et  al.,  1998)  as  would  be  expected  if Zn2+  potentiation
interacts  with  this  process.  Though  this  study  has  not  proved  that  T151  is  the
exclusive element from the cys-loop in order for the Zn2+ potentiation site to mediate
its effect, disruption of two acidic residues, and Q150 in this domain, did not affect
enhancement  by  Zn2+.  Moreover  C l52,  an  immediate  neighbour  of  T151,  is
involved  in  formation  of  the  cys-loop  bridge,  critical  for  receptor  gating  and
assembly, making it an unlikely mediator in the Zn  enhancement process.  Thus
T151  would appear to be a specific control element that transduces the binding of
Zn2+ at the potentiation site to increase the efficacy of the receptor.
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Figure 6.1  Homology model presenting 
the molecular basis of the inhibitory Zn2+  
site  and  its  transduction  apparatus 
(viewed from the inside aspect; see inset).
A,  The  intersubunit  nature  of  the 
inhibitory Zn2+  site (expanded in (C), red 
dashed  box)  between  the  *+'  and 
interfaces  is  presented,  as  is  the
hydrophobic  Zn2r  inhibition  transduction  domain  (expanded  in  (B),  blue  dashed 
box), which leads to the agonist binding site (Top picture, green residues.  A more in 
depth view of the proposed agonist binding site can be viewed in Fig 1.6B,C).
191Figure  6.2  The  GlyR  Zn2+  potentiation  site.
Above in (A) is a presentation of the residues in the 
Zn2+  potentiation site viewed from above (see inset).
The comparative locations of the agonist binding site 
(green) and the Zn2+  inhibition site (orange) are also 
shown.  Note  the  clear  intersubunit  nature  of the 
inhibitory  site  on  the  inside  face  compared to the 
intrasubunit location of the Zn“^ potentiation site on the external face.  B, Side view 
(see  inset)  of the  Zn2   potentiation  site  with  labels  for  the  three  potential  Zn“ 
coordinating residues,  El92,  D194  and  H215  and the control  element T151  (blue). 
This highlights the location of T151  on the gating element cys-loop (blue) in close 
proximity to the pi-2  loop (green) and M2-3  loop (red)  gating elements.  The four 
transmembrane domains are also shown, with the pore lining helix, M2, in yellow.
192Perhaps the most revelatory discovery to result  from the site directed mutagenesis 
studies reported here, was the determination of an entire hydrophobic transduction 
pathway required  for  allosteric  interplay between  the  Zn2+   inhibition  site  and  the 
agonist binding site.  The ability to determine a genuine and selective role for these 
residues in transduction, something that is notoriously hard to do, was a fortuitous 
consequence  of  ZAG  induction  (Chapter  4)  upon  substitution  of  hydrophobic 
residues, L98, F99, F100, F108,1132 and L134 with alanine.  These residues were all 
predicted from the structural GlyR model to line up in a pathway from the inhibitory 
Zn2+  site  face across to  the  agonist-binding site  (Fig 6.1).  Other hydrophobic 
residues  surrounding  the  pathway  did  not  induce  such  an  effect.  Previously, 
transduction had been predicted to occur from the  face of the Zn  inhibition site 
due to the unique ability of the GlyR (3   subunit to only donate a Zn2+  binding site 
residue from its *+’ face (Chapter 3).  This ZAG formation was linked to the original 
inhibitory Zn2+ site, as not only was Zn2+ inhibition ablated upon substitution of the 
hydrophobic  residues  in  question  but  also  these  ZAG  receptors  relied  on  HI09, 
formerly of the inhibitory Zn2+ site, to elicit Zn2+ activated currents.  This suggested 
that in ZAG receptors the function of the inhibitory site had been switched to induce 
activation  and  therefore  these  hydrophobic  residues  were  important  in  the 
transduction process  of the Zn2+  inhibition  site.  To  confirm this  discovery really 
requires dynamic protein data.  In this case, the dynamic data was elucidated using 
functional mutagenesis  studies  to  modify the protein,  and therefore  its  energetics, 
then observe the consequences.  Though this pathway marks an apparent allosteric 
transduction route across the protein, it may be that such a communication event also 
represents  a  more  significant  role  in  the  general  function  of the  receptor  itself. 
Despite a model structure of the extracellular domain of cys-loop receptors, based on 
AChBP, it has, as yet, not proved possible to decipher the order and importance of 
downstream transduction events that mediate the communication between the agonist 
binding loops and the three base loops, the pi-2 loop, cys-loop and the P8-9 loop so 
that agonist binding can induce channel opening.  The mechanism of action of the 
inhibitory Zn2+ site clearly suggests that Zn2+ stabilises the closed conformation of 
the  receptor  by  fixing  the  inhibitory  site  face  in  a  set  orientation  with  the 
inhibitory site *+’ face of a neighbouring subunit (Chapter 3).  Clearly then, binding 
of agonist to open the receptor results in movement of the inhibitory site  face such
193that Zn2+ can no  longer bind and inhibit the receptor,  a process that the  evidence 
reported  here  suggests  is  mediated  via  a  hydrophobic  transduction  domain. 
Reorganisation  of the receptor’s hydrophobic  pathway and  inhibitory Zn2+  site 
face may therefore be part of the GlyR activation procedure.  How important this 
event is in activation of the receptor, i.e. whether it is a driving force for receptor 
activation or a side effect of receptor activation, remains to be seen, but undoubtedly 
this will come under scrutiny in the near future.
The data presented in this study represents a significant contribution to understanding 
the  molecular  basis  of Zn2+  modulation  of GlyRs.  Where  an  understanding  is
9 -4 - currently  lacking  is  in  the  appreciation  of  any  physiological  role  Zn  may  be 
exerting  over  GlyRs.  The  hippocampus,  an  ideal  preparation  to  study  NMDA
9 -4 - receptors, is also the favoured preparation for research on synaptic Zn  release and 
several studies have attained indirect evidence that Zn2+ can endogenously modulate 
NMDA receptors (Ueno et al., 2002;Vogt et al., 2000).  Furthermore pathways by 
which  Zn2+  can  be  released  in  the  hippocampus  have  been  characterised 
(Frederickson  et al.,  2000)  and due to  the very high  affinity of NR2A  containing 
NMDA receptors it would seem likely that these receptors experience a significant 
level  of background modulation by Zn2+ (Paoletti et al.,  1997).  Unfortunately the 
hippocampus appears to  express only extrasynaptic  GlyRs (Mori  et al.,  2002)  and 
these are less prominent than NMDA and GABAaRs, therefore limiting the extent to
9 .
which  studies,  especially dynamic  endogenous Zn  modulation  studies on  GlyRs, 
can be carried out.  Spinal cord, the ideal preparation to acquire information about 
synaptic  GlyR modulation,  has  yet to become  the  subject of any study addressing
9 i
endogenous release of Zn  as  a neuromodulator.  Though  studies in Xenopus  do
9 -4 - suggest  that  background  concentrations  of  Zn  may  be  sufficient  to  elicit 
potentiation  of GlyRs  and  therefore  have  physiological  significance  (Suwa  et  al., 
2001).  With regards to future progress in this field it may prove possible to use the 
high  potency ZAG receptors  developed  in  this  report  as  probes  for Zn2+  release. 
Transfection of such receptors into neuronal preparations to be expressed at synapses 
could provide an exciting opportunity, to detect for the first time, direct release of 
Zn2+ at the synapse.
194In conclusion, the data reported here provide a tantalising insight into  some of the 
complex  interactions  that  can  occur  in the  extracellular portion  of the  GlyR.  To 
dissect the processes that occur in a novel protein merely from a structural image is 
as futile as attempting to appreciate the picture of a face without any understanding 
of expressions.  The dynamic information dissected in this report offer a glimpse into 
two expressions, Zn2+ potentiation and inhibition, available to the GlyR during the 
course  of its  routine  role  to  process  activation  in  response  to  the  binding  of an 
agonist.
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